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Background: NHS Stop Smoking Services (SSSs) provide free at the point of use treatment for smokers
who would like to stop. Since their inception in 1999 they have evolved to offer a variety of support
options. Given the changes that have happened in the provision of services and the ongoing need for
evidence on effectiveness, the Evaluating Long-term Outcomes for NHS Stop Smoking Services (ELONS)
study was commissioned.
Objectives: The main aim of the study was to explore the factors that determine longer-term abstinence
from smoking following intervention by SSSs. There were also a number of additional objectives.
Design: The ELONS study was an observational study with two main stages: secondary analysis of routine
data collected by SSSs and a prospective cohort study of service clients. The prospective study had
additional elements on client satisfaction, well-being and longer-term nicotine replacement therapy
(NRT) use.
Setting: The setting for the study was SSSs in England. For the secondary analysis, routine data from
49 services were obtained. For the prospective study and its added elements, nine services were involved.
The target population was clients of these services.
Participants: There were 202,804 cases included in secondary analysis and 3075 in the prospective study.
Interventions: A combination of behavioural support and stop smoking medication delivered by
SSS practitioners.
Main outcome measures: Abstinence from smoking at 4 and 52 weeks after setting a quit date,
validated by a carbon monoxide (CO) breath test.
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Results: Just over 4 in 10 smokers (41%) recruited to the prospective study were biochemically validated
as abstinent from smoking at 4 weeks (which was broadly comparable with findings from the secondary
analysis of routine service data, where self-reported 4-week quit rates were 48%, falling to 34% when
biochemical validation had occurred). At the 1-year follow-up, 8% of prospective study clients were CO
validated as abstinent from smoking. Clients who received specialist one-to-one behavioural support were
twice as likely to have remained abstinent than those who were seen by a general practitioner (GP)
practice and pharmacy providers [odds ratio (OR) 2.3, 95% confidence interval (CI) 1.2 to 4.6]. Clients who
received group behavioural support (either closed or rolling groups) were three times more likely to stop
smoking than those who were seen by a GP practice or pharmacy providers (OR 3.4, 95% CI 1.7 to 6.7).
Satisfaction with services was high and well-being at baseline was found to be a predictor of abstinence
from smoking at longer-term follow-up. Continued use of NRT at 1 year was rare, but no evidence of
harm from longer-term use was identified from the data collected.
Conclusions: Stop Smoking Services in England are effective in helping smokers to move away from
tobacco use. Using the 52-week CO-validated quit rate of 8% found in this study, we estimate that in the
year 2012–13 the services supported 36,249 clients to become non-smokers for the remainder of their
lives. This is a substantial figure and provides one indicator of the ongoing value of the treatment that the
services provide. The study raises a number of issues for future research including (1) examining the role of
electronic cigarettes (e-cigarettes) in smoking cessation for service clients [this study did not look at
e-cigarette use (except briefly in the longer-term NRT study) but this is a priority for future studies];
(2) more detailed comparisons of rolling groups with other forms of behavioural support; (3) further
exploration of the role of practitioner knowledge, skills and use of effective behaviour change techniques
in supporting service clients to stop smoking; (4) surveillance of the impact of structural and funding
changes on the future development and sustainability of SSSs; and (5) more detailed analysis of well-being
over time between those who successfully stop smoking and those who relapse. Further research on
longer-term use of non-combustible nicotine products that measures a wider array of biomarkers of
smoking-related harm such as lung function tests or carcinogen metabolites.
Funding: The National Institute for Health Research Health Technology Assessment programme. The UK
Centre for Tobacco and Alcohol Studies provided funding for the longer-term NRT study.
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Adjusted odds ratio Odds ratio from a logistic regression model where other variables have been taken
into account.
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Service (usually a general practitioner practice or pharmacy), but is trained in assisting with quit attempts as
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‘community practitioners’ or ‘local enhanced service practitioners.’
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Specialist practitioner Practitioner who is employed directly by the Stop Smoking Service management
and assisting with quit attempts is the sole or main part of their role.
Stop Smoking Services These are government-funded smoking cessation services. At the time of
the data collection they were administered through the NHS but are now administered through
local authorities.
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Plain English summary
What was the problem/question?
The UK Stop Smoking Services (SSSs) have provided free treatment for smokers who would like to stop
since 1999. The last major evaluation of English services took place from 2000–4 and since that time the
services have undergone many changes. Thus, a new evaluation was appropriate.
What did we do?
This study involved routine data from 49 of 150 English SSSs and a study of long-term outcomes of service
clients in nine areas of England.
What did we find?
Routinely collected 4-week follow-up data revealed that 34% clients reported that they had quit and had a
consistent breath test result. Services were reaching up to 10% of smokers in their area.
At 1 year, 8% of the 3057 clients who took part in the long-term study stated that they had remained quit
and had a supporting breath test. Clients who received specialist one-to-one support were twice as likely
to quit and those who attended groups were three times more likely to stop than those seen by general
practitioner practice and pharmacy staff. Of the 996 clients who responded to a satisfaction survey,
87% were satisfied or very satisfied.
What does this mean?
If the 1-year quit rates from this study are applied to all of England, we estimate that in the year 2012–13
the services supported 36,249 clients to become non-smokers for the rest of their lives. Thus, SSSs make
a valuable and valued contribution to tobacco control.
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Scientific summary
Background
NHS Stop Smoking Services (SSSs) provide free at the point of use treatment for smokers who would like
to stop. They were piloted in 1999 and rolled out across the UK from 2000. Since their inception they have
evolved to offer a variety of support options. In particular, the services have moved away from offering
support in groups, to providing a range of one-to-one support options in different settings. There are now
also a wider variety of types of practitioner offering stop smoking support, with a particular growth in
pharmacy-based provision. Significant differences have been identified between the quit rates ‘achieved’
by services in different locations, which may be partly because of the quality of behavioural support
delivered by the practitioner who offers it. Members of our team conducted a previous national evaluation
of SSSs in England between 2000 and 2004. This included a longer-term follow-up element, carried out
1 year after participating smokers had set a quit date. Given the changes that have happened in the
provision of services over this decade, and the ongoing need for evidence on effectiveness, the Evaluating
Long-term Outcomes for NHS Stop Smoking Services (ELONS) study was commissioned. This report sets
out the findings.
Aim and objectives
The principal aim of the study was to explore the factors that determine longer-term abstinence from
smoking following intervention by SSSs.
The study objectives were to:
1. examine the effectiveness of SSSs by primary care trust (PCT) and intervention type using routine data
2. explore the reach of services by identifying what proportion of the local population set a quit date with
services using routine data
3. describe the factors that determine longer-term abstinence from smoking or relapse to smoking among
clients who set a quit date with services in a sample of PCTs in England
4. examine the relationship between client characteristics [in particular socioeconomic status (SES),
age, gender, disability and ethnicity], adherence to treatment, intervention type received and
longer-term abstinence
5. create an evidence base to guide delivery of interventions by SSSs so that these interventions will have
maximal effect on smoking cessation and population health.
Method
The ELONS study was an observational study with two main stages:
1. secondary analysis of routine data collected by SSSs
2. a prospective cohort study of SSS clients with three additional elements:
i. a client satisfaction survey (CSS)
ii. a well-being survey
iii. a study of longer-term nicotine replacement therapy (NRT) use.
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The setting for the study was SSSs in England. For the secondary analysis, routine data from 49 services
were obtained. For the prospective study and its added elements, nine services were involved. The
target population was service clients.
Results
Secondary analysis of routine data collected by Stop Smoking Services
QuitManager (North 51, Nottingham, UK), an online database for recording information on SSS clients,
provided the data for analysis. A total of 202,804 clients records were extracted for analysis over
two separate time periods: July–December 2010 and January–June 2011.
Key findings from this element were:
l The estimated number of clients treated by SSS from mid-2010 to mid-2011 was 5–10% of their
smoking population.
l The self-reported and carbon monoxide (CO)-validated quit rates were 48% and 34% respectively at
4 weeks post quit date. Highest quit rates were found among older people, men and clients with
higher SES. January was the month with the highest number of quit dates set and successful quitters.
l Affluent smokers were more likely to be abstinent from smoking at 4 weeks than
disadvantaged smokers.
l Varenicline (Champix®, Pfizer) and combination NRT were both used frequently and increased the
chances of quitting compared with a single NRT product.
l The majority (79%) of clients received one-to-one behavioural support. This type of support was
significantly less successful than open rolling groups [adjusted odds ratio for open groups 1.28,
95% confidence interval (CI) 1.15 to 1.41 compared with one to one].
l Clients who saw specialist practitioners had higher quit rates than those who saw other types
of practitioners.
l As a result of SSS treatment, the estimated number of ex-smokers per 100,000 population was
184 from mid-2010–mid-2011.
Prospective study
The secondary analysis phase of the ELONS study (phase 1) identified SSSs (based on various criteria,
e.g. type of behavioural support offered) to be invited to take part in the prospective study. Nine agreed to
recruit clients into the prospective study, which required practitioners to consent clients to the study and
collect additional client and treatment data. This recruitment approach presented several challenges and
the final sample achieved was 3075. Weights were created to correct for non-response as only a small
proportion of all eligible clients in each study area were recruited. Key findings include:
l In terms of smoking cessation in the short term, the CO-validated quit rate at 4 weeks was 44.1%.
With weighting this reduced marginally to 41.2%.
l For smoking cessation in the longer term, the CO-validated quit rate at 1 year was 9.3% but after
weighting this reduced to 7.7%.
l Predictors of abstinence at 52 weeks included:
¢ attending group behavioural support or receiving one-to-one support from a specialist practitioner
¢ taking varenicline
¢ attending in the New Year
¢ being older
¢ being more affluent
¢ having a lower dependence on tobacco
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¢ having a higher well-being score
¢ having support from a spouse or partner
¢ having a social network not populated with smokers.
l Taking stop smoking medication and attending support sessions (described here as ‘adherence’) was
significantly associated with smoking cessation – more so at 4 weeks than at 1 year.
l Limited comparisons with previous evaluations of SSSs are possible. Quit rates for 4 and 52 weeks
from the ELONS prospective study were lower than those identified in the previous national evaluation
in England, but higher than a more recent study in Glasgow that examined closed group and
pharmacy-based services.
Client satisfaction
All clients who participated in the prospective study (regardless of the outcome of their quit attempt)
were sent a client satisfaction survey to give feedback on the service they received. There were 1006
questionnaires received and the final data set had 996 cases. Key findings were:
l A consistent pattern emerged that suggested that smokers who accessed SSSs in the study areas
and responded to the survey had a positive experience. This was the case for both quitters and
non-quitters. The vast majority who replied to the questionnaire indicated that they would
recommend the service to others and return should the need arise.
l Additional comments highlighted the importance of practitioner/client rapport and previous research
suggests that this is an important factor in a successful quit attempt.
l Despite survey findings suggesting that stop smoking medication was easy to acquire, additional
comments pointed to a more complex picture where the process of obtaining this medication was over
complicated and time-consuming for some respondents.
l Suggested improvements included evening appointment times, having a choice of group or one-to-one
support, and a longer period of behavioural support.
Well-being study
Well-being can improve after smoking cessation, but smokers often have concerns about stopping because
they believe smoking itself brings benefits such as reduced stress levels. As part of the baseline monitoring
data collection for the prospective study, clients were asked additional questions about their health and
well-being. In addition, all clients, regardless of whether or not they had quit smoking, were sent postal
questionnaires at 4 and 52 weeks post quit date, which included questions on well-being. Key
findings include:
l Smokers who had higher levels of well-being when they first started attending were more likely to be
non-smokers at 4 weeks and 1 year later.
l The most consistent baseline factors associated with well-being at baseline, 4 weeks and 52 weeks
were having a diagnosed mental health condition, being dependent on tobacco, and young or
older age.
l Clients aged 45–54 years had lower well-being scores than younger and older clients at all three time
points, although differences were not always significant.
l Clients who had higher levels of well-being were consistently more likely to agree that they enjoyed a
challenge, were doing well in life and felt more in control than other clients. A mediator of the
association between dependence on tobacco and well-being appeared to be not being able to cope
with stress.
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Longer-term nicotine replacement study
Additional funding was obtained to add an element that focused on longer-term NRT use. This involved
collecting saliva samples from participants at baseline and at 1 year and using these to test for relevant
biomarkers. Just over one-third of prospective study participants provided information on longer-term NRT
use (n= 1047) and were included. There were 258 participants (8.5% of the whole ELONS study sample)
who provided baseline and follow-up saliva samples that were analysed for biomarkers. Key findings were:
l Of clients followed up at 12 months, 61.5% reported that they had used NRT during their quit
attempt. However, this is likely to include over-the-counter use, as this number is substantially higher
than the number of participants recorded as using NRT by the services (34.4%).
l Most clients who started on NRT used it for at least 8 weeks and more than one in five (21.5%) used it
for longer than the standard 3 months.
l Long-term use was relatively rare with fewer than 1 in 10 participants still using non-combustible
nicotine products at the 12-month follow-up (8.4%).
l Within this category of non-combustible nicotine products were electronic cigarettes (e-cigarettes). Few
participants reported their use at 1 year (2.9%), although these data include smokers and non-smokers
and most people had relapsed by 1 year post quit date. However, e-cigarettes were the most popular
single product at 1 year.
l Long-term ex-smokers had much higher odds of still using non-combustible nicotine products at the
12-month follow-up than those who relapsed. Concurrent use among relapsers was 3.7% compared
with 14.0% of continuous abstainers. This difference remained significant even after removing those
who used e-cigarettes only.
l In terms of the biomarker analysis, 258 participants (8.5% of the whole ELONS study sample) provided
baseline and follow-up saliva samples and were included. Greater levels of cotinine were associated
with greater self-reported dependence. As expected, within-group analysis showed that smokers who
had stopped had significantly lower cotinine levels at follow-up than those who had relapsed to
smoking at follow-up. However, this was the case only for ex-smokers who did not use NRT. Cotinine
levels for smokers who had stopped at follow-up but who used NRT long term had not changed
from baseline to follow-up and neither did cotinine levels for those who had relapsed to smoking
(irrespective of NRT use). There were no differences as a function of NRT use and smoking status at
follow-up in baseline levels of alpha-amylase, a biomarker of stress.
Conclusions
In terms of smoking cessation in the short term, findings are broadly comparable with those from routinely
collected data from services. From our prospective study of just over 3000 smokers attending SSSs in nine
areas of England, we found that just over 4 in 10 (41.2%) were biochemically validated as abstinent from
smoking at 4 weeks post quit date. Our secondary analysis of routine data from 49 of 150 services in
England found 4-week quit rates of 48% when self-reported data were included, falling to 34% when
biochemical validation had occurred. This same analysis found that services were reaching up to 10% of
smokers in their area in the year from July 2010. National Institute for Health and Clinical Excellence
guidance previously recommended that services aim to reach at least 5% of their smoking population in
1 year. These results provide a useful indicator that (a) routine data provide a helpful and not inaccurate
indicator of short-term smoking cessation outcomes and (b) services are continuing to effectively reach
smokers and support them to stop.
No routine data exist for longer-term cessation outcomes at 1 year and it is some time since a study in
England has looked at this issue. We found that just fewer than 8% of smokers were still abstinent from
smoking 1 year after setting a quit date. If these results are applied to all of England, then we estimate
that in the year 2012–13 the services supported 36,249 clients to become non-smokers for the remainder
of their lives.
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A range of factors, including many linked to the characteristics of clients and also SSS characteristics,
influenced outcomes. For example, smokers supported to quit with the specialist service were more likely
to stop smoking in the longer term. In addition, the ELONS study has shown that longer-term outcomes
are influenced by the type of behavioural support a smoker receives; open groups resulted in better
outcomes than other forms of behavioural support.
Three additional elements were added to the ELONS study that were more exploratory in nature and have
a number of limitations. These focused on client satisfaction, well-being and longer-term NRT use. Overall,
we found that those who responded to the satisfaction survey were positive about the support that they
received and would recommend SSSs to others. We found that assessment of well-being could be included
in routine monitoring and that positive well-being at baseline was a significant predictor of smoking
abstinence at 1-year follow-up. Fewer than 1 in 10 clients who had stopped smoking at 1 year were still
using non-combustible nicotine products, suggesting that long-term use is not that prevalent. However,
among those who did continue to use these products we found no evidence of harm from longer-term
use in the data we collected.
The study raises a number of issues for future research including:
l examining the role of e-cigarettes in smoking cessation for service clients. This study did not look at
e-cigarette use (except briefly in the longer-term NRT study) but this is a priority for future studies
l more detailed comparisons of rolling groups with other forms of behavioural support
l further exploration of the role of practitioner knowledge, skills and use of effective behaviour change
techniques in supporting service clients to stop smoking
l surveillance of the impact of structural and funding changes on the future development and
sustainability of SSSs
l more detailed analysis of well-being over time between those who successfully stop smoking and those
who relapse
l further research on longer-term use of non-combustible nicotine products that measures a wider array
of biomarkers of smoking-related harm such as lung function tests or carcinogen metabolites.
Funding
The National Institute for Health Research Health Technology Assessment programme. The UK Centre for
Tobacco and Alcohol Studies provided funding the longer-term NRT study.
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Chapter 1 Introduction
Tobacco use is one of the leading causes of preventable death in the world. Each year an estimated5.1 million people die from smoking and another 600,000 die from second-hand smoke exposure.1,2
As nearly 80% of these deaths occur in low- and middle-income countries,3 tobacco causes over 90,000
deaths in the UK each year, reflecting decades of high smoking prevalence. Although smoking rates have
reduced from 51% of men and 41% women in 1974 to 19% today (21.1% of men and 16.5% of
women)4 they still remain high in the UK compared with countries such as Australia, Canada and Sweden.
In addition, smoking rates in Britain are strongly socially patterned, with 29% of adults in routine and
manual occupations smoking compared with 13% in managerial and professional groups.4
Countries such as the UK have made concerted efforts to reduce smoking rates over several decades.
Many of the policies and interventions that have been put in place form part of the Framework
Convention on Tobacco Control (FCTC), the world’s first global public health treaty that was adopted by
the World Health Assembly under the auspices of the World Health Organization (WHO). There are now
178 countries parties to the convention, including the UK.5 The treaty seeks to reduce the burden of
tobacco use through key supply and demand measures, which are laid out in its articles. Demand
measures are highlighted in WHO’s ‘MPOWER’ report including ‘Monitoring tobacco use and prevention
policies’, ‘Protecting people from tobacco smoke’, ‘Offering help to quit tobacco use’, ‘Warning about the
dangers of tobacco’, ‘Enforcing bans on tobacco advertising, promotion, and sponsorship’, and ‘Raising
taxes on tobacco’.6 Guidance on ‘offering help to quit’, including the provision of services to support
smokers to stop, offering counselling and effective smoking cessation medications, is contained in article
14 of the FCTC.5 This is an important element of efforts to reduce smoking rates, as the success of
unaided quit attempts is generally extremely low (around 5%). The chances of successfully stopping can be
significantly raised if effective aids to quitting are made available.7
The UK has played a significant role in developing the evidence to underpin effective interventions for
smoking cessation as set out in article 14 of the FCTC.5 This has its origins in early studies on smoking and
health, to research on nicotine replacement therapy (NRT) and behavioural support, through to real-world
evidence on how a national treatment service for smoking can be developed and established. To introduce
this study, we set out some of this historical background here, before outlining how the current study
helps to bring this evidence base up to date and should inform the design of future services.
Early research on smoking cessation in the UK
The first evidence of clear links between tobacco smoking and ill-health emerged in the 1950s when Doll
and Hill published the first paper showing that smoking caused lung cancer.8 This, and other evidence, led
to the production of two important reports – one in the UK and one in the USA – on smoking and health.
In the UK the Royal College of Physicians report of 1962 outlined the need for a comprehensive approach
to reduce smoking rates.9 This described a series of needed policy measures including tobacco taxes,
restricting advertising and availability, education on the risks of smoking and, importantly, support for
smokers wanting to quit. In the end, it would take almost 50 years for all the recommendations in
Smoking and Health to be implemented, but in the meantime a range of important studies were
conducted that provided better evidence on smoking as an addiction, rather than a ‘habit’, and
consequently how it should be treated.10 A number of early studies on nicotine and NRT were conducted
by Professor Michael Russell and colleagues at the Addiction Research Unit at the University of London.
These contributed to the licensing of the first pharmacological treatment for smoking cessation in 1981 –
nicotine gum. From that period onwards a number of important research and policy developments on
smoking cessation took place in the UK. Members of our team summarised these in an earlier study and
we reproduce these here, outlined in Table 1.10
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TABLE 1 Key events and tobacco control initiatives 1950–2000 in the UK
Year Event
The 1950s
1950 Doll and Hill paper published in the BMJ8
1951 British doctors’ study commences
1959 First smoking dependence treatment clinic opens in Salford, Greater Manchester, UK
The 1960s
1962 First RCP report, Smoking and Health9
1962 Tobacco Practitioners Council (representing the tobacco industry) agreed to implement a code of advertising
practice for cigarettes
1965 Television cigarette advertising ban
1967 Creation of Health Education Council
The 1970s
1970 Mike Russell starts building a smoking research team at the Addiction Research Unit
1971 Second RCP report, Smoking and Health Now11
1971 Voluntary agreements on advertising began
1971 Creation of ASH
Voluntary agreements on health warnings
1977 Third RCP report, Smoking or Health12
1977 Government health circular expressed need for smoking policies on all health premises
The 1980s
1981 NRTs ‘blacklisted’
1983 Fourth RCP report, Health or Smoking?13
Voluntary agreements on product modification
Excise duties on tobacco begin to rise significantly
1986 British Medical Association join campaign against tobacco industry
The 1990s and 2000s
1991 Illegal sales law strengthened
1992 Fifth RCP report, A Review of Your People Smoking in England14
1993 Government commits to 3% above inflation tax increase on cigarettes
1993 Ban on oral snuff throughout European Union
1997 Government commits to 5% above inflation tax increase on cigarettes
1998 White Paper, Smoking Kills15
1998 First English evidence-based guidelines on smoking cessation16
1999 First smoking cessation treatment services established in the English NHS
2000 NHS smoking cessation treatment services established nationally
2013 SSSs transferred from NHS to local authorities
ASH, Action on Smoking and Health; BMJ, British Medical Journal; RCP, Royal College of Physicians; SSSs, Stop
Smoking Services.
Reproduced with permission from McNeil A, Raw M, Whybrow J, Bailey P. A national strategy for smoking cessation
treatment in England. Addiction 2005;100(Suppl. 2); pp. 1–11. Copyright © 2005, John Wiley and Sons.
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NHS Stop Smoking Services
The NHS Stop Smoking Services (SSSs) were established following the publication of the 1998 White
Paper, Smoking Kills.15 Initially piloted in deprived areas of England in 1999, they were rolled-out across
the UK from 2000. The services were developed on the basis of national guidance issued by the
Department of Health (DH) that built on a review of the evidence of the effectiveness of smoking cessation
interventions published in the journal Thorax.16 This evidence emphasised the efficacy of intensive
behavioural support (in groups or one to one) plus pharmacotherapy for smoking cessation. Services were
established by primary care trusts (PCTs) and operated primarily in primary care settings delivering
behavioural support and providing access to NRT and bupropion (Zyban®, GlaxoSmithKline). From 2000–4,
a national evaluation of the services in England was conducted by members of our team. The evaluation
found that the services were effective in supporting smokers to quit in the short term (at 4 weeks)17 and
the longer term (at 1 year),18 and were reaching smokers from more deprived groups.19 A subsequent
analysis by our team also found that they were making a contribution to reducing inequalities in health
caused by smoking.20 However, since these studies were conducted, NHS SSSs have continued to evolve,
attempted to adapt to meet local needs and encountered various financial and structural challenges.
National developments, including the National Institute for Health and Care Excellence (NICE)’s guidance
on services (published in 2008),21 have influenced what is available and smoking cessation medications
have also diversified, with new NRT products and the medication varenicline (Champix®, Pfizer) providing
additional options for smokers trying to stop.
One element that has changed in the past decade is the type and variety of behavioural support options
available to smokers using the services. In particular, a heavier reliance on one-to-one support options in a
far wider range of settings. The existing evidence base from systematic reviews of trials would suggest that
there is no significant difference in outcomes for smokers receiving group or one-to-one behavioural
support. In a review of 50 randomised controlled trials22 and another review of 23 studies since January
2000,23 a group format for a behavioural intervention was not found to be significantly different from an
individual format; yet real-world evidence may be different from trials in this respect. Findings from our
earlier studies with NHS SSSs suggest that group interventions may be more effective in practice24 but that
smokers, given a choice, will choose one-to-one support. Issues of perceived preference may have led to
the dominance of one-to-one support in today’s services although new forms of group counselling (such
as ‘rolling groups’ where clients can join without having to wait for a new group to start) have emerged.
Another element that has evolved is who provides support to stop smoking. Before the services existed,
this was primarily doctors and nurses in primary care or hospitals with a few examples of specialist clinics.
Today, a wider variety of professionals are involved in delivering support. In some cases this is described as
different ‘levels’ of support. We describe these levels here.
l Level 1 practitioners are typically primary care professionals who deliver ‘brief interventions’, which
usually involves opportunistic advice, discussion, awareness raising and/or referral to SSSs.
l Level 2 practitioners (known elsewhere as community practitioners) do not work exclusively as stop
smoking specialists but instead work in other health and social care roles and deliver stop smoking
support as one of a number of job tasks. The majority of level 2 service provision takes place in general
practitioner (GP) practices (usually delivered by nurses and health-care assistants) and pharmacies
(delivered by practitioners with a variety of posts from pharmacists to pharmacy assistants). Generally
one-to-one support is offered.
l Level 3 practitioners’ sole remit is to deliver smoking cessation working as smoking cessation
‘specialists’. They offer a wider variety of behavioural support which can include: open and closed
groups, one to ones, drop-in services, text and telephone support,25 and work in various locations such
as community centres, GP practices and workplaces.
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
For clarity, throughout this report we will differentiate between level 2 and level 3 service providers by
using the terms ‘level 2′ and ‘specialist’ practitioners. Data on level 1 support are not collected by the SSS
and is not part of the study.
A growing proportion of clients now receive support from level 2 practitioners. Large differences have now
been identified between the quit rates achieved by services in different locations, which may be partly
because of the quality of behavioural support delivered by the practitioner who offers it.26–28
The organisational context within which SSSs operate has also changed since our earlier studies. Some of
these changes preceded the Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS) study
(e.g. reorganisation of PCTs in England) but possibly the most significant change occurred in April 2013,
just after the fieldwork was completed, when commissioning of local SSSs moved from NHS to local
authority control. This resulted in change to the funding and delivery structure of local SSSs, with some
areas either reducing funding for the specialist service in favour of a greater reliance on level 2 providers or
tendering out previously in-house services which has sometimes led to SSSs being run by private and
voluntary sector companies. This structural change poses challenges for the services and preparation for
the move also, to some extent, affected study recruitment, which is discussed further in Chapter 4.
As a result of all these changes, current research is needed to examine the longer-term efficacy of the
different methods employed by NHS SSSs to deliver support to smokers trying to stop. Current evidence is
also required to explore the effectiveness of services with different groups of smokers, particularly those
from more disadvantaged groups. This report sets out findings from a study designed to examine
these issues.
Structure of this report
This is a detailed report of a complex study with a number of different elements. Chapter 2 presents an
overview of the research including aims and objectives, study design and settings. It was also describes the
ethical approval and local research permissions process.
Chapters 3 and 4 present the methods and main findings of the secondary analysis element of the ELONS
study respectively. Chapters 5 and 6 describe the methods and analysis (see Chapter 5) and the results and
key findings (see Chapter 6) for the second (and main) part of our study. This was a prospective cohort
study of smokers using the services who were followed up in the short (4 weeks post quit date) and longer
term (at 1 year).
The subsequent three chapters present findings from elements that were added to the ELONS prospective
study. For ease and clarity, they are presented as standalone chapters including the methods and results
for each. The focus of Chapter 7 is an exploration of client satisfaction with the support received from their
local SSS. Chapter 8 examines the relationship between well-being and smoking status of ELONS study
participants. Chapter 9 outlines findings from a study of longer-term NRT use that was made possible by
additional funding from the UK Centre for Tobacco Control Studies [now the UK Centre for Tobacco and
Alcohol Studies (UKCTAS) – www.ukctas.ac.uk]. The remaining two chapters include the discussion
(see Chapter 10) with conclusions presented in Chapter 11.
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Chapter 2 Evaluating Long-term Outcomes of NHS
Stop Smoking Services overview
This purpose of this chapter is to present an overview of the ELONS study including aims and objectives,study design, setting and the rationale for the methods used. It also describes the ethical approval
and the local research permissions process.
Aim and objectives
The principal aim of the study was to explore the factors that determine longer-term abstinence from
smoking following intervention by SSSs in England.
The study objectives were to:
l examine the effectiveness of SSSs by PCT and intervention type using routine data
l explore the reach of services by identifying what proportion of the local population set a quit date with
services using routine data
l describe the factors that determine longer-term abstinence from smoking or relapse to smoking among
clients who set a quit date with services in a sample of PCTs in England
l examine the relationship between client characteristics [in particular socioeconomic status (SES),
age, gender, disability and ethnicity], adherence to treatment, intervention type received and
longer-term abstinence
l create an evidence base to guide delivery of interventions by SSSs so that these interventions will have
maximal effect on smoking cessation and population health.
Overview of study design
The ELONS study was an observational study with two main stages:
l secondary analysis of routine data collected by SSSs
l a prospective cohort study of SSS clients with three additional elements (which are presented as
standalone chapters on the report):
¢ a client satisfaction survey (CSS)
¢ a well-being survey
¢ a study of longer-term NRT use.
The overall aim of the prospective element of the ELONS study was to collect long-term follow-up data at
52 weeks. A subsidiary aim was to collect detailed information about clients and the treatment they
received in a consistent manner. Data were collected at three key stages: baseline (i.e. when a client
registered with the SSS), 4-week follow-up and 52 weeks post quit date. The 52-week follow-up data
were collected by a research company, TNS BMRB (Taylor Nelson Sofres, British Market Research Bureau),
that had worked with the academic team on a previous study.29 Table 2 describes the data collected at
each time point and also summarises the data collected for the three additional elements (client
satisfaction, well-being and long-term NRT). Further detail of the data collected at each stage and data
collection tools can be found in Appendix 1. A flow chart depicting sample sizes and sampling frames is
also available (Figure 1).
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English SSSs
≈150 PCTs 
(na = 724,247)
QuitManager data management
≈ 60 PCTs
In-house or other 
data management company
Did not give permission for
data to be used for research
Agree for data to be used for
research purposes
49 PCTs
Nine services (12 PCTs) recruited 
to ELONS prospective study 
(n = 75,100)
Recruited and data available
for analysis
(n = 3057)
Quit status collected
at 4 weeks
(n = 2411)
Quit status collected
at 12 months
(n = 1051)
Available to be recruited
(n = 65,937)
In sampling frame
(n = 35,006d)
Pregnancy 
Aged under 16 years
Practitioner unknown
Level 2 providersc who did not
consent 
Outside level 2/specialist
recruiting period at site
Exclusions:b
Provided saliva
(for long-term 
NRT-use study)
at baseline and 
12 months
(n = 258)
Postal survey at 
4 weeks CSSe (n = 996)
Well-being (n = 953)
Postal survey at 12 months
Well-being (n = 479)
Well-being from three time points (n = 325)
FIGURE 1 Flow diagram for the ELONS prospective study. a, n refers to quit attempts at the SSS from March/April
2012 to March 2013; b, more detail is available in Chapters 5 and 6; c, providers’ employees provide smoking
cessation support rather than specialists employed directly by SSSs; d, this is an overestimate because level 2
providers who did recruit did not usually recruit for the level 2 recruitment period at each site; and e, CSS.
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Definitions of smoking cessation
Smoking cessation, or ‘quitting’, was defined in the following ways for this study.
Short-term (4 weeks after quit date) self-reported quitting
In normal SSS treatment, 4 weeks after their quit date, advisors ask their clients (either in person at a
session or, if they have stopped attending treatment, by telephone) whether or not they have smoked a
cigarette in the last 2 weeks. Clients who indicate that they have not smoked in this period are classified
as a ‘self-report’ quitter at 4 weeks.
Short-term (4 weeks after quit date) carbon monoxide-validated quitting
During treatment sessions clients are asked to breathe into a carbon monoxide (CO) monitor, which
records the CO parts per million (p.p.m.). If clients reduce the number of cigarettes smoked their CO level
falls. This can be motivating as it provides a visual representation of how stopping smoking reduces
exposure to CO, which is a harmful chemical. If a client has not been smoking for the past 24 hours then
the level usually falls below 10 p.p.m.30 Thus, at 4 weeks if a client has self-reported that they have
stopped smoking and their CO level is < 10 p.p.m. then they are said to be a CO-validated quitter at
4 weeks. In this report, we refer to CO-validated quitting and in places also as ‘biochemically validated’
quitting or abstinence. Where we state biochemical validation, we mean CO validation.
If the client refuses to take a CO test then they are classified as a self-report quitter only. In a minority of
cases, clients may self-report that they have stopped smoking but their CO level will be ≥ 10 p.p.m. In this
case they are said to be a ‘self-reported quitter who has been refuted by CO validation’. For this study, this
small minority were classified as non-quitters in quit rate and regression analysis.
Longer-term (52 weeks after quit date) self-reported quitting
The research team (in this case TNS BMRB) contacted clients who self-reported quitting at 4 weeks by
telephone 12 months after their quit date and asked if they had smoked within the last 7 days. Those that
had not smoked in this period were then asked if they had smoked since their quit date. If they had
smoked up to but not more than five cigarettes they were classified as achieving ‘self-reported continuous
abstinence’, as consistent with the Russell standard30 (the recognised standard for smoking cessation
studies and also validating cessation in clinical practice). If they had smoked more cigarettes they were
classified as achieving ‘self-reported point prevalence abstinence’. For the analysis outlined here, only those
achieving continuous abstinence and whose self-report was not refuted by the CO breath test were
classified as 52-weeks self-report quitters.
Longer-term (52 weeks after quit date) carbon monoxide-validated quitting
All clients who had achieved point prevalence self-report abstinence were asked if a researcher could make
a home visit and carry out a CO breath test. For the analysis reported here clients with a CO level of
< 10 p.p.m. and who had also self-reported that they were continuously abstinent since their quit date
were classified as 52 week CO-validated quitters. Biochemically (CO-validated) abstinence from smoking at
52 weeks was the primary outcome for this study.
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Setting
The setting for the study was SSSs in England. For the secondary analysis, routine data from 49 services
were obtained. For the prospective study, nine services were involved. These were Bristol, County Durham
and Darlington, Hull and East Riding, Leicestershire County and Rutland, North and North East Lincolnshire,
Northamptonshire, Oldham, Rotherham, and South East Essex. The target population was clients of these
services. The health technologies that the ELONS study assessed were the treatment provided by SSSs – a
combination of behavioural support and medication intended to increase the chance of a successful quit
attempt. A key focus was to evaluate outcomes for smokers who received one of the five main forms of
behavioural support (also called intervention types) provided by the services:
l closed groups (scheduled group sessions of around 1–2 hours dependent on the number of clients,
normally delivered once per week and facilitated by a specialist practitioner
l open/rolling groups (drop-in groups run at a variety of times of day and in a variety of locations where
clients can attend without an appointment and for as many weeks as they wish)
l one-to-one drop-in (a clinic hosted at a regular time where clients can attend without an appointment
for one-to-one support)
l one-to-one sessions with a specialist practitioner (scheduled one-to-one sessions with a practitioner
whose main role it is to help people stop smoking)
l one-to-one sessions with a level 2 practitioner.
Ethics and local permissions
Ethical approval for the ELONS study was obtained from NHS Lothian (South East Scotland Research Ethics
Committee) in June 2011. During the recruitment phase of the prospective study a total of four substantial
amendments were made for alternations to the study protocol and consent process. In addition to ethical
approval, we also obtained local research and development (R&D) approval for each SSS. For three SSSs,
single R&D office approvals were required but for the remainder two sets of approvals were required
owing to the location of the SSSs and the NHS trusts involved. All the necessary local approvals
were obtained before data collection began. It was also a requirement that the research team obtain
NHS research passports and, for one site, it was necessary to obtain Caldicott Guardian approval.
Public involvement
Members of the public were involved in the ELONS study in a number of ways. Within the prospective
study, the public were research participants and the study was designed to provide feedback on an
important public service for the benefit of future users. However, more direct forms of involvement were
also included in the research.
First, the study principal investigator, Professor Bauld, serves as the public engagement lead for UKCTAS,
a UK Clinical Research Collaboration Centre for Public Health Excellence that covers 13 universities (the
co-investigators for the study are also UKCTAS members). In this role she convenes a panel of continuing
smokers and recent quitters who meet in Bath. The original design for the ELONS study was discussed with
the panel at meetings in 2010 and again in 2011, and feedback sought. Initial results were also circulated
to panel members at a meeting in 2013. One of the panel members, Robert Graham, was asked to join
the study steering group as a lay adviser and did so. Although he was not able to attend all steering group
meetings, he maintained contact with Professor Bauld and, having used NHS SSSs himself in the past,
provided very useful input.
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In addition to panel contributions and Mr Graham’s involvement, we had the participant information
leaflets and consent forms for the study reviewed by a patient representative. This was organised through
the Primary Care Research Network (PCRN) Patient and Public Involvement Manager, and we are grateful
to them for facilitating this process.
We also prepared the ELONS study newsletters for all the participating services in the prospective study.
There were three of these during the study. These were intended to be available to service clients as well
as staff and we sent these to each site for distribution.
Finally, tailored feedback from the study was prepared for each study site and for one site an event was
held that involved a varied audience and presentations on study findings. Dissemination at a number of
academic and practitioner conferences is currently under way.
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Chapter 3 Secondary analysis of routine data:
methods and analysis
This chapter outlines the rational, sample and analytical approach for the secondary analysis element ofthe ELONS study, with results presented in Chapter 4.
Rationale for secondary analysis
All SSSs in England are required to submit routine monitoring data to the Health and Social Care
Information Centre.31 These data include basic information on client characteristics and the types of
treatment received. They also include self-reported smoking status at 4 weeks post quit date. These
monitoring data are supplied as aggregated summary returns and so cannot be used to analyse which
factors are associated with individual-level smoking cessation outcomes.
Increasingly, however, SSS outsource management of these data to private companies. The most
commonly used is QuitManager (North 51, Nottingham, UK).7,27 QuitManager provides a framework for
SSSs to collect the minimum data set required by the DH, plus any additional client and service information
thought to be useful locally. The research team includes the Director of the National Centre for Smoking
Cessation and Training (NCSCT), who has good links with North 51 and has been able to access their data
for previous research and training activities. We were therefore able to obtain QuitManager data for the
ELONS study in an anonymised form. This was important as by having access to these data made it
possible to examine individual-level information not available from the Health and Social Care Information
Centre returns. Data were available from 49 services in England. These data were analysed to fulfil
objectives 1 and 2, to examine the effectiveness and reach of services. Results from this first stage also
informed the selection of SSSs for the prospective cohort study.
The secondary analysis had two aims:
l to explore the reach of services by identifying the proportion of the local population who set a quit
date with services using routine data
l to examine the effectiveness of NHS SSSs by PCT and intervention type using routine data.
Sample
QuitManager32 is an online database for recording information on NHS SSS clients, including
sociodemographic and treatment characteristics, in accordance with the DH’s standard SSS monitoring
requirements. Collection of data starts at baseline (first contact with the SSS) and should be updated at
each contact point. The data are collected by the stop smoking practitioner and entered onto QuitManager
in ‘real time’ (via the computer software) or recorded on a paper form and entered at a later date. PCTs may
elect not to ask clients questions, and clients themselves may not answer every question, leading to missing
data. Within PCTs clients whose data are collected on paper forms may answer a slightly different set of
questions to those whose data are entered electronically.
At 4 weeks post quit date clients are asked whether or not they have quit smoking for the past 14 days
(self-report quit) and clients may also perform a CO breath test. Clients who have self-reported as quit and
have CO readings of < 10 p.p.m. are said to be CO validated as quit. The DH guidelines suggest 85% of
clients should be CO validated.33
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More than 60 out of the ≈ 150 English PCTs use QuitManager and 49 of these gave permission to the
NCSCT for their data to be used for research purposes. Thus, data from these 49 PCTs were included in
the analysis.
Data on clients who set quit dates from July to December 2010 were downloaded from QuitManager in
January 2012 and data on clients with quit dates between January and June 2011 were downloaded in
July 2011. In total there were 202,804 client records included in the database. Each record is a ‘treatment
episode’ where the client sets a quit data and receives treatment. It is possible for clients who relapse to
have more than one treatment episode in a year.33
Measures
Outcomes
Efficacy of services: quit rates and carbon monoxide-validation rate
There were three dependent variables explored: self-report quit, CO-validated quit and CO validation.
CO validation is the proportion of self-report quit who were also CO validated. We included CO-validated
quit because some clients may state they have quit when they have not quit. We included self-report quit
because some CO-validation rates vary so by using both of these outcomes, the results are rendered
more robust.
The DH considers clients to be quitters only if self-report data are collected between 25 and 42 days after
the quit date.33 Inspection of the QuitManager database suggested that this narrow range may be
underestimating the number of quitters, so all clients who self-reported as quit were included in
the analysis.
As outlined above, we adhered to the Russell Standard for smoking cessation analysis by taking an
intention-to-treat approach where clients with missing quit data were categorised as not quit.30 Clients
setting quit dates in December 2010 and June 2011 were therefore excluded from the analysis as they
would not have reached 4 weeks post quit date (when self-report quit and CO validation occurs) when the
data were downloaded. Thus, the months included were July–November 2010 and January–May 2011
(n= 19,481). Cases were also excluded from the main analysis if they were missing age (n= 201) and
gender (n= 43) because too few were missing to include as a separate category. Additionally, cases were
excluded if the practitioner who provided behavioural support was missing (n= 5573) because of the
multilevel structure of the data. Thus, the number of cases used in the bi-variable and multilevel
multivariable analysis of the efficacy of the services was 177,291.
Uptake: distribution of client groups and reach of services
In order to assess uptake we looked first at whether or not clients from all sociodemographic groups were
accessing the services and which service options clients were accessing.
To understand the reach of services it is necessary to know the target population: the number of smokers
in the PCT. Smoking is not asked in the UK census thus estimates have to be made from smoking rates
collected by government surveys and populations that have been updated from 2001 census data. The
most recent estimation of adult (≥ 16 years) smoking rates for PCTs was for 2003–5.34 These were based
on the Health Survey for England. Between 2004 and 2009 the smoking rate for Great Britain fell from
25% to 21%, thus PCT smoking rate estimates were reduced by 4% to estimate more recent smoking
rates. Mid-year adult (≥ 16 years) population estimates of PCTs were available for 2010. The population
multiplied by the smoking rate gave an estimate of the number of smokers in the PCT. These numbers
were compared with the number of QuitManager clients aged ≥ 16 years between July 2010 and
June 2011.
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There were some PCTs where this formula was not suitable. First, a few PCTs started using QuitManager or
gave permission for their data to be used after July 2010 so these PCTs were included only in the second data
download in July 2011. For these PCTs the number of clients was doubled to provide an estimate of the
annual number of clients. Second, one PCT had to a large extent merged with another and a population
estimate was available only for the overall area and a smoking rate estimate for the overall estimate was
calculated by taking the average of the two constituent PCTs. Third, a PCT was known to include only clients
who saw practitioners through the specialist service in QuitManager. Thus it was not possible to provide an
estimate of reach for this PCT. It is possible that other PCTs may not include all their clients on QuitManager.
So far, however, none of the other PCTs contacted regarding the prospective study have raised this as an issue.
Predictors
The data have a multilevel structure: clients received behavioural support interventions from practitioners
and practitioners are employed through SSSs. Originally each PCT had its own SSS although now some
PCTs have a joint SSS so a few practitioners worked for more than one PCT, usually where both PCTs had
a joint SSS.
The independent variables used cover client characteristics: age (divided into quartiles); gender (not pregnant
women, pregnant woman, men); ethnicity (white, black, Asian, mixed, other, unknown); SES (eligibility for
free prescriptions exempt, pays, unknown); National Statistics Socio-Economic Classification (NSSEC)35
(routine and manual occupation, intermediate occupation, managerial or professional occupation, retired or
caring for the home, sick or disabled and unable to work, never worked or long-term unemployed, in prison,
other); Index of Multiple Deprivation (IMD)36 (at PCT level) divided into quintiles of all English PCTs and quit
attempt related characteristics [month set quit date, treatment episode number (first, second, third, fourth or
more)]; medication (NRT alone, combination NRT, buproprion, varenicline, mixed medications, and other
or no medication); intervention type (one to one, drop-in, open/rolling group, closed group, other); and
practitioner type (specialist SSS practitioner employed by SSSs, practitioner who does cessation advice work
as part of their role divided into GP, nurse, health-care practitioner, pharmacy employee, and other
and unknown).
Impact: throughput and quitters per 100,000 population
Colleagues from University College London and the UK NCSCT have developed the methodology for
measuring impact. Impact is calculated as ‘throughput’ (number of treated smokers per 100,000 adult
population)× [percentage successfully quit at 4 weeks – 25 (if CO-verified quit or – 35 if self-report quit)]/100.
The number of quitters is expressed per 100,000 of the population, not per 100,000 of the smoking
population. The reason for CO-verified quit minus 25 being used in the calculation is that 25% of smokers
trying to quit are estimated to be CO-verified quit at 4 weeks unaided or by use of medication alone without
behavioural support. For self-reported quits minus 35 is used because of average differences between SSS
self-report and CO-validated quit rates.
Owing to first to marked differences between CO-validation rates of PCTs and second to different services
having a negative impact depending on whether or not the CO-validated or the self-report quit rate was
used in the calculation, for this report an overall impact score was calculated. The overall impact score was
the average of the CO-validated impact score and the self-report impact score.
To estimate impact on the population, unique clients were used rather than client records. The client
records were aggregated so that for clients who had more than one record their age and quit status at
their most recent episode at the SSS was used.
It was not possible to calculate impact for some PCTs and for others there were caveats, generally this was
where there were issues in calculating uptake. Additionally, the unique patient identifier was of poor
quality for four PCTs. For a further three PCTs, clients were included only in the second data download so
to estimate impact the number of client records was doubled. This may be an overestimate of client
records and it would be expected that some clients from the first 6 months would have revisited the
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services in the second 6 months so it may also be an overestimate of unique clients. Thus, these three
PCTs were excluded from statistical summaries of impact data although impact data was calculated
for them.
Analytic approach
The analyses were carried out using SPSS [SPSS version 19.0 (SPSS Inc., Armonk, NY, USA) and PASW
version 18.0.3 (SPSS Inc., Chicago, IL, USA)]; Microsoft Excel® 2010 (Microsoft Corporation, Redmond,
WA, USA); Stata (StataCorp LP, College Station, TX, USA) and MlwiN version (MLwiN, Centre for Multilevel
Modelling, Bristol, UK) as follows.
See Table 3 for overall quit rates and validation rates for all clients and then for clients where their age,
gender and practitioner were identified. Uptake (distribution), quit rates and CO-validation rates for
subgroups of these clients with various client and quit attempt-related characteristics are presented.
Chi-squared was used to assess significance.
Second, a descriptive table (see Table 4) provides further information about the PCTs. Each row represents
a different PCT. It includes the number of practitioners within each PCT, the number of clients per PCT
(throughout the year) and the average number of clients per practitioner (clients/practitioner) in addition to
estimates of the smoking rate, population, clients aged over 16 years and reach of services of each PCT.
The analysis included a large number of predictors and three measures of SES, so in order to assess
potential multicollinearity in multivariable models, the variance inflation factor (vif) and corresponding
tolerance were calculated from a logistic regression using interaction expansion (part of the Stata xi suite).
In this xi suite analysis, PCT was entered as a cluster variable and practitioner was entered as an
explanatory variable as only one cluster variable is allowed.
Multilevel modelling (see Tables 5 and 6) allows PCT and practitioner to be treated as separate levels in the
analysis – otherwise known as random effects. Thus there were three levels in the models: client (level 1),
practitioner (level 2) and PCT (level 3). Other independent variables were entered as fixed effects.
Practitioner types were entered as a level 2 fixed effects, IMD quintiles of the PCT entered as level 3 fixed
effects and all other fixed effects were at client level. MLwiN second order penalised quasi-likelihood
iterative generalised least squares (IGLS) estimation was used for the analysis.
Odds ratios (ORs) are reported for self-report quit, CO-validated quit and CO validation. Some changes
were made to the predictors for the multilevel analysis. So that practitioner should completely nest within
a PCT, PCTs that shared practitioners were merged. There were 63 practitioners who worked in more than
one PCT. The IMD score was then recoded for the new merged PCTs so that it was the average of both
PCTs taking into account the number of clients contributed by each PCT.
In preliminary analysis (not shown) MLwiN IGLS multilevel models were compared with Stata Survey Suite
models. Anomalous results were explored further using SPSS crosstabulations, Stata xt and MLwiN Markov
chain Monte Carlo. Full models did not converge in either Stata xt or MLwiN Markov chain Monte Carlo.
However, the results that were produced tended to support IGLS results; thus only MLwiN IGLS models are
presented here.
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Ideally we would look at how much variance of the higher levels was explained by the fixed variables;
however, when a binary outcome is modelled and there is more than one higher level, it is not possible to
calculate because the level 1 variance is always constrained to be 3.29.37 Thus the impact observed on the
higher-level variances from adding a fixed-effect variable to the model may be because of the overall
variance changing to allow for the addition of the variable since the level 1 variance cannot change, rather
than because the new variable in the model has explained the higher-level variance.38,39 It is not currently
possible to accurately estimate how much of the change is caused by real changes in variance and
how much is caused by the constrained level 1 variance (Yang M, University of Nottingham, 2012,
personal communication).
The higher-level variance is shown later in the report (see Table 7). The first and second columns show
higher-level variance in the CO-validated modelling. The first column displays PCT-level variance and the
second column displays practitioner-level variance. The next two columns show variance for the self-report
modelling and the other columns show higher-level variance for the CO-validation modelling with or
without exclusions of extreme PCTs (see Table 4). The first row displays variance in null models with no
fixed effects entered. The subsequent rows display variance when fixed effects are entered one at a time
so there is only one fixed effect in a model. The final row displays variance for the multivariable model
when all fixed effects are entered. PCTs with significantly below and above average residuals
were identified.
Residuals for the PCTs were calculated and graphed using caterpillar plots.
For measures of impact by PCT, see Table 8. Each row represents a different PCT. Throughput (numbers
setting a quit date per 100,000 population), CO-validated and self-report quit rates for all unique clients
age 16 years or over, impact (numbers of 4-week quitters per 100,000 population) calculated using
CO-validated quits only, all self-report quits and overall (average of previous two impacts) are shown and
the results are also presented in a graphical format. Summary measures of unique patients, quit rates,
throughput and impact, and correlations between them are provided (see Table 9).
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Chapter 4 Secondary analysis of routine data:
findings
As described in Chapter 3, the first part of the ELONS study involved secondary analysis of data fromclients who had used SSSs in 49 of 150 PCTs in England. These PCTs’ SSSs used the QuitManager
database to record and report on their routine data.
The results are ordered by topic: uptake, quitting and CO validation. Under uptake we consider client
distribution of client characteristics and estimates of the percentage of each PCT’s smoking population that
were using the service. Under quitting we discuss self-report quit and CO-validated quit in bivariable and
multivariable multilevel models, and finally we explore the proportion of self-reported quit who were CO
validated (CO validation) in bivariable and multivariable multilevel models. Please note that in addition, we
have already published a paper based on this work,26 which had a particular focus on the relationship
between SES and the types of behavioural support offered by the services.
Uptake
Table 3 shows which groups of clients were more or less common among service users and the service
options that they were more or less likely to use.
TABLE 3 Distribution of client characteristics (uptake) and 4-week self-report and CO-validated quit rates, and
CO-validation rate
Client characteristics
4-week quit rates CO-validation rate
n %
Self-report
quit,
% (p-value)
CO-validated
quit, % (p-value)
Self-report
quit, n
Self-reports
CO-validated,
% (p-value)
Total: intention-to-treat
quit available (December
and June starts excluded)
182,603 100.0 44.1 30.7 89,085 73.9
Total: intention-to-treat
quit and age, gender,
practitioner identifieda
177,291 100.0 48.8 34.1 86,512 74.3
Age quartiles (years)
< 30 44,968 25.4 39.2 24.9 17,647 68.2
31–42 47,719 26.9 49.6 34.4 23,651 73.6
45–53 40,410 22.8 50.7 36.2 20,485 75.8
≥ 54 44,194 24.9 56.0 41.4 24,729 78.1
p-value – – < 0.001 < 0.001 – < 0.001
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TABLE 3 Distribution of client characteristics (uptake) and 4-week self-report and CO-validated quit rates, and
CO-validation rate (continued )
Client characteristics
4-week quit rates CO-validation rate
n %
Self-report
quit,
% (p-value)
CO-validated
quit, % (p-value)
Self-report
quit, n
Self-reports
CO-validated,
% (p-value)
Gender
Female (not pregnant) 88,246 49.8 48.1 33.9 42,451 74.9
Female (pregnant) 5650 3.2 45.8 26.5 2585 62.0
Male 83,395 47.0 49.7 34.9 41,476 74.5
p-value – – < 0.001 < 0.001 – < 0.001
Ethnic origin
White 158,377 89.3 49.3 34.6 5237 74.0
Black, Asian, mixed,
other
12,165 6.9 43.1 30.9 78,149 74.6
Unknown 6749 3.8 46.3 28.4 3126 67.1
p-value – – < 0.001 < 0.001 – < 0.001
Occupation
Routine and manual 43,741 24.7 51.7 36.1 22,621 74.0
Intermediate 13,376 7.5 54.2 36.6 7251 70.7
Managerial and
professional
23,661 13.4 56.6 39.6 13,400 75.0
Retired or home care 32,388 18.3 54.4 39.7 17,627 77.5
Sick or disabled and
unable to work
11,852 6.7 41.7 28.5 4943 73.2
Never worked or
long-term unemployed
24,512 13.8 38.8 27.0 9520 73.6
In prison 2223 1.3 48.0 42.4 1066 90.0
Other 25,538 14.4 39.5 26.0 10,084 70.6
p-value – – < 0.001 < 0.001 86,512 < 0.001
Prescription charges
Exempt 104,304 58.8 46.2 33.0 48,194 75.8
Pays 56,903 32.1 54.2 38.1 30,843 74.5
Unknown 16,084 9.1 46.5 27.2 7475 63.8
p-value – – < 0.001 < 0.001 – < 0.001
Average IMD 2010 score (PCT)
≤ 30 49,101 27.7 44.3 30.1 21,757 72.7
31–60 25,695 14.5 48.5 37.0 12,457 80.7
61–90 22,123 12.5 49.9 35.8 11,031 72.8
91–120 40,793 23.0 50.4 36.9 20,539 76.8
≥ 121 39,579 22.3 52.4 33.5 20,728 70.5
p-value – – < 0.001 < 0.001 – < 0.001
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TABLE 3 Distribution of client characteristics (uptake) and 4-week self-report and CO-validated quit rates, and
CO-validation rate (continued )
Client characteristics
4-week quit rates CO-validation rate
n %
Self-report
quit,
% (p-value)
CO-validated
quit, % (p-value)
Self-report
quit, n
Self-reports
CO-validated,
% (p-value)
Month set quit date
July 2010 15,244 8.6 46.4 31.4 7066 72.9
August 2010 13,892 7.8 48.0 32.8 6670 73.7
September 2010 14,765 8.3 49.5 33.8 7314 73.6
October 2010 15,535 8.8 49.3 33.7 7654 74.1
November 2010 13,901 7.8 48.2 30.3 6694 69.8
January 2011 26,924 15.2 52.9 38.8 14,242 76.4
February 2011 22,565 12.7 51.4 36.9 11,595 75.0
March 2011 22,490 12.7 47.8 33.7 10,740 73.8
April 2011 17,221 9.7 47.4 33.6 8161 75.6
May 2011 14,754 8.3 43.2 31.2 6376 75.5
p-value – – < 0.001 < 0.001 – < 0.001
Treatment episode
Episode 1 114,369 64.5 48.5 34.3 55,420 75.0
Episode 2 36,154 20.4 49.1 33.5 17,748 72.7
Episode 3 14,391 8.1 49.6 33.9 7134 73.6
Episode 4 or more 12,377 7.0 50.2 34.9 6210 74.0
p-value – – < 0.001 0.0 – 0.003
Medication used
Single NRT 40,607 22.9 37.5 25.4 15,222 74.0
Combination NRT 67,703 38.2 49.7 37.0 33,646 78.1
Bupropion only 1129 0.6 52.1 32.9 588 69.7
Varenicline only 45,149 25.5 60.2 43.0 27,167 75.8
Mixed NRT/bupropion/
varenicline
4479 2.5 46.6 34.3 2085 76.6
No medication or
missing
18,224 10.3 42.8 21.0 7804 52.9
p-value – – < 0.001 < 0.001 – < 0.001
Intervention type
One to one 140,119 79.0 47.6 33.8 66,621 74.5
Drop-in clinic 24,736 14.0 50.7 33.3 12,550 74.8
Open (rolling) group 4780 2.7 65.5 52.1 3130 85.3
Closed group 2512 1.4 63.5 50.1 1595 80.9
Other or missing 5144 2.9 50.9 23.3 2616 49.8
p-value – – < 0.001 < 0.001 – < 0.001
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Client characteristics
There were slightly more women setting quit dates than men, with 3.2% of clients pregnant at the time of
data entry. Seven per cent of clients were from ethnic minorities, although 4% of client ethnicities are
unknown. One-quarter of the clients were under 30 years and one-quarter were aged ≥ 54 years. A large
proportion was exempt from paying prescription charges (58.8%), and for 9% this information was
unavailable. The largest category of occupation in the sample was routine and manual (24.4%), with the
second largest being retired or home carer (18.1%). There were over 2000 prisoners who set quit dates.
Service type characteristics
Between 13,000 and 27,000 clients set quit dates each month. The highest numbers of clients set quit
dates in January to March and the lowest numbers were in August and November. The PCTs providing
client data were fairly evenly divided by disadvantage. The majority of clients (64.5%) had not used the
SSS previously (treatment episode 1). Combination NRT (more than one type of NRT) was the most
commonly used medication (38.2%). Less than 1% used bupropion alone. Among intervention types,
one-to-one behavioural support was by far the most common (79%) whereas only 14% took part in
drop-ins, 2.7% took part in open/rolling groups and 1.4% were members of closed groups. Practitioner
type had a large proportion of missing values (41.8%), so it was not possible to assess how accurately the
proportions of the other categories reflect the distribution of practitioner types, however, the largest
category displayed was specialist practitioner at 31.4%.
Each row in Table 4 displays information about a different PCT. For each of these, the first column displays
information on the number of practitioners within each PCT (ranging from 14–334). The subsequent
column shows the number of clients seen in each PCT with practitioner identified and this is followed by an
average of clients per practitioners for each PCT (ranging from 8–310). There was variation in the number
of practitioners recorded by the PCTs (from 20–300). In some PCTs it appeared that practitioners
saw over 250 clients on average whereas in others practitioners saw fewer than 10 clients each.
TABLE 3 Distribution of client characteristics (uptake) and 4-week self-report and CO-validated quit rates, and
CO-validation rate (continued )
Client characteristics
4-week quit rates CO-validation rate
n %
Self-report
quit,
% (p-value)
CO-validated
quit, % (p-value)
Self-report
quit, n
Self-reports
CO-validated,
% (p-value)
Practitioner type
Specialist 55,603 31.4 55.6 37.7 30,902 74.6
GP 3535 2.0 45.1 34.9 1593 78.7
Nurse 18,091 10.2 42.3 28.3 7660 69.5
Health-care assistant 7070 4.0 45.4 35.2 3206 80.4
Pharmacy 18,890 10.7 40.6 29.7 7670 76.5
Other or unknown 74,102 41.8 47.9 33.9 35,481 73.9
p-value – – < 0.001 < 0.001 – < 0.001
Total 177,291 100.0 < 0.001 < 0.001 86,512 < 0.001
a ‘Intention to treat’ refers to missing cases included as not quit. ‘Age, gender, practitioner identified’ indicates that cases
missing one or more of these characteristics were excluded from analysis.
Source: QuitManager (completed treatment episodes between 1 January 2011 and 30 June 2011, excluding quit dates set
in December 2010 and June 2011).
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TABLE 4 Primary care trusts characteristics (each row is a different PCT)
Number of
practitioners in
QuitManager
database
Clients with
practitioner
identified,
July 2010–
June 2011
Mean clients
per practitioner
Estimated PCT
smoking rate (%)
in 2003–5 aged
≥ 16 years
(95% CI)a
Estimated
population
2010 aged
≥ 16 yearsb
SSS clients
aged
≥ 16 years,
July 2010–
June 2011c
Estimate
of PCT
smokers
reached
(%)d
77 2876 37.4 32.1 (28.0 to 36.5) 135,000 2849 7.5
106 2673 25.2 27.8 (24.1 to 31.9) 182,100 2659 6.1
15 4398 293.2 24.9 (22.1 to 28.0) 315,500 6132 9.3
22 5441 247.3 24.9 (22.1 to 28.0) 278,200 5400 9.3
137 6635 48.4 30.3 (27.4 to 33.4) 114,300 6597 21.9
74 4000 54.1 20.1 (18.6 to 21.7) 259,300 4000 9.6
256 5887 23.0 24.8 (22.0 to 27.7) 368,300 5868 7.7
121 2546 21.0 21.9 (19.0 to 25.2) 251,200 2584 5.7
95 6236 65.6 19.6 (18.5 to 20.8) 373,100 6164 10.6
302 10,038 33.2 25.0 (23.6 to 26.5) 422,400 10,083 11.3
58 1662 28.7 27.9 (24.7 to 31.5) 81,400 1683 8.6
128 4573 35.7 26.8 (24.3 to 29.5) 255,200 4576 7.9
276 3804 13.8 25.0 (22.4 to 27.8) 199,700 3769 9.0
44 7229 164.3 23.5 (22.4 to 24.5) 599,500 7097 6.1
177 3113 17.6 18.6 (16.5 to 20.9) 256,600 3125 8.3
83 2862 34.5 21.2 (19.1 to 23.6) 282,000 2834 5.8
87 1936 22.3 14.5 (11.9 to 17.5) 185,400 1965 10.1
102 3573 35.0 24.9 (22.1 to 28.0) 215,500 3718 8.2
332e 8203 24.7 22.9 (21.8 to 24.1) – – –
334e 6293 18.8 19.8 (18.7 to 21.0) – – –
–
e
– – 21.4 (20.3 to 22.6) 886,500 14,512 8.8
188 3689 19.6 28.2 (25.8 to 30.7) 161,600 3626 9.3
95 3861 40.6 22.0 (19.4 to 24.9) 190,100 3942 11.5
73 4878 66.8 40.9 (36.4 to 45.5) 217,100 4824 6.0
131 3432 26.2 27.5 (22.9 to 32.6) 163,100 3708 9.7
81 1154 14.2 18.8 (14.4 to 24.2) 141,800 1963 9.4
79 637 8.1 21.7 (18.7 to 24.9) 138,400 619 2.5
142 4993 35.2 30.1 (26.1 to 34.4) 243,300 4921 7.8
228 7400 32.5 21.9 (20.8 to 22.9) 564,000 7286 7.2
100 2996 30.0 26.8 (24.1 to 29.7) 212,600 2985 6.1
280 10,778 38.5 23.3 (22.2 to 24.5) 583,300 10,634 9.4
43 1493 34.7 24.6 (22.0 to 27.3) 128,100 1487 5.6
123 3111 25.3 18.4 (16.4 to 20.6) 173,900 3115 12.4
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TABLE 4 Primary care trusts characteristics (each row is a different PCT) (continued )
Number of
practitioners in
QuitManager
database
Clients with
practitioner
identified,
July 2010–
June 2011
Mean clients
per practitioner
Estimated PCT
smoking rate (%)
in 2003–5 aged
≥ 16 years
(95% CI)a
Estimated
population
2010 aged
≥ 16 yearsb
SSS clients
aged
≥ 16 years,
July 2010–
June 2011c
Estimate
of PCT
smokers
reached
(%)d
21 6518 310.4 25.9 (24.6 to 27.1) 550,800 12,920f 10.7
36 2215 61.5 33.5 (29.7 to 37.4) 128,400 2207 5.8
62 5060 81.6 36.2 (32.1 to 40.6) 256,600 4994 6.0
27 5268 195.1 29.0 (26.4 to 31.8) 171,100 5203 12.1
89 1273 14.3 17.6 (15.1 to 20.3) 211,600 1532 5.3
63 582 9.2 19.3 (16.1 to 23.0) 152,900 573 2.4
130 5105 39.3 25.3 (22.6 to 28.1) 205,800 5013 11.5
14 459 32.8 29.0 (26.1 to 32.0) 230,900 1754 3.0
113 4224 37.4 21.3 (20.2 to 22.5) 241,500 4163 10.0
21 603 28.7 21.1 (20.0 to 22.2) 429,700 1356f NA
268 4155 15.5 24.5 (22.9 to 26.2) 275,500 8254f 14.6
90 1774 19.7 27.7 (24.2 to 31.5) 236,500 1772 3.2
75 3562 47.5 25.2 (22.7 to 27.9) 129,500 3501 12.7
113 2100 18.6 25.8 (23.4 to 28.4) 203,200 4140f 9.3
293 3937 13.4 21.3 (20.2 to 22.5) 438,000 7798f 10.3
93 4099 44.1 21.7 (20.3 to 23.1) 193,000 4061 11.9
6040 196,511 32.5 (average) – – – –
CI, confidence interval; NA, not available.
a Estimated smoking rates based on the Health Survey for England.34
b Estimated mid-year PCT population estimate 2010.40
c From QuitManager.
d Derived from (population estimate in 2010/100)× [% smoking estimate – 4% (because of the decline in smoking
since 2003–541)].
e Population data were available only for a county, whereas SSS data were available for constituent PCTs.
f PCT contributed to only second data download so clients for whole year estimated by doubling client numbers achieved
in January–June 2011.
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Reach of services by primary care trust
Estimated smoking rates varied from 15% to 41%. PCT populations varied from 80,000 to nearly
900,000. Most services saw between 5% and 10% of their population of smokers between July 2010 and
June 2011. Note that smoking estimates were accompanied by confidence intervals (CIs) of approximately
6% thus these should be treated with caution.
Cessation
Bivariable results
The overall quit rates of the entire database (see Table 3) without exclusions for missing data in the
gender, age or practitioner type variables were 44.1% (self-report) and 30.7% (CO validated). The quit
rates of the sample used in the analysis were 48.8% (self-report) and 34.1% (CO validated).
The SSSs target is at least 35% for self-report and CO-validated quit.33 Overall, the self-report quit rate
comfortably passed this level and the CO-validated quit rate almost reached this level. Three PCTs did not
reach the 35% target for self-report quitting. Some subgroups met this target for CO-validated quitting,
they were: clients who were working or who were retired or caring for the home, prisoners, clients who
paid for prescriptions, clients in PCTs who were not particularly disadvantaged or affluent, clients who set
quit dates in January or February, clients who took combination NRT or just varenicline, clients who
attended groups and clients whose practitioner was a specialist or a health-care assistant. Of the 49 PCTs,
28 met this target for CO-validated quitting.
Multivariable results
Multivariable modelling in Stata indicated the extent of multicollinearity. All vifs were below 2.54 for
self-reported and CO-validated models so there was no significant multicollinearity in the data (concerns
are raised if a vif is ≥ 10). Multilevel multivariable ORs for client variables are presented in Table 5 and ORs
of quit attempt-related variables are presented in Table 6.
TABLE 5 Multilevel multivariable ORs (95% CI) of CO-validated quit, self-report quit and CO validation: client
characteristic fixed effects
Outcome
Self-report quit,
OR (95% CI)
(n= 177,291)
CO-verified quit,
OR (95% CI)
(n= 177,291)
CO validation,
OR (95% CI)
(n= 86,512)
CO validation,
OR (95% CI)
(n= 80,002)
Exclusions – – – Extreme PCTsa
Null model (constant) 0.34 (0.27 to 0.43) 0.13 (0.09 to 0.19) 1.58 (0.77 to 3.25) 1.69 (0.98 to 2.90)
Age (years) at quit date quartiles
10–30 1 1 1 1
31–42 1.44 (1.40 to 1.48) 1.53 (1.48 to 1.58) 1.29 (1.22 to 1.35) 1.34 (1.27 to 1.41)
43–53 1.54 (1.49 to 1.59) 1.73 (1.67 to 1.79) 1.48 (1.40 to 1.57) 1.60 (1.51 to 1.69)
54–100 2.02 (1.96 to 2.09) 2.28 (2.20 to 2.37) 1.69 (1.60 to 1.80) 1.87 (1.76 to 1.99)
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TABLE 5 Multilevel multivariable ORs (95% CI) of CO-validated quit, self-report quit and CO validation: client
characteristic fixed effects (continued )
Outcome
Self-report quit,
OR (95% CI)
(n= 177,291)
CO-verified quit,
OR (95% CI)
(n= 177,291)
CO validation,
OR (95% CI)
(n= 86,512)
CO validation,
OR (95% CI)
(n= 80,002)
Gender
Female (not pregnant) 1 1 1 1
Female (pregnant) 1.29 (1.20 to 1.38) 1.16 (1.07 to 1.26) 0.93 (0.82 to 1.05) 0.87 (0.77 to 1.00)
Male 1.07 (1.04 to 1.09) 1.04 (1.02 to 1.07) 0.97 (0.94 to 1.01) 0.97 (0.93 to 1.00)
Ethnicity
Black, Asian, mixed, other 1 1 1 1
White 1.02 (0.98 to 1.07) 1.04 (0.99 to 1.09) 1.05 (0.97 to 1.13) 1.05 (0.97 to 1.14)
Unknown 1.02 (0.95 to 1.09) 0.96 (0.89 to 1.03) 0.90 (0.80 to 1.02) 0.89 (0.79 to 1.01)
NSSEC
Routine and manual 1 1 1 1
Intermediate 1.14 (1.10 to 1.19) 1.09 (1.04 to 1.14) 0.96 (0.89 to 1.03) 0.96 (0.89 to 1.03)
Managerial and professional 1.19 (1.15 to 1.24) 1.14 (1.10 to 1.18) 1.02 (0.97 to 1.08) 1.02 (0.96 to 1.09)
Retired or home carer 1.07 (1.03 to 1.11) 1.06 (1.02 to 1.11) 1.02 (0.96 to 1.09) 1.02 (0.96 to 1.09)
Sick or disabled and unable
to work
0.70 (0.67 to 0.73) 0.70 (0.67 to 0.74) 0.85 (0.78 to 0.93) 0.83 (0.76 to 0.90)
Always/long-term
unemployed
0.75 (0.72 to 0.78) 0.76 (0.73 to 0.79) 0.96 (0.90 to 1.02) 0.94 (0.88 to 1.01)
In prison 1.15 (1.00 to 1.32) 1.98 (1.71 to 2.29) 3.82 (2.92 to 4.98) 4.84 (3.61 to 6.47)
Other 0.84 (0.81 to 0.87) 0.82 (0.78 to 0.85) 0.91 (0.85 to 0.97) 0.89 (0.83 to 0.96)
Prescription payment
Exempt 1 1 1 1
Pays 1.24 (1.21 to 1.27) 1.18 (1.14 to 1.21) 0.98 (0.93 to 1.02) 0.97 (0.93 to 1.02)
Unknown 1.08 (1.03 to 1.13) 0.92 (0.88 to 0.97) 0.84 (0.78 to 0.90) 0.80 (0.74 to 0.86)
Average IMD score 2010 (PCT)
Ranked 1–30 (disadvantaged) 1 1 1 1
Ranked 31–60 1.20 (0.85 to 1.69) 1.58 (0.91 to 2.77) 3.61 (1.14 to
11.47)
1.67 (0.72 to 3.86)
Ranked 61–90 1.29 (0.88 to 1.89) 1.34 (0.72 to 2.51) 0.61 (0.17 to 2.19) 0.60 (0.25 to 1.45)
Ranked 91–120 1.25 (0.92 to 1.70) 1.43 (0.88 to 2.35) 1.34 (0.49 to 3.67) 1.19 (0.59 to 2.42)
Ranked ≥ 121 (affluent) 1.36 (0.96 to 1.91) 1.61 (0.92 to 2.81) 1.06 (0.34 to 3.33) 1.01 (0.45 to 2.22)
a Three PCTs with particularly high or low CO-validation rates were excluded.
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TABLE 6 Multilevel multivariable ORs (95% CI) of CO-validated quit, self-report quit and CO validation:
quit attempt-related fixed effects
Outcome
Self-report quit,
OR (95% CI)
(n= 177,291)
CO-verified quit,
OR (95% CI)
(n= 177,291)
CO validation,
OR (95% CI)
(n= 86,512)
CO validation,
OR (95% CI)
(n= 80,002)
Exclusions – – – Extreme PCTsa
Quit date month
July 2010 1 1 1 1
August 2010 1.04 (0.99 to 1.09) 1.04 (0.99 to 1.10) 1.05 (0.96 to 1.15) 1.05 (0.96 to 1.15)
September 2010 1.14 (1.08 to 1.20) 1.11 (1.05 to 1.17) 1.02 (0.93 to 1.11) 1.02 (0.93 to 1.11)
October 2010 1.10 (1.05 to 1.16) 1.08 (1.02 to 1.14) 1.01 (0.92 to 1.09) 1.00 (0.91 to 1.09)
November 2010 1.02 (0.97 to 1.07) 0.88 (0.84 to 0.93) 0.82 (0.75 to 0.89) 0.77 (0.71 to 0.85)
January 2011 1.33 (1.27 to 1.39) 1.34 (1.28 to 1.41) 1.11 (1.02 to 1.19) 1.11 (1.03 to 1.21)
February 2011 1.17 (1.12 to 1.22) 1.19 (1.14 to 1.25) 1.06 (0.98 to 1.15) 1.06 (0.97 to 1.15)
March 2011 1.02 (0.98 to 1.07) 1.04 (0.99 to 1.09) 0.98 (0.90 to 1.06) 0.96 (0.88 to 1.05)
April 2011 0.96 (0.91 to 1.01) 1.02 (0.97 to 1.08) 1.08 (0.99 to 1.17) 1.08 (0.99 to 1.18)
May 2011 0.85 (0.81 to 0.89) 0.97 (0.91 to 1.02) 1.08 (0.99 to 1.19) 1.10 (1.00 to 1.21)
Episode
Episode 1 1 1 1 1
Episode 2 0.97 (0.94 to 0.99) 0.97 (0.94 to 0.99) 1.00 (0.96 to 1.05) 1.00 (0.95 to 1.05)
Episode 3 1.00 (0.96 to 1.04) 0.98 (0.94 to 1.03) 1.00 (0.94 to 1.07) 0.99 (0.93 to 1.07)
Episode 4 or more 1.04 (1.00 to 1.08) 1.04 (1.00 to 1.09) 1.05 (0.98 to 1.13) 1.04 (0.96 to 1.13)
Medication
Single NRT 1 1 1 1
Combination NRT 1.88 (1.83 to 1.94) 2.06 (2.00 to 2.13) 1.55 (1.47 to 1.65) 1.66 (1.56 to 1.76)
Bupropion only 1.79 (1.58 to 2.03) 1.48 (1.29 to 1.69) 0.97 (0.79 to 1.20) 0.96 (0.77 to 1.18)
Varenicline only 2.57 (2.49 to 2.65) 2.31 (2.24 to 2.40) 1.31 (1.23 to 1.39) 1.37 (1.29 to 1.45)
Mixed NRT/bupropion/
varenicline
1.46 (1.37 to 1.57) 1.64 (1.53 to 1.76) 1.46 (1.30 to 1.65) 1.55 (1.37 to 1.76)
No medication or missing 1.13 (1.08 to 1.18) 0.80 (0.76 to 0.84) 0.74 (0.68 to 0.80) 0.68 (0.63 to 0.74)
Intervention type
One to one 1 1 1 1
Drop-in clinic 0.96 (0.91 to 1.01) 1.02 (0.96 to 1.07) 1.01 (0.93 to 1.10) 0.97 (0.89 to 1.06)
Open (rolling) group 1.15 (1.04 to 1.27) 1.28 (1.15 to 1.41) 1.39 (1.18 to 1.64) 1.45 (1.23 to 1.73)
Closed group 1.12 (1.00 to 1.26) 1.11 (0.99 to 1.24) 1.15 (0.96 to 1.37) 1.16 (0.96 to 1.39)
Other or missing 1.12 (1.03 to 1.21) 0.62 (0.57 to 0.68) 0.46 (0.40 to 0.51) 0.41 (0.36 to 0.46)
SSS practitioner
Specialist 1 1 1 1
GP 0.46 (0.38 to 0.55) 0.53 (0.42 to 0.66) 1.15 (0.83 to 1.61) 1.43 (0.97 to 2.10)
Nurse 0.58 (0.52 to 0.64) 0.70 (0.62 to 0.78) 1.11 (0.95 to 1.29) 1.19 (0.99 to 1.43)
Health-care assistant 0.69 (0.60 to 0.78) 0.86 (0.74 to 0.99) 1.29 (1.05 to 1.58) 1.42 (1.11 to 1.80)
Pharmacy 0.67 (0.61 to 0.73) 0.91 (0.82 to 1.02) 1.80 (1.55 to 2.10) 2.20 (1.84 to 2.64)
Other or unknown 0.78 (0.72 to 0.84) 0.88 (0.80 to 0.97) 1.25 (1.10 to 1.41) 1.34 (1.16 to 1.55)
a Three PCTs with particularly high or low CO-validation rates were excluded.
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The results for CO-validated quit and self-report quit are mostly similar so they are discussed
simultaneously with differences alluded to. Generally unknown and other classifications were associated
with less chance of quitting than reference groups.
Demography
The relationship between client-related characteristics and CO-validated or self-report quits were mostly
similar. As age increased so did the chances of quitting. Clients aged over 53 years were twice as likely to
quit as those age 30 years or under. Men and pregnant women were more likely to quit than non-pregnant
women. In the bivariable results pregnant women had the lowest quit rate. Further exploration (not shown)
suggested that the change in the multivariable results was attributed to pregnant women being less likely to
take medication. Ethnicity was not significantly related to quitting.
Socioeconomic status
Compared with clients with routine and manual occupations, clients with intermediate, managerial and
professional occupations, the retired, home carers and prisoners were more likely to quit. Those who paid
for prescriptions were more likely to quit than those who were exempt. PCT deprivation was not
significantly related to quitting.
Stop Smoking Service related
September, January and February appeared to be particularly successful months for setting a quit date with
a SSS. Lower chances of quitting in May and November might partly be because of late quit information
not being included in the database owing to cut off points at the end of December and June. However,
differences between these months and the other months were not always significant, suggesting this had
a minimal effect. Clients who had used the service once before were less likely to quit than those who had
never used the service before and those who had used the service four or more times were more likely to
quit. Taking any medication other than single NRT increased the chances of quitting. The highest ORs were
for clients who took varenicline alone. These people were more than twice as likely to self-report and CO
validate as quit.
For intervention type, the highest chances of quitting were among clients who took part in open/rolling
groups. Closed-group clients were significantly more likely to self-report as quit than those who undertook
one-to-one counselling but the difference did not quite reach significance for CO validation. Further
analysis (not shown) suggested this was caused by a number of factors such as the practitioner, SES
and medication.
Among the practitioner types, clients of specialist advisers were more likely to quit than clients of other
(and unspecified) practitioner types. This difference was significant for all categories except for CO
validation among practitioners who held pharmacy posts. ORs were surprisingly low for GPs given
bivariable results. Further analysis (not shown) suggested this was because the majority of GPs worked in
one PCT (Warwickshire) where quit rates were similar to other practitioner types, but in most other PCTs,
with more than 20 clients seen by GPs, GPs were achieving fewer CO-validated quits than other
practitioner types.
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Primary care trust and practitioner
Figure 2 is a caterpillar plot of PCT residuals for the multilevel multivariable model of self-report quit. PCT
CIs that do not overlap 0.0 represent significant departures from the average. The lowest chances of
self-reported quitting were found in the PCT ranked 1.
Figure 3 is a caterpillar plot of PCT residuals for CO-validated quit. PCT CIs that do not overlap 0.0
represent significant departures from the average. Further exploration (not shown) suggested that
excluding clients from the lowest ranked PCT made little difference to the results.
There is little that can be said with certainty about the higher-level variance (Table 7), as it is not possible
to tell how much of the change in variance between models is owing to fixed effects in the model and
how much is the result of level one variance being constrained to 3.29, leading to inflated or deflated
higher level variance.
We can safely say that there was significant variance between practitioners and between PCTs even after
all fixed effects had been included for both self-report and CO-validated quit. It is probably also safe to
say that there was less variance between PCTs and between practitioners for self-report quits than
CO-validated quits.
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FIGURE 2 Residual caterpillar plot of PCTs for multivariable multilevel model of self-report quits.
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FIGURE 3 Residual caterpillar plot of PCTs for multivariable multilevel model of CO-validated quits.
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TABLE 7 Primary care trust-level and practitioner-level variance for models with no fixed effects, one fixed effect
and all fixed effects
Models
CO validated Self-report CO validation
PCT variance
(95% CI)
Practitioner
variance
(95% CI)
PCT variance
(95% CI)
Practitioner
variance
(95% CI)
PCT variance
(95% CI)
Practitioner
variance
(95% CI)
No fixed effects
Null model
(constant)
0.36
(0.20 to 0.53)
0.54
(0.51 to 0.58)
0.14
(0.07 to 0.20)
0.41
(0.38 to 0.43)
1.83
(1.03 to 2.63)
1.32
(1.23 to 1.42)
One fixed effect
Quit date month 0.36
(0.20 to 0.52)
0.54
(0.51 to 0.58)
0.14
(0.07 to 0.20)
0.41
(0.38 to 0.43)
1.83
(1.02 to 2.64)
1.33
(1.23 to 1.42)
Age (years) at quit
date quartiles
0.38
(0.21 to 0.55)
0.55
(0.51 to 0.58)
0.14
(0.08 to 0.21)
0.40
(0.38 to 0.43)
1.84
(1.03 to 2.65)
1.35
(1.25 to 1.44)
Gender 0.36
(0.20 to 0.53)
0.54
(0.51 to 0.57)
0.14
(0.07 to 0.20)
0.41
(0.38 to 0.43)
1.82
(1.01 to 2.63)
1.32
(1.23 to 1.41)
Ethnicity 0.37
(0.20 to 0.53)
0.54
(0.51 to 0.57)
0.13
(0.07 to 0.20)
0.40
(0.38 to 0.43)
1.83
(1.02 to 2.64)
1.32
(1.23 to 1.42)
NSSEC 0.36
(0.20 to 0.51)
0.52
(0.49 to 0.56)
0.12
(0.07 to 0.18)
0.39
(0.36 to 0.41)
1.83
(1.03 to 2.63)
1.31
(1.22 to 1.40)
Prescription payment 0.36
(0.20 to 0.52)
0.53
(0.50 to 0.57)
0.13
(0.07 to 0.20)
0.40
(0.37 to 0.43)
1.82
(1.02 to 2.63)
1.30
(1.21 to 1.39)
IMD 2010 (PCT) 0.30
(0.17 to 0.44)
0.53
(0.49 to 0.56)
0.11
(0.06 to 0.16)
0.40
(0.38 to 0.43)
1.40
(0.78 to 2.02)
0.74
(0.68 to 0.80)
Episode 0.37
(0.20 to 0.53)
0.54
(0.51 to 0.58)
0.14
(0.07 to 0.20)
0.40
(0.38 to 0.43)
1.83
(1.02 to 2.63)
1.32
(1.23 to 1.42)
Medication 0.38
(0.21 to 0.55)
0.53
(0.50 to 0.57)
0.15
(0.08 to 0.23)
0.40
(0.37 to 0.43)
1.84
(1.02 to 2.65)
1.29
(1.19 to 1.38)
Intervention type 0.35
(0.20 to 0.51)
0.53
(0.50 to 0.56)
0.13
(0.07 to 0.19)
0.40
(0.37 to 0.42)
1.80
(1.00 to 2.60)
1.29
(1.20 to 1.38)
SSS practitioner 0.37
(0.20 to 0.53)
0.53
(0.50 to 0.57)
0.13
(0.07 to 0.19)
0.38
(0.35 to 0.40)
1.91
(1.07 to 2.75)
1.29
(1.20 to 1.38)
All fixed effects
Multivariable model 0.34
(0.19 to 0.50)
0.49
(0.46 to 0.52)
0.13
(0.07 to 0.18)
0.36
(0.33 to 0.38)
1.47
(0.82 to 2.11)
0.71
(0.65 to 0.76)
Multivariable MCMC
model
0.43
(0.22 to 0.65)
0.53
(0.49 to 0.57)
– – – –
Multivariable model
without extreme
PCTs
– – – – 0.64
(0.34 to 0.94)
1.02
(0.94 to 1.10)
MCMC, Markov chain Monte Carlo.
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Carbon monoxide validation
The CO-validation rate (self-reports that were CO validated) of the database was 73.9% and was 74.3%
among clients with gender, age and practitioner identified (see Table 3). The DH has recommended that SSSs
should aim to CO validate 85% of clients.33 Client groups where CO validation of 85% was achieved were
prisoners and clients enrolled in open groups. Of the 49 PCTs, 13 achieved CO-validation rates of 85% or more.
Multivariable results
Odds ratios for IMD at PCT level and multilevel variance changes suggested that some PCTs were having a
disproportionate effect on the results, as an intermediate quintile was most associated with quitting
(see Table 4) and including this variable in the model was associated with a major reduction in PCT-level
variance (see Table 7). Two PCTs, with very high CO-validation rates and one PCT with a particularly low
validation rate were consequently excluded. Both models are shown (see Table 6). Multivariable modelling
in Stata provided vifs and tols. All were below 3.20, so there was no significant multicollinearity in the data.
Demography
As age increased, CO validation was more likely. Non-pregnant women were more likely to be CO
validated than men and pregnant women. Ethnicity had no effect on CO-validation rates.
Socioeconomic status
Prisoners were much more likely to be CO validated than other groups, approximately four times more
likely than routine and manual workers. Eligibility for paying for prescriptions and PCT deprivation
(once extreme PCTs were excluded) did not significantly affect CO-validation rates.
Stop Smoking Service related
Self-report quitters who set quit dates in January were most likely to be CO validated and November
quitters were least likely. Clients who took varenicline, combination NRT or a mixture of medications were
more likely to be CO validated than those who took single NRT. Self-report quitters who enrolled in
open groups were more likely to be CO validated. CO-validation rates were lowest among specialist
practitioners. Health-care assistants, pharmacy employees and unclassified practitioners were significantly
more likely to CO validate clients than specialist practitioners (see Table 6).
Primary care trust and practitioner
Residuals suggest (Figure 4) that, after taking other demographic- and service-related factors into account,
there was significant variation in PCT validation rates.
There is little that can be said with certainty about the higher-level variance, as it is not possible to tell how
much of the change in variance between models (see Table 7) is owing to fixed effects in the model and
how much is the result of level one variance being constrained to 3.29 in binary outcome models.
3.5
C
o
n
s
–2.6
–1.8
–0.9
0.0
0.9
1.8
2.6
1 11 21
Rank
31 41
FIGURE 4 Caterpillar plot of residuals for multivariable multilevel model predicting CO validation (model excluding
extreme PCTs).
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The variance between PCTs appeared to halve when PCT deprivation was entered into the model. The
fixed effects suggested that PCTs that were fairly, but not the most, disadvantaged were three times more
likely to be CO validated. This suggested that idiosyncrasies were responsible rather than an effect
of deprivation. When extreme PCTs were excluded the variance between PCTs halved and there was no
longer significant variation between practitioners.
Impact
In general, the services had a positive impact over and above what would be expected from quitting
spontaneously or with medication only. When the impact was calculated using all self-report quitters, two
services were estimated to have a negative impact as did six services when only CO-validated quitters were
included. However, only one service was judged to have a negative impact when both CO-validated
quitting and all self-report quitting were taken into account. At the other end of the scale, two PCTs were
estimated to have independently added over 400 ex-smokers per 100,000 population between mid-2010
and mid-2011 (Table 8).
TABLE 8 Unique clients number and quit rates, throughput and impact per 100,000 population by PCT (each row is
a different PCT)
Unique clients aged ≥ 16 years
Clients per 100,000 PCT populationa
Throughput
Impact (4-week quitters) calculated
n
Client
records
unique
clients (%)
CO-validated
quit (%)b
Self-report
quit (%)b
From
CO-validated
quit
From
self-report
quit
Overall (average
self-report and
CO validated)
2658 93.3 39.5 47.9 1969 285 254 270
2496 93.9 49.6 53.2 1371 337 249 293
5565 90.8 38.8 46.2 1764 243 198 220
4776 88.4 31.7 42.0 1717 115 120 118
5718 86.7 5.8 36.3 5003 – – –
3556 88.9 23.1 49.6 1371 –26 200 87
5429 92.5 35.3 46.4 1474 152 168 160
2463 95.3 36.8 44.6 980 116 94 105
5555 90.1 25.3 47.0 1489 4 179 92
9618 95.4 42.9 53.1 2277 408 412 410
1611 95.7 41.3 50.5 1979 323 307 315
4010 87.6 38.1 48.9 1571 206 218 212
3453 91.6 40.8 61.4 1729 273 456 365
6748 95.1 45.7 57.3 1126 233 251 242
2657 85.0 36.7 55.1 1035 121 208 165
2655 93.7 45.3 64.8 941 191 281 236
2991 95.2 31.3 37.5 1667 105 42 73
1822 92.7 35.4 42.1 983 102 70 86
3433 92.3 40.0 45.5 1593 239 167 203
7197 87.8 27.2 55.7 – – – –
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TABLE 8 Unique clients number and quit rates, throughput and impact per 100,000 population by PCT (each row is
a different PCT) (continued )
Unique clients aged ≥ 16 years
Clients per 100,000 PCT populationa
Throughput
Impact (4-week quitters) calculated
n
Client
records
unique
clients (%)
CO-validated
quit (%)b
Self-report
quit (%)b
From
CO-validated
quit
From
self-report
quit
Overall (average
self-report and
CO validated)
5620 89.1 28.1 55.1 – – – –
12,817 88.3 27.7 55.4 1446 38 295 167
3324 91.7 20.1 45.6 2057 –101 218 59
3374 85.6 23.9 45.7 1775 –20 190 85
4409 91.4 41.5 60.8 2031 335 524 430
3395 91.6 24.3 39.5 2082 –15 94 40
1892 96.4 15.2 52.3 1334 –131 231 50
580 93.7 53.3 64.9 419 119 125 122
4403 89.5 37.0 44.2 1810 217 166 192
6842 93.9 44.8 61.7 1213 240 324 282
2828 94.7 34.7 41.8 1330 129 90 110
9679 91.0 41.4 55.6 1659 272 342 307
1407 94.6 52.1 60.8 1098 298 283 291
2826 90.7 35.2 48.3 1625 166 216 191
2071 93.8 56.9 64.1 1613 515 469 492
4533 90.8 28.4 53.1 1767 60 320 190
4626 88.9 26.8 41.1 2704 49 165 107
1487 97.1 34.6 54.4 703 67 136 102
549 95.8 45.3 58.9 359 73 86 79
4474 89.2 40.2 56.1 2174 330 459 395
1422 81.1 31.0 33.2 616 37 –11 13
1296c 95.6 47.3 65.8 – – – –
7880c 95.5 28.2 46.7 2860 92 335 213
1683c 95.0 18.0 26.4 712 –50 –61 –56
3974c 96.0 38.7 45.4 1956 268 203 236
7646c 98.1 39.6 49.9 1746 255 260 257
3676 90.5 26.3 41.1 1905 25 116 70
a Estimated mid-year PCT population estimate 2010. Impact calculations could not take place for some PCTs for the
following reasons: first, poor-quality unique client identifiers; second, a markedly low CO-validation rate; third,
population data being available only for a county whereas SSS data were available for constituent PCTs; and fourth, only
specialist service clients included in QuitManager.
b Quit rates for unique clients are calculated using all QuitManager clients aged ≥ 16 years. For returning clients, their quit
status at their last visit was used. Note that it was not possible to calculate quit rates for clients who set quit dates in
December and June.
c Client records from four PCTs were included only in the second data download thus client records were doubled to
estimate 1-year downloads. This is likely to have resulted in an overestimate of client records and also unique clients.
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To represent quit rates, throughput and impact on the same graph (Figure 5), different scales were used.
Thus, a point of 100 on the y-axis represents 100 extra ex-smokers per 100,000 population (impact),
1000 clients setting quit dates per 100,000 population (throughput) or a quit rate of 10%. The graph
suggests that impact is more strongly related to quit rates than throughput. Two London PCTs displayed
high quit rates but low throughput whereas three others displayed particularly high throughput but low
CO-validated quit rates.
Summary statistics for unique clients (as opposed to client records) and impact in general were also
calculated. There were 171,830 unique clients (note that unique clients could not be identified for three
PCTs) and 157,479 clients where quit rates could be calculated (i.e. did not quit in December or June).
The CO-validated quit rate of unique clients was 34.4%, the self-report quit rate was 49.8% and the
CO-validation rate for clients who self-reported as quit was 73.3%. There were 169,909 unique clients
aged ≥ 16 years altogether. The CO-validated quit rate for these clients was 34.5% and the self-report
quit rate was 50.0%.
Impact rate summaries and correlations between impact rates throughput and quit rates were calculated
for 40 PCTs for adults aged ≥ 16 years. The distribution of client records and unique clients among the
PCTs were skewed, and quit rates and impact measures were normally distributed.
The median number of client records per PCT was 3713 (interquartile range 2101–5136) and the median
number of unique clients was 3385 (interquartile range 2169–4603). There were 92.0% (interquartile
range 89.7–94.7) of client records that referred to unique clients.
The mean quit rates for unique clients aged ≥ 16 years in the PCTs used for calculations were 36%
(CO validated) and 50% (self-report) (Table 9). On average 1487 unique clients set a quit date per
100,000 population and 184 ex smokers per 100,000 population were added. If only CO-validated quits
were taken into account there were 152 extra ex-smokers and if all self-report quits were included there
were 216 extra ex-smokers.
Overall, impact was significantly positively associated with CO-validated quitting, self-report quitting and
impact, taking into account either only CO-validated quits or taking into account all self-report quits.
Throughput was not significantly associated with quitting or impact, taking into account CO-validated
quits but it was significantly associated with impact taking into account all self-reported quits and overall
impact. Thus, PCTs with a better throughput did have a higher increase in the number of self-reported
smokers in the population but such PCTs were not CO validating sufficiently to be sure that the number of
ex-smokers is increasing with a higher number of clients.
Impact and quitting
Two PCTs with particularly low CO-validated quit rates were reaching the highest proportion of smokers in
their local area. It is therefore possible that these PCTs were focusing on reach at the expense of achieving
quits. This was corroborated by the impact analysis.
The PCTs with the highest impact were generally those with high quit-rates and vice versa.
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Socioeconomic status
Results presented in the published multivariable analysis26 showed that affluent smokers were more likely
to be abstinent from smoking at 4 weeks post quit date than disadvantaged smokers as measured by
either eligibility for free prescriptions or by occupational group (as measured by the NSSEC), for example
adjusted odds ratio (aOR) 1.38 (95% CI 1.35 to 1.42) for clients who paid for prescriptions compared
with those eligible for free prescriptions. In total, almost 80% of the service clients received one-to-one
counselling but open group forms of behavioural therapy were more successful [main effect aOR 1.26
(95% CI 1.12 to 1.41)] except among some of the most disadvantaged clients (prisons and long-term
unemployed). Closed groups were little deployed and they were not significantly more successful than
one-to-one behavioural therapy after controls. Practitioner type did make a difference for some clients,
with all but the most affluent less likely to be successful if they had been treated by a nurse compared
with other types of practitioners, including smoking cessation specialists [main effect aOR 0.73 (95% CI
0.65 to 0.83)]. More details are found in the published paper.26
Summary of key points
l The estimated number of clients treated by SSSs from mid-2010 to mid-2011 was 5–10% of their
smoking population.
l The self-reported and CO-validated quit rates were 49% and 34% respectively at 4 weeks post
quit date.
l Smokers attempting to stop with NRT and minimal behavioural support have previously been estimated
to have quit rates of 25% (for CO-validated quits) and 35% (for self-reported quits) at 4 weeks, so SSS
interventions need to show rates higher than these and they should aim for rates of at least 50% for
self-report and at least 35% for CO validated.33,42
l The lower CO-validation rate was likely to be the result of the CO-validation rate of self-report quits
being below recommended levels (74% compared with the recommended 85%).33 This was, however,
slightly better than that reported for all PCTs in 2009/10 (69%).33
TABLE 9 Summary of average impact and throughput per 100,000 population, quit rates for 40 PCTs and
correlations for unique clients aged 16 years and over
Measure Mean (SD)
Correlation
with throughput
Correlation with
CO-validated
impact
Correlation
with self-report
impact
Correlation
with overall
impact
r p-value r p-value r p-value r p-value
CO-validated quit 35.9% (9.7%) –0.204 0.207 0.845 < 0.001 0.439 0.005 0.716 < 0.001
Self-report quit 50.0% (8.9%) –0.133 0.414 0.505 0.001 0.735 < 0.001 0.675 < 0.001
Throughput 1487 (521) – – – –
Impact (CO validated) 152 (144) 0.218 0.177 1 – 0.657 < 0.001 0.919 < 0.001
Impact (self-report) 216 (131) 0.450 0.004 – – 1 – 0.901 < 0.001
Impact overall 184 (125) 0.361 0.022 – – – – 1 –
SD, standard deviation.
SECONDARY ANALYSIS OF ROUTINE DATA: FINDINGS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
l The self-reported quit rate for all English SSSs from April 2010 to March 2011 was also 49%, with
70% of these CO validated43 compared with 74% in the current sample. Overall, 787,527 people set a
quit date43 compared with the 202,084 client records in the QuitManager database used here. Thus,
the North 51 PCTs that allowed their data for research purposes comprised roughly one-quarter of the
total and have similar self-report quit and CO-validation rates. It must be noted that the self-report quit
rate used was not as narrow as the DH quit rate regarding time of data collection but was more
stringent in that it was an intention-to-treat analysis.
l Highest quit rates were found among older people, men and clients with higher SES. January was the
month with the highest number of quit dates set and the most successful quitters.
l Affluent smokers were more likely to be abstinent from smoking at 4 weeks post quit date than
disadvantaged smokers.
l Varenicline and combination NRT were both used frequently and increased the chances of quitting
compared with a single NRT product.
l The majority (79%) of clients received one-to-one behavioural support. This type of support was
significantly less successful than open rolling groups [aOR open groups 1.28 (95% CI 1.15 to 1.41)
compared with one to one].
l Clients who saw specialist practitioners had higher quit rates than those who saw other types
of practitioners.
l As a result of SSS treatment, the estimated number of ex-smokers per 100,000 population was 184
from mid-2010 to mid-2011.
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Chapter 5 Prospective study: methods and analysis
This chapter describes the methods used in the prospective study element of the ELONS study, includingthe rationale, recruitment, sample and approach to data analysis. A particular focus of this chapter is
recruitment challenges faced during this part of the research and strategies implemented by the research
team to address these.
Rationale for the second element: prospective cohort study
Stop Smoking Services in England are not required to routinely collect data on longer-term cessation
outcomes. Only outcomes 4 weeks after a client’s quit date are collected and reported. Furthermore, the
routine data collected by SSSs are limited in scope, and the quality and quantity of data collected varies
between service providers. Consequently, there was a need for a prospective cohort study to collect
long-term (12-month) follow-up data and more detailed and consistent information on client and service
characteristics. Data from the prospective study were used to fulfil study objectives 3, 4 and 5 of the
ELONS study, to explore the relationship between client characteristics, treatment characteristics and
longer-term abstinence from smoking.
Recruitment
Stop Smoking Service clients were eligible to be recruited to the ELONS study if they were aged 16 years
or over and were not pregnant. In order to compare behavioural support types, initial power calculations
suggested that we needed data from quit attempts made by 5000 individuals, with at least 370 quit
attempts within each behavioural support type with 90% power and an average quit rate of 15%.
This quit rate was based on the previous evaluation of long-term outcomes of the English services.18
Recruitment to the ELONS study was a multistage process:
l Secondary analysis of QuitManager data was conducted (see Chapter 3 and 4). The PCTs became
the sampling frame of services. To achieve statistical power we initially approached services on the
basis that they offered clients a range of behavioural support types. In order for our PCTs to be
representative we also approached services with a range of short-term (4 week) quit rates and
geographies (urban and rural areas, affluent and disadvantaged areas, and include areas from most
regions of England).
l Once services were identified within this sampling frame, a member of the research team made contact
with the service commissioner and service manager to invite them to take part in the study.
l After the service manager had agreed to participate, the research team obtained permission from the
local PCT R&D department, and service support costs used to reimburse SSSs for staff time spent on
the ELONS study were negotiated.
l While this process was under way, the team liaised with services to decide whether to include only
specialists or additionally include level 2 providers.
l If it was decided that level 2 providers could be included, they needed to be approached individually
(as each is a separate contractor, i.e. a pharmacy) to determine if they would take part.
l Once participation of a service (and if relevant its linked level 2 practitioners) was confirmed, a study
briefing was delivered to smoking cessation practitioners to enable them to recruit clients to the
ELONS study.
l After these elements were in place, stop smoking advisors recruited clients to the study. Inclusion
criteria were all clients who were over 16 years old, were not pregnant and had set a quit date.
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The recruitment process was aided considerably by the involvement of the PCRN staff, who helped us
make initial contact with SSS managers and colleagues in R&D, promoted the study to level 2 providers,
finalised service support costs and delivered study briefings. Two service managers (Northamptonshire
and Rotherham) did not want their practitioners to be burdened with recruitment to the ELONS study or
collecting the extra monitoring data. In these sites, PCRN-funded staff recruited clients, and collected client
and treatment characteristics on paper forms. However, as PCRNs are organised by area and each have
their own budget, the level of support available did vary across the nine ELONS study sites.
Recruitment challenges
Recruitment was a particular challenge for the prospective study. The initial hurdle was that the data
collected in QuitManager did not consistently differentiate between behavioural support types. The main
ambiguity was between one-to-one specialist practitioner support and level 2 support and, to a lesser
extent, between one to one and drop-in. To overcome this, to some extent, the likely behavioural support
range was checked with site managers when they were first contacted.
The second hurdle was securing the participation of SSSs as study sites. If services agreed to take part, this
would involve SSS practitioners consenting clients to the study and collecting additional client and treatment
data. This could be perceived as onerous in the context of limited appointment times and with local targets to
meet. In addition, when we approached SSSs they were preparing for their busiest time of the year (post
Christmas/New Year and No Smoking Day on 14 March. Moreover, local service funding was contracting
in the face of NHS reforms and the move of public health from the NHS to Local Authorities in England
(see Chapter 1). This led to some staff being made redundant or having their employment grade changed.
Despite this, only three PCTs that the research team approached declined to participate in the study. The main
reasons for declining were that they perceived available service support costs to be inadequate, it was an
onerous consent process and there were factors related to service reorganisation.
Eight services were initially recruited to the study. From the numbers of clients attending these services
recorded in the data set used for secondary analysis, it was thought that the target of 5000 participants
(as set out in the original study proposal) would be achievable. However, the process of site recruitment
took longer than expected (it was common for this process to take months rather than weeks): site
managers needed to engage with colleagues and senior staff to explain what participation would involve
before they could agree to take part; R&D permissions, liaison with local PCRN and service support cost
calculation also were needed before a site could be confirmed as taking part and start recruitment. As a
result of this, client recruitment started later than planned, after the busy New Year period had ended.
In addition, the recruitment start date was staggered by site.
The third recruitment challenge was engaging with level 2 providers. As discussed previously, SSSs are
delivered via specialist providers (their remit is purely smoking cessation) and level 2 providers such as GP
practices, pharmacies and dentists (also called community providers) whose staff deliver smoking cessation
in conjunction with their other responsibilities. Level 2 provision has grown over the past decade44 and
thus it was important to involve these providers as well as specialists. Level 2 providers have different
management arrangements to the specialist service, so each level 2 provider needed to be contacted
separately. We therefore had to implement a recruitment strategy, which is summarised below (note there
was some deviation between sites depending on the extent of SSS management commitment to the study,
PCRN involvement and service support costs):
1. we identified which sites had level 2 service provision
2. we agreed with SSS managers whether or not we could approach their level 2 providers
3. where permission was granted, we publicised the study and letters were sent to all level 2 providers
(via the SSS) to describe the evaluation and invite them to opt in by completing an ‘expression of
interest form’ and returning in a reply paid envelope
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4. to increase the number of providers, telephone calls were made by the research team and PCRN staff to
practice managers and pharmacy managers/pharmacists from GP practices and pharmacies who had
been active in the previous 6 months
5. a news article was added to the newsfeed page of QuitManager for each site, with instructions on how
to register interest as a recruitment site
6. the research team and PCRN staff briefed the level 2 providers through lunchtime and early evening
briefing events (with refreshment and buffet to encourage attendance) or individual face-to-face and
telephone briefings for those who were unable to attend events.
Six sites recruited level 2 service providers. The number of individual providers recruited varied between
4 and 23.
The fourth challenge was obtaining informed consent. In order to secure PCRN help and to be able to
reimburse SSSs for their time using service support costs, we asked the NHS Ethics Committee to classify
the ELONS study as a research study rather than an audit or evaluation. This classification differed from
that taken in ethical review processes for our previous national study of SSSs, conducted between 2001
and 2004.18 In the earlier study, the National Institute for Health Research (NIHR) and PCRNs, etc., did not
exist, there were no service support costs available and ethical requirements were arguably not as onerous.
At that time we were permitted to merely add consent to take part in the research as a single question on
existing service data collection sheets, but not for this study. For the ELONS study, the Research Ethics
Committee required a consent form for each client with a section relating to each element of the study.
Clients were asked to consent to each part. This procedure and the length of the consent form was
undoubtedly a barrier to participation and SSSs reported that it resulted in serious time implications, which
was the fifth recruitment barrier.
One of our study sites served as a within-study pilot and we tried out our recruitment methods there. This
was Country Durham and Darlington, where we were able to estimate that the process of recruiting a
client, seeking informed consent, asking the additional monitoring questions and collecting saliva samples
added an additional 10–15 minutes to the appointment. This meant that the ELONS study added
additional time to each consultation, which affected the number of people that the service could see. From
a service manager perspective, this was of concern because they had local targets to meet (in terms of the
number of clients they see and successful ‘quits’ at 4-week follow-up) with ongoing funding dependent on
these targets being met. Some sites found this easier to manage than others, depending on how they
delivered their service. Situations where there were particular problems included:
l Groups where the consent process and collection of baseline data had to be done for all group
members. With limited staff, this could take up the majority of a session.
l One-to-one sessions where slots were doubled/triple booked because of a high did-not-attend rate in
order to keep service busy. This meant the additional time required to recruit clients to the ELONS study
was limited.
A sixth recruitment challenge was ‘buy-in’ from both the SSS practitioner and clients. The ELONS study
mostly relied on practitioners to recruit clients and some were more confident and committed to this than
others. This is an issue in any research study that recruits in routine practice. Some practitioners were
genuinely interested in, and could see the value of, research and so made extra efforts to encourage their
clients to consent to participate. Others were not so enthusiastic, or had more limited time. Client ‘buy-in’
was also an important issue for recruitment. Some practitioners, particularly pharmacy employees, reported
that clients simply did not want to take part. Practitioner feedback suggests that the main reasons were
that clients did not have time to go through the recruitment process (particularly for working people who
scheduled appointments) or did not want to be contacted for follow-up (often older people).
A further challenge was failure to set quit dates. In the previous English longer-term evaluation,18 clients
were included in a study only if they ‘set a quit date’ (i.e. gave the SSS a particular day when they were
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going to attempt to stop smoking). In some of the services, clients were recruited to the study when they
registered with the SSS, which was sometimes before they set a quit date. Some of these clients never did
set a quit date. Comparing the QuitManager prospective study extracts with the saliva samples database
for the long-term NRT use study revealed further clients who had been initially recruited to the ELONS
study (as they had provided saliva samples) but had been dropped from QuitManager owing to lack of
progress with their quit attempt.
The last challenge was footfall. Several sites reported a general decrease in the number of people using
their service during the study period. Analysis of the number of quit dates set over the recruitment period
for the ELONS study (March 2012–March 2013) suggests that this was a reality. The number of quit dates
set in SSSs in England for 2011/12 was 816,444 and in 2012/13 this has decreased by 11% to 724,247.31
The decline continued after recruitment was completed, and much or at least some of this has been
attributed to more smokers using electronic cigarettes (e-cigarettes) for cutting down or quitting rather
than more established methods.
Strategies to address recruitment challenges
By late July 2012 it became clear that the client recruitment rate was considerably below the level that was
expected from the previous English long-term evaluation, where up to 80% of clients in the two study
areas had been recruited.18 Various strategies were implemented to improve recruitment:
l We negotiated further assistance from the PCRN/Clinical Research Unit and we were able to boost the
number of level 2 providers.
l A substantial amendment was submitted to the ethics committee requesting to simplify the consent
form from six points, each of which the client was asked to initial, to three tick boxes. This request was
approved (we initially asked for a move away from written to verbal consent which was rejected).
l In order to support and motivate sites, we encouraged practitioners who were recruiting well to share
their approach with their peers who were performing less well. We also supplied fortnightly updates to
site leads with a breakdown of recruits by practitioner name so that they could monitor performance
and discuss with staff when appropriate. Practitioners were sent a newsletter and either a mug or a
pen with the ELONS study logo to both thank them and act as a reminder to keep recruiting.
l A further two sites were approached to take part in the ELONS study. One of these, Hull and East
Riding, agreed to take part.
l Clients who had agreed to be recruited to the ELONS study but where there was no record of quit date
set were included in the analysis.
l We postponed the end of recruitment from the end of November 2013 to the end of January 2014
where sites were willing.
Sample
Despite efforts to boost recruitment, the challenges described above meant that our initial target baseline
sample of 5000 (as set out in our original research proposal) was too ambitious. Therefore, in consultation
with the chairperson of the NIHR Health Technology Assessment (HTA) Board and statistical practitioner we
revised our sample size calculation to a more realistic target sample of 3000, which allowed us to maintain
a sufficient level of power to detect meaningful effect sizes between the intervention groups (90% to
80% power).
The NIHR HTA agreed the revised sample size of 3000 and the study was also granted a 7-month
extension to allow us to successfully recruit this number of participants.
The measures taken and the timing of measures are presented in Chapter 2 and Table 2.
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Prospective study analysis
For the prospective study, seven stages of analysis were undertaken. These were:
l preliminary analysis of short-term quit rates using unweighted data
l comparison with the ‘all cases’ data set to develop weights
l short- and longer-term unweighted and weighted quit rates
l multivariable and multilevel logistic regression modelling of CO-validated abstinence at 4 weeks
l multivariable logistic regression modelling of CO-validated abstinence at 52 weeks
l adherence to treatment
l comparison of longer-term quit rates with those in other evaluations.
Preliminary analysis of short-term quit rates using unweighted data
We present tables of 4-week quit rates for variables grouped into 10 key themes: location; demography;
SES; health and well-being; smoking behaviour; support; behavioural support type; medication;
introduction to the service; and finally, data collection variables. We also created crosstabulations of
relationships between each variable and location, behavioural support type and sociodemographic
characteristics, and results from these are referred to where relevant. These figures are not tabulated in
this report, as they are very detailed, but are available on request.
Unless it is stated otherwise ‘quitting’ refers to CO-validated abstinence at 4 weeks. We have taken a
finding to be significant at the traditional p< 0.05 level. Sometimes the chi-squared test result was invalid
owing to low numbers of expected cases in cells, in which case significance was recorded as p= not
available. For contingency (2 × 2) tables we could have used Fisher’s exact test but in practice most
variables we used generated tables greater than 2× 2.
Weighting
As the requirements for detailed consent (along with the other pressures on services outlined above)
meant that it was not possible to recruit a high proportion of clients, weighting was undertaken to correct
for non-response so that the quit rates would take into account any differences in important variables such
as demographics between the ELONS study sample and the population. In order to create the weights, the
ELONS study research team requested a QuitManager extract of all quit attempts (with quit dates) that
took place at the nine study sites from March 2012 to March 2013 (the months where any ELONS study
client set a quit date). All nine SSS managers gave permission for the data from their service to be made
available. The database included the majority of the routine data that was collected by the sites but
without identifying information. This database is referred to as ‘all cases’ in the remainder of the report.
The ‘all cases’ database was used to develop weights in order to calculate quit rates generalisable to the
nine services that took part in the ELONS study. The weights were trimmed rim weights, which were
provided by TNS BMRB. Rim weights are created using an iterative algorithm to ensure that the weight is
the best fit to the proportions of various characteristics in the population. Trimming reduces the size of
overly large weights so that they cannot go above a particular value. The weights were created using these
variables: behavioural support type, age, gender and SES (measured by NSSEC). Note that the ‘other/unclear’
group of behavioural support in the ELONS study was too small for weighting so quit attempts in this
group were redistributed to either the nearest group or the group of which they were most likely to be a
member (three quit attempts to GP practice service and the remainder to one-to-one specialist). We also
intended to weight for location (study site) but there were large differences in proportions recruited by
location, which led to instability in the weighting and so the decision was made to exclude this, with
behavioural support used to explain some of the differences by location. As an alternative, quit rates were
calculated taking into account clustering by location.
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Short- and longer-term weighted quit rates: variable definitions
Short- (4 week) and longer-term (52 week) raw and weighted CO-validated quit rates are presented for
the variables that were significant predictors of 4-week quitting. Clients lost to follow-up were coded as
still smoking, consistent with conducting an intention-to-treat analysis as set out in the Russell Standard.30
The same rim weights were used for the 12-month quit rates as the 4-week quit rates to allow our
estimates to be generalisable to the nine services that took part in the ELONS study.
Data were collected from all nine study sites. The behavioural support types used in the analysis were
specialist closed groups, open groups, drop-ins and one-to-one sessions; GP practice, pharmacy service and
other/unknown. Seasonality effects were analysed through the time of year that a quit attempt started.
Quit attempts that started during the main summer holiday period, the post-summer holiday ‘back to
school’ period and the New Year were differentiated from those starting at other times of year.
Demographic variables included age, gender and ethnicity. Age at first contact was included in the analysis
as data were available for all respondents. Ethnicity was categorised as white British, other white, Asian
(including mixed white and Asian) and other.
Socioeconomic status was measured through a count of the number of indicators of disadvantage. The
indicators of disadvantage were routine and manual occupation/unemployed/permanently sick; no
educational qualifications or highest qualification is General Certificate of Secondary Education or
equivalent; eligible for free prescriptions; housing is rented and single parent (see Table 11) for details
of these indicators. The variable was dichotomised into 0 to 1 indicators compared with two or
more indicators.
Medication was operationalised by whether or not clients had taken varenicline at week 1. Combination
NRT (using more than one NRT product concurrently) was not included because it was not associated with
quitting in preliminary analysis. This is further discussed in Chapter 6, Adherence to treatment. This may be
because one of the more successful sites and the only user of open groups used very little combination
NRT. We could not explore this further because of multicollinearity between site and medication.
Varenicline at week 1 was measured because abstinence from smoking was strongly associated with
higher numbers of records of smoking medication and clients who had more records had more
opportunity to change medication (see Chapter 6, Adherence to treatment).
For the element assessing well-being, following standard practice the WHO-5 Well-being Index45 items
were converted to a percentage. Thus, a score of 0 indicates the lowest well-being and a score of 100
represents the highest well-being.
Initial analysis of dependence showed that high daily consumption of cigarettes and smoking within
5 minutes of waking were associated with low quit rates. However, the highest quit rates were associated
with quitting between 6 and 60 minutes after waking (47–49% in preliminary analysis); quit rates of
clients who smoked over 60 minutes after waking had quit rates similar to clients who smoked within
5 minutes of waking (42% and 41% respectively). Furthermore there was not a linear relationship
between cigarettes smoked per day and quitting. Thus the Heaviness of Smoking Index was of only
borderline significance in preliminary analysis and had a non-linear relationship with quitting. Thus
concerns arose that the true importance of being dependent might be missed if the Heaviness of Smoking
Index was used to represent dependence in the analysis, so instead a dichotomous variable was used:
clients who smoked > 30 cigarettes per day or who smoked within 5 minutes of waking were coded as
dependent and contrasted with all other clients.
Clients who were very or extremely determined to quit were differentiated from other clients. Clients who
stated that their spouse or partner was supporting them during their quit attempt were also differentiated
from other clients, as were clients who indicated that a half, a few or none of their friends and
family smoked.
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Multivariable predictors of quitting at 4 weeks in the prospective study
Multilevel logistic regression was conducted using MLwiN version 2.29. The dependent variable was
CO-validated abstinence at 4 weeks. Weighting is not recommended in multilevel modelling, including
variables where differential recruitment has occurred is preferred.46 Thus all final models using prospective
study data needed to include behavioural support types and locations.
Fixed effects
The fixed-effects variables are described in Short- and longer-term weighted quit rates: variable definitions.
Four other fixed effects were tested because preliminary bivariable analysis (see Chapter 6) suggested they
might be of importance but were excluded from the final model:
l Marital status (non-significant in multivariable analysis).
l Practitioner had the ELONS study clients who did not set a quit date (non-significant in multi-
variable analysis).
l Saliva collected (non-significant in multivariable analysis).
l Serious previous quit attempt with or without quitting aids (clients who had made a quit attempt in the
last 12 months but had not used aids were less likely to quit than both those who had not made a quit
attempt and those who had made a quit attempt with quitting aids. Owing to the non-intuitive results
and the desire for simplicity, this variable was excluded).
Random effects
There were potentially five levels:
l client quit attempt
l client – only 22 clients were recruited to the ELONS study twice, so the client level was not included
l practitioner
l service provider – the models failed to run because of conflicts with practitioner and location
l location – there was no significant level 2 variance as there were only nine locations, so location was
included as a fixed effect.
Thus in the final models two levels were included: the first level was client quit attempt and the second
level was practitioner. There were 234 practitioners in the prospective study and the median number of
clients recruited was four.
Modelling
Modelling occurred in three stages. First, all fixed effects were entered into the model individually, second,
all fixed effects were entered into the model simultaneously, and third, all fixed effects were entered into
the model.
The model was then tested for multicollinearity by comparing the size of the CI when each variable was
added individually with the CI when each variable was added simultaneously.46 If the standard error
increased by 50% or more multicollinearity was deemed to be present.46 This did not occur.
Multivariable logistic regression modelling of carbon monoxide-validated
cessation at 52 weeks
Initial multilevel modelling revealed that there was consistently no evidence of variance between
practitioners (i.e. the practitioner made no difference to the chances of long-term quitting), so single level
logistic regression modelling was undertaken using SPSS. All significant fixed effects at 4 weeks (analysis 2)
were entered into the model and a backwards-stepwise method was used to eliminate non-significant
variables. However, the a priori variables, behavioural support, location, time of year and sociodemographic
variables, (with the exception of ethnicity) were kept in the model irrespective of statistical significance.
Variables that did not reach statistical significance in the 4-week multivariate analyses (marital status,
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medical conditions, how introduced to the service) were then added to the model; however, none of these
reached statistical significance in the multivariable model. Multicollinearity was tested by comparing the
standard error in models with each variable added individually and simultaneously. If the standard error
increased by 50% or more multicollinearity was present. This did not occur.
Adherence to treatment
Adherence – or continuing to attend SSSs – could not be included in multilevel modelling. This was owing
to issues with direction of causality: it is not clear whether failure to adhere reduces the chances of
quitting or whether clients relapse and then stop attending sessions and taking medication.
There were two measures of adherence collected in the prospective study: number of behavioural support
sessions attended and number of occasions that medication was recorded. Sample distributions and
weighted quit rates at 4 and 52 weeks were calculated for adherence, adherence and medication, and
medication taken on any occasion and on the first occasion. Medication types included ‘single NRT’
(one form of NRT recorded), ‘combination NRT’ and varenicline. The other/mixed medication category
included bupropion or clients who had taken more than one of the aforementioned medication types.
In an attempt to overcome issues with direction of causality we have followed work by Shiffman and
colleagues47,48 and we have considered adherence prior to a person being abstinent. Thus we have
analysed whether or not adherence was associated with 52-week quitting only in those who attained
4 weeks abstinence; we have assessed their attendance prior to 4 weeks using weighted means.
Comparing longer-term outcomes with those in other evaluations
Quit rates and follow-up rates in the ELONS study were compared with previous evaluations of SSSs in the
UK. This type of comparison is not normally attempted or appropriate for observational studies, but was
included here as the studies in question were conducted by the same research team and employed an
almost identical research design. The previous studies were of two English services in 2002 (the ‘national
evaluation’ in England described in the introduction to this report)17–19 and of pharmacy and group-based
services in Glasgow in 2007. Raw data rather than weighted data are presented. This is because none of
the three data sets include data from all SSSs in England – all collected data from a small number of
locations. In addition, weights for the final percentage (CO-validated quit rate of those successfully
followed-up) could not be calculated because not all clients were included in the denominator. Thus the
only meaningful comparison is between the raw data from all three studies.
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Chapter 6 Prospective study findings
This chapter presents findings from the prospective cohort study. Findings from the additional elementsof the prospective cohort study (CSS, well-being and longer-term NRT) are presented in Chapters 7–9.
Sections of this chapter describe findings from the different stages of analysis conducted in the prospective
study including:
l analysis of short-term outcomes using unweighted data
l comparing the ELONS study and the ‘all cases’ data sets
l short- and longer-term quit rates
l adjusted ORs from logistic regression of quitting in the short and long term
l adherence with treatment
l comparison of longer-term quit rates with those in other evaluations.
Analysis of short-term outcomes using unweighted data
This section describes the characteristics of the ELONS study clients, the types of support they received
from services and how these were associated with stopping smoking in the short term (4 weeks after their
quit date). Note: this material represents an early stage of work, using unweighted data, in order to inform
further refining of the variables and multivariable analysis. Thus, these are not the main findings of
our study.
Data were available from 3075 clients; there were, however, six participants that were excluded from this
preliminary analysis because they were pregnant, leaving 3069 cases. Overall, at 4 weeks post quit date
just over a half of study participants reported that they had quit smoking (56.6%). Most of these clients
had their report of abstinence confirmed by CO validation – the 4-week CO-validated quit rate was 44%.
Note that chi-squared tests test only the significance of the greatest difference between categories: they
cannot differentiate intermediate categories. For several variables, particularly those that were collected
only for the ELONS study clients, it was the other/unknown category that was the least likely to quit. This
was because clients who did not complete the ELONS study monitoring form often were those also who
failed to engage properly with the service and many did not set a quit date. For these variables we
therefore do not know whether or not the categories of interest differ significantly at this stage but we
can assess if quit rates are in the expected direction.
Demographic characteristics
As Table 10 shows, short-term quit rates varied between clients with different characteristics.
Age
Smokers recruited in the study were from all age groups, but primarily 25–54 years (68%). The older a
client, the more likely they were to stop smoking at 4 weeks (69% of 65- to 85-year-olds compared with
41% of 16- to 24-year-olds; p< 0.001). In addition, more of the older clients had their self-report of
abstinence validated by CO breath test. For example, 41% of 16- to 24-year-olds reported that they had
quit but only 25% were validated with a CO test, a gap of 16%. In contrast, the gap between self-report
and CO-validated quits at 4 weeks was just 8% for clients aged 65–85 years (69% and 61% respectively).
Gender
Around a half of both males and females self-reported as quit at 4 weeks (58% and 55% respectively;
p= 0.06) but there was no significant gender difference at 52 weeks.
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Ethnicity
Most (94%) of the recruited population were white British, 2% were ‘other white’ ethnicities or Asian
(including mixed Asian and white). About 1% were either black (or mixed black and white) or
‘other/unknown’. Clients in this final category were significantly more likely to quit than Asians (59%
compared with 27%; p< 0.001) although the numbers are very small. There was no difference in
self-reported quit rates possibly because of the gap between self-report and CO-validated quit rates for
Asians. The majority of Asian clients (80%) were men.
Marital status
Clients who reported that they were married were more likely to have stopped smoking at
4 weeks (p< 0.001).
Socioeconomic status
Baseline data collection included a range of questions about SES; these are described below and presented
in Table 11.
TABLE 10 Demographic variables: distribution and quit rates
Demographic variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Age (years)
16–24 330 10.8 41.2 24.9
25–34 676 22.0 53.4 38.2
35–44 760 24.8 55.5 41.8
45–54 631 20.6 59.0 47.5
55–64 458 14.9 65.3 57.2
65–85 214 7.0 69.2 60.8
p-value – – < 0.001 < 0.001
Gender
Male 1355 44.2 58.5 44.9
Female 1714 55.9 55.1 43.3
p-value – – = 0.60 = 0.408
Ethnicity
White British 2877 93.7 56.7 44.1
Other white 70 2.3 61.4 48.6
Asian (including mixed white and Asian) 64 2.1 46.9 26.6
Black (including mixed white and black) 24 0.8 54.2 41.7
Other/unknown 34 1.1 64.7 58.8
p-value – – = 0.393 < 0.001
Marital status
Separated/divorced 369 12.0 57.5 46.1
Single (including widowed) 684 22.3 50.4 36.8
Married/living with partner 1443 47.0 61.5 48.1
Other/unknown 573 18.7 51.3 40.8
p-value – – < 0.001 < 0.001
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TABLE 11 Socioeconomic status: distribution and quit rate
SES n (N= 3069) % Self-report quit (%) CO-validated quit (%)
NSSEC
Routine and manual 941 30.7 59.4 46.3
Intermediate 284 9.3 58.5 44.0
Managerial/professional 434 14.1 65.4 51.2
Retired 344 11.2 69.2 59.0
Home carer 197 6.4 46.2 35.5
Sick/disabled and unable to work 220 7.2 50.0 36.8
Never worked/long-term unemployed 443 14.4 46.5 35.2
Full-time student 102 3.3 41.2 23.5
Other/unknown 104 3.4 40.4 31.7
p-value – – < 0.001 < 0.001
NSSEC (four category)
Routine and manual 941 30.7 59.4 46.3
Managerial/professional and intermediate 718 23.4 62.7 48.3
Sick/disabled and never worked/long term 663 21.6 47.7 35.8
Other/unknown 747 24.3 55.3 44.2
p-value – – < 0.001 < 0.001
Education
None 602 19.6 56.6 46.2
GCSE or equivalent 855 27.9 56.8 44.2
Apprenticeship/vocational 148 4.8 60.8 48.0
A-level or equivalent 316 10.3 60.8 44.6
Degree or equivalent 290 9.5 62.8 46.2
Other/unknown 858 28.0 52.1 40.6
p-value – – = 0.011 = 0.231
Eligibility for free prescriptions
Eligible for free prescriptions 1437 46.8 48.6 37.2
Pays 1081 35.2 63.6 48.0
Outside 19–59 years age group/unknown 551 18.0 63.9 53.9
p-value – – < 0.001 < 0.001
Housing tenure
Private renting 742 24.2 51.8 37.3
Social/council renting 753 24.5 49.1 39.0
Buying on a mortgage 789 25.7 65.3 51.7
Own outright 468 15.3 69.9 57.9
Other/unknown 317 10.3 44.8 31.6
p-value – – < 0.001 < 0.001
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Occupation
Around one-third of clients (31%) reported working in routine and manual occupations, with other types of
occupational group fairly evenly distributed. The best 4-week outcomes were found in the managerial/
professional and retired groups (65% and 69% self-report compared with 51% and 59% CO validated,
respectively). There was a significant difference between retired and other/unknown SES. Outcomes for
full-time students were among the poorest and also had the largest gap between self-report and CO-validated
quits (41% compared with 23%). This is not surprising considering that the majority of students will be under
24 years and similar outcomes were found when looking at 4-week outcome by age; 16- to 24-year-olds had
the poorest outcomes. Only 20% of clients with professional, managerial and intermediate occupations
reported having degrees, which seems low. In the general population, 30% women and 20% men have
a degree.49
Education
Highest educational qualification was an extra question added for the ELONS study, not required in routine
monitoring. It was particularly poorly answered by most sites, with 28% missing overall. From the data
available, there was no relationship between reported education and CO-validated quitting, although there
was a relationship in the expected direction for self-report [i.e. better outcomes for clients with a degree
than those with no qualifications (63% compared with 57%)] (p= 0.011).
Eligibility for free prescriptions
Clients who reported paying for prescriptions were more likely to have better 4-week outcomes than those
who did not (64% compared with 49% self-report outcomes) but those whose eligibility was unknown or
were outside the 19–59 years age range where eligibility reflects SES were most likely to quit (p< 0.001).
Housing tenure
Short-term quit rates were higher among homeowners compared with those reporting living in rented
accommodation. Those buying outright were most likely to quit, which is likely to reflect age and those
whose tenure was unknown were least likely, which is likely to reflect lack of engagement with the
services (p<0 .001).
Lone parents
Of the sample, 80% stated that they were lone parents. Overall, lone parents had very low quit rates
(36%). Of these lone parents, 16% were men (p< 0.001).
Health and well-being
A number of medical conditions can affect which stop smoking medications are appropriate for clients and,
probably for this reason, data on health issues were well recorded by practitioners who completed
monitoring forms with clients. Some key results are described here and presented in Table 12.
TABLE 11 Socioeconomic status: distribution and quit rate (continued )
SES n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Household type
Lone parenta 232 7.6 48.3 38.4
≥ 2 adults and children 912 29.7 57.6 41.7
No children in household 1839 59.9 58.2 46.7
Other/unknown 86 2.8 36.0 26.7
p-value – – < 0.001 < 0.001
A-level, advanced level; GCSE, General Certificate of Secondary Education.
a Given the age distribution a minority may be lone grandparents, etc.
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TABLE 12 Distribution and quit rates of the health and well-being variables
Health and well-being variables n (N= 3069) %
Self-report
quit (%)
CO-validated
quit (%)
Any medical condition
Has one or more medical condition(s) 1725 56.2 57.3 45.3
Has no medical condition 1344 43.8 55.8 42.3
p-value – – = 0.414 = 0.089
Mental health condition(s)a
Has mental health condition 486 15.8 50.8 38.9
Does not have mental health condition 2583 84.2 57.7 45.0
p-value – – = 0.005 = 0.014
Heart/blood/circulation condition
Has heart/blood/circulation condition(s) 532 17.3 61.3 51.1
Does not have heart/blood/circulation condition(s) 2537 82.7 55.7 42.5
p-value – – = 0.017 < 0.001
All lung and respiratory illnessb
Has lung and respiratory illness 648 21.1 53.7 43.1
Does not have any lung and respiratory illness 2421 78.9 57.4 44.2
p-value – – = 0.090 = 0.590
Other conditionc
Has other condition 354 11.5 60.2 47.2
Does not have any other condition 2715 88.5 56.2 43.7
p-value – – = 0.153 = 0.199
Medical conditions limiting
Severely limiting 202 6.6 57.9 43.6
Moderately limiting 562 18.3 56.9 47.3
No limiting effects 961 31.3 57.3 44.5
No medical condition 1344 43.8 55.8 42.3
p-value – – = 0.867 = 0.230
Self-assessment of health
Not good 658 21.4 51.1 38.8
Fairly good 1325 43.2 56.5 44.6
Good 1003 32.7 61.9 47.4
Unknown 83 2.7 39.8 35.0
p-value – – < 0.001 = 0.002
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Medical conditions
Having a medical condition was not related to abstinence at 4 weeks and neither was having a more
severe medical condition. This may be because the type of medical condition was important: clients who
had a mental health condition were less likely to quit than those without (39% compared with 45%;
p= 0.014) whereas clients with a heart, blood or circulation condition were more likely to quit than those
without (51% compared with 43%; p< 0.001). There was no relationship for respiratory conditions or
other medical conditions. Heart, blood and circulation conditions were 25 times more prevalent in the
oldest age group than in the youngest age group (49% compared with 2%; p< 0.001). Mental health
conditions were about twice as common among clients claiming sickness or unemployment benefits as
among clients overall (29% compared with 15%; p< 0.001). Mental health conditions were about twice
as prevalent in the 45–54 years age group as in the youngest and oldest age group (20% compared with
10% and 12% respectively; p= 0.003).
Self-assessed health and well-being
The ELONS study participants were also asked about their own perceptions of health and well-being.
Interestingly, clients who chose not answer these questions had the lowest chances of stopping smoking.
Thus we cannot tell from the chi-squared tests whether or not there were significant differences in quitting
by self-assessed health or well-being.
Around two-fifths of people aged 45 years and younger assessed their health as good before age 45 years,
compared with one-quarter of people aged 46 years and above (p< 0.001).
Over a half of the sample (54%) had a concerning level of well-being. A concerning level of well-being
was more common in people who had a mental health condition (71% vs. 53%; p< 0.001). Clients
receiving group-based treatment were more likely to have good levels of well-being than those receiving
one-to-one treatment (51–55% vs. 41–44%; p< 0.001). Highest levels of well-being (about a half
reporting good well-being) were found in the two youngest age groups. Lowest levels of good well-being
(35%) were found in the 45–54 years age groups, who were also more likely than other age groups to
have a mental health condition (p< 0.001). Well-being was similar among clients with professional/
managerial/intermediate occupations and clients with routine and manual occupations (49% to 50%) but
poorer among clients claiming sickness or unemployment benefits (35%; p< 0.001).
Smoking behaviour
Questions on smoking behaviour were centred on assessing nicotine dependence and motivation to stop
smoking. The pattern of responses is shown in Table 13.
TABLE 12 Distribution and quit rates of the health and well-being variables (continued )
Health and well-being variables n (N= 3069) %
Self-report
quit (%)
CO-validated
quit (%)
WHO-5 Well-being Index
Concerning level of well-being 1646 53.6 55.1 41.9
Good level of well-being 1325 43.2 59.9 47.3
Missing 98 3.2 37.8 34.7
p-value – – < 0.001 = 0.002
a Including addiction and degenerative.
b Including chronic obstructive pulmonary disorder, emphysema, asthma and other respiratory conditions.
c Not mental health, heart, blood, circulation or respiratory.
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TABLE 13 Smoking behaviour variables: distribution and quit rate
Smoking behaviour variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
HSI tobacco dependence score
0 – little or no dependence 144 4.7 67.4 49.3
1 – lower dependence 194 6.3 60.8 43.3
2 363 11.8 60.3 44.6
3 834 27.2 61.4 48.
4 839 27.3 53.3 41.8
5 487 15.9 51.3 42.7
6 – higher dependence 179 5.8 46.4 36.9
Missing 29 0.9 – –
p-value – – < 0.001 = 0.049
Smoking after waking
≤ 5 minutes 1334 43.5 52.0 41.0
6–30 minutes 1158 37.7 59.8 47.1
31–60 minutes 290 9.4 62.4 48.6
> 60 minutes 268 8.7 60.8 42.2
Missing 19 0.6 – –
p-value – – < 0.001 = 0.007
Cigarettes smoked per day
≤ 10 498 16.2 65.3 48.0
11–20 1634 53.2 56.6 43.4
21–30 695 22.7 54.7 45.5
≥ 31 230 7.5 44.8 35.7
Other/unknown 12 0.4 41.7 33.3
p-value – – < 0.001 = 0.025
Number of years smoked
< 10 472 15.4 49.4 35.4
11–20 873 28.5 52.6 38.8
21–30 699 22.8 57.7 45.1
31–40 566 18.4 61.3 50.5
> 40 438 14.3 66.9 58.0
Missing 21 0.7 14.3 14.3
p-value – – < 0.001 < 0.001
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Smoking dependence
Of those who smoked ≤ 10 cigarettes per day, 65% reported that they were abstinent at 4 weeks in
comparison with just 45% of those who smoked ≥ 31 cigarettes per day. There was not a linear
relationship for the intermediate categories. Clients who smoked within 5 minutes of waking were least
likely to quit by 4 weeks (41% compared with 42–49%; p< 0.001). However, the relationship was not
linear. There were better outcomes for those who smoked the longest; 67% of those smoked for
≥ 40 years had quit, in comparison with just 49% of those who smoked for ≤ 10 years (p< 0.001). This
variable is, however, strongly correlated with age and older people are more likely to be successful in
stopping smoking. The sick/unemployed (p< 0.001), males (p= 0.002) and middle-age groups (p< 0.001)
reported higher nicotine dependency than other groups.
Motivation
Over half (51%) of clients were extremely determined to quit and they had the highest quit rates, with
62% self-reported abstinence at 4 weeks. There were no SES or gender differences in determination to
quit. As outlined above, clients in midlife were most dependent on tobacco (4–9% had the highest
dependency score compared with 3% in the oldest and youngest age groups; p< 0.001) but were also
the most determined to quit (50–54% compared with 44–47%; p= not available).
Support for the quit attempt
Participants were also asked about sources of support to stop smoking other than SSS staff, and about
previous experience of smoking cessation. This included support from friends and family, work colleagues,
number of previous quit attempts and previous use of pharmacotherapy. Results are summarised here and
further detail is available in Table 14.
Social support
The best outcomes were found in clients who were not surrounded by smokers: 30% of clients who
reported that all their friends and family were CO validated as quit at 4 weeks compared with 53% who
reported that none of their friends or family members smoked (p< 0.001).
There was very little difference in quit rates between the 87% who had sources of support to stop and the
11% who did not. Clients who did not provide information about this type of support were less likely to
quit – 27% compared with 43–45% (p= 0.007). Quit rates were slightly higher for clients who had a
spouse/partner or work colleagues supporting their quit attempt and slightly lower for clients who had
family or friends supporting their quit attempt. It was not possible to tell whether or not these differences
were significant because those who did not provide any information about support were much less likely
to quit.
TABLE 13 Smoking behaviour variables: distribution and quit rate (continued )
Smoking behaviour variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
How determined to quita
Not at all or quite determined 263 8.6 43.4 30.0
Very determined 1183 38.6 54.5 42.4
Extremely determined 1557 50.7 61.7 48.6
Unknown 66 2.2 27.3 19.7
p-value – – < 0.001 < 0.001
HSI, Heaviness of Smoking Index.
a Forty-seven study site 2 clients were asked this question on a 6-point scale ranging from 5 ‘I know I should’ to 10
‘desperate’. These were incorporated into the above variable as follows: 5–7 coded as ‘not at all/quite’, 8–9 coded as
‘very’ and 10 as ‘extremely’.
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TABLE 14 Distribution and quit rates of the support variables
Support variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Smokers in the home
Other smokers at home 1266 41.3 55.1 42.5
No one else smokes at home 1619 52.8 58.5 45.4
Missing 184 6.0 50.5 41.9
p-value – – = 0.045 = 0.247
Friends and family smokers
All smoke 104 3.4 45.2 29.8
Most smoke 577 18.8 50.8 36.4
About half smoke 611 19.9 54.3 42.6
A few smoke 1424 46.4 60.9 48.0
None smoke 259 8.4 64.9 52.5
Not applicable or missing 94 3.1 33.0 30.9
p-value – – < 0.001 < 0.001
Work or study smokers
All smoke 60 2.0 46.7 25.0
Most smoke 300 9.8 55.0 42.7
About half smoke 396 12.9 60.4 45.2
A few smoke 926 30.2 60.0 45.9
None smoke 324 10.6 62.0 48.8
Not applicable or missing 1063 34.6 51.7 41.9
p-value – – < 0.001 = 0.008
Access to support
Supporter available 2669 87.0 54.7 44.6
No one supporting 322 10.5 58.5 42.9
Missing 78 2.5 34.6 26.9
p-value – – < 0.001 = 0.007
Family support
Family supporting attempt 1185 38.6 55.4 41.9
No family support 1806 58.9 58.4 46.1
Missing 78 2.5 34.6 26.9
p-value – – < 0.001 < 0.001
Friend support
Friend supporting attempt 561 18.3 54.9 41.5
No friend support 2430 79.2 57.7 45.1
Missing 78 2.5 34.6 26.9
p-value – – (< 0.001) (= 0.003)
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TABLE 14 Distribution and quit rates of the support variables (continued )
Support variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Spouse support
Spouse supporting attempt 1556 50.7 61.1 48.3
No spousal support 1435 46.8 53.0 40.3
Missing 78 2.5 34.6 26.9
p-value – – < 0.001 < 0.001
Colleague support
Work colleague support attempt 200 6.5 60.5 46.0
No work support 2791 90.9 57.0 44.3
Missing 78 2.5 34.6 26.9
p-value – – < 0.001 = 0.008
Number of previous attempts
Serious previous quit attempt in the last year 1253 40.8 57.2 44.0
No serious quit attempt in last year 1755 57.2 57.3 44.7
Unknown 61 2.0 24.6 24.6
p-value – – < 0.001 = 0.008
SSS attendance
Attended SSS in LPA 394 12.8 56.9 44.4
Did not attend SSS in LPA 859 28.0 57.4 43.8
Missing 1816 59.2 56.2 44.0
p-value – – = 0.846 = 0.977
Varenicline use
Used varenicline in LPA 347 11.3 62.5 48.1
Did not use varenicline 906 29.5 55.2 42.4
Missing 1816 59.2 56.2 44.0
p-value – – = 0.055 = 0.187
Previous use of over-the-counter NRT
Used NRT over the counter in LPA 281 9.2 59.8 44.8
Did not use NRT bought over the counter 972 31.7 56.5 43.7
Missing 1816 59.2 56.2 44.0
p-value – – = 0.530 = 0.946
Previous use of prescribed NRT
Used NRT prescribed by GP in LPA 232 7.6 57.8 46.1
Did not use NRT prescribed by GP 1021 33.3 57.1 43.5
Missing 1816 59.2 56.2 44.0
p-value – – = 0.846 = 0.766
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Female participants were more likely than male participants to have other smokers in the home (43% vs.
39%; p= 0.007) and not to have support from a spouse/partner (53% vs. 41%; p< 0.001).
Previous serious quit attempt in the last year
Clients who did not answer questions about their previous quit attempt were less likely to quit (25%) but
there was little difference between clients who had and had not made a quit attempt (44–45%). Those
who had used some sort of support in their previous quit attempt (e.g. varenicline or the SSS) were
significantly more likely to quit than those who had not (33% vs. 46%; p= 0.003).
Behavioural support
Behavioural support describes the format of counselling that participants received from the SSS (e.g. closed
groups, open groups, drop-in and one to one) (Table 15).
At the basic level, using the unweighted data, key findings (see Table 15) included:
l more than 40% of clients who received three of the four ‘specialist’ type of behavioural support
(closed group, open group, and one to one) were CO validated as quit
l fewer than 40% of clients who received behavioural support in a GP practice or pharmacy setting, or
who attended a specialist drop-in were CO validated as quit
l open-group clients were the most likely to be CO validated as quit (53%; p< 0.001) but the self-report
quit rates of one-to-one clients and open-group clients were similar (approximately 60%).
TABLE 14 Distribution and quit rates of the support variables (continued )
Support variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Bupropion use
Used bupropion in LPA 17 0.6 64.7 58.8
Did not use bupropion 1236 40.3 57.1 43.8
Missing 1816 59.2 56.2 44.0
p-value – – = 0.706 = 0.462
Use of smoking helpline
Used smoking helpline in LPA 11 0.4 72.7 54.6
Did not use smoking helpline 1242 40.5 57.1 43.9
Missing 1816 59.2 56.2 44.0
p-value – – = 0.500 = 0.777
Use of support
Used nothing in LPA 208 6.8 45.2 33.2
Used some form of support 1045 34.1 59.6 46.1
Missing 1816 59.2 56.2 44.0
p-value – – = 0.001 = 0.003
LPA, latest previous attempt.
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TABLE 15 Behavioural support type variables: distribution and quit
Behavioural support type variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Practitioner level
Level 2 379 12.4 48.0 38.7
Specialist 2679 87.3 58.0 45.2
Missing 11 0.4 – –
p-value – – < 0.001 = 0.001
Support type
Closed-group specialist 102 3.3 52.9 43.1
Open-group specialist 550 17.9 61.6 53.0
Drop-in specialist 887 28.9 52.1 39.4
One-to-one specialist 1131 36.9 61.4 46.3
GP practice service 270 8.8 48.9 35.9
Pharmacy service 97 3.2 45.4 38.1
Other or unclear 32 1.0 40.6 21.9
p-value – – < 0.001 < 0.001
Intervention type
Closed group 102 3.3 52.9 43.1
Open (rolling) group 550 17.9 61.6 53.1
Drop-in clinic 887 28.9 52.1 39.4
One-to-one support (any provider) 1517 49.4 57.8 43.6
Other 10 0.3 50.0 20.0
Missing 3 0.1 – –
p-value – – = 0.009 < 0.001
Practitioner type
Specialist 2679 87.3 58.0 45.2
Health-care assistanta 134 4.4 57.5 38.8
Practice nurse 120 3.9 40.0 32.5
Assistant (pharmacy) 35 1.1 40.0 28.6
Dispenser/technician 37 1.2 37.8 35.1
Pharmacist/manager 25 0.8 64.0 56.0
Other 27 0.9 48.2 40.7
Missing 12 0.4 – –
p-value – – < 0.001 = 0.0003
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What might explain these patterns? There are a number of potential confounders:
l Pharmacy clients were less likely to be prescribed varenicline (20% of pharmacy clients were prescribed
varenicline compared with ≥ 40% for the other behavioural support types; p< 0.001).
l Older clients were more likely to attend GP practices than other clients (12% of 65- to 85-year-olds
received GP practice services compared with 6% of 16- to 17-year-olds), whereas younger clients were
more likely to attend pharmacy services (5% of 16- to 17-year-olds received pharmacy services
compared with 2% of 65- to 85-year-olds; p= 0.026).
l Drop-in clients were likely to have a lower SES. Drop-in groups had the highest percentage of sick/
unemployed clients (25% of drop-in clients were sick/unemployed compared with ≤ 24% of clients
participating in other behavioural support types), clients eligible for free prescriptions (54% drop-in
clients were eligible compared with ≤ 52% of clients in other behavioural support types; p< 0.001)
and social rent (28% of drop-in clients were social renters compared with ≤ 25% of clients in other
behavioural support types; p< 0.001).
l Medication was more likely to be recorded on three or more occasions by specialists (46% of clients
who received specialist support has medication recorded compared with 36% of clients who received
GP or pharmacy services; p< 0.001).
TABLE 15 Behavioural support type variables: distribution and quit (continued )
Behavioural support type variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Intervention setting
Pharmacy 121 3.9 45.5 37.2
GP practiceb 1592 51.9 57.7 43.8
Community-oriented building 634 20.7 59.0 47.2
Well-being centre (e.g. healthy living centre) 67 2.2 50.8 37.3
Workplace or education 161 5.3 59.6 49.1
Children’s centre 92 3.0 60.9 51.1
Sports and leisure 88 2.9 59.1 48.9
Dedicated SSS shop or stall 110 3.6 42.7 27.3
Other 204 6.7 52.0 41.7
p-value – – = 0.007 = 0.003
Sessions
One session 449 14.6 19.8 14.7
Two sessions 331 10.8 15.7 4.5
Three sessions 348 11.3 25.3 15.8
Four sessions 336 11.0 47.3 28.9
Five sessions 374 12.2 70.3 55.4
Six sessions 360 11.7 83.6 65.3
Seven or eight sessions 467 15.2 88.9 76.0
Nine or more sessions 374 12.2 97.3 84.5
Unknown 30 1.0 23.3 13.3
p-value – – < 0.001 < 0.001
a Includes a few phlebotomists.
b Includes a few clients who were seen at polyclinics.
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l Group clients had higher levels of well-being (51–55% of group clients had higher well-being scores
compared with 41–45% of clients who received other behavioural support types; p< 0.001).
l Clients of level 2 providers were less determined to quit (43% of clients who attended level 2 providers
were extremely determined compared with 52% of specialist clients; p= 0.003) and were less likely
to have a heart/blood/circulation condition (2% of level 2 clients compared with 8% of specialist
clients; p= 0.002).
However, specialists were more likely to see clients with some characteristics associated with lower
quit rates:
l mental health condition (16% of specialist clients compared with 12% of level 2 clients; p= 0.041)
l permanently sick/unemployed (23% of specialist clients compared with 14% of level 2 clients; p< 0.001)
l high dependency on tobacco (6% of specialist clients compared with 5% of level 2 clients scored
highest on dependence and 5% of specialist clients compared with 6% of level 2 clients scored lowest
on the dependence scale (p= 0.007)
l higher proportion of smokers among friends and family (23% compared with 16% all or most of
friends and family smoke; p= 0.031).
Practitioner type
Clients were supported to stop by a range of types of practitioner working in for a number of different
service providers (see Table 15).
l Most clients (87%) were seen by a specialist practitioner.
l About 8% of clients were seen by practice nurses and health-care assistants based in GP practices.
Only two-thirds of people seen in a GP practice by a health-care practitioner who claimed to be quit
were actually validated to be so.
l About 3% of clients were seen by pharmacy practitioners.
¢ Pharmacy practitioners had the most extreme quit rates (i.e. the highest and lowest), but altogether
pharmacy practitioners recruited only 97 clients so subgroups are very small.
¢ Clients who saw pharmacy assistants were least likely to be CO validated as quit, and clients who
saw pharmacy managers or pharmacists were most likely to have a CO-validated quit compared
with all other practitioner types (p= 0.0003).
l One per cent of clients were seen by other types of practitioners. Most of these were GP practice staff
who worked in roles such as administration and receptionists and/or those who worked in a general
well-being improvement field such as health trainers and people working in healthy living centres.
There were a few clients who were seen by dental practice staff.
Intervention setting
Clients were treated in a wide range of venues (see Table 15). Over a half of the ELONS study participants
were seen in GP practices (52%) and one-fifth (21%) in a community-oriented building such as a
community centre. Clients who attended sessions in a children’s centre were most likely quit (51%) and
those who attended a dedicated SSS shop or stall were least likely to quit (27%; p=0 .003). However, this
might reflect who was recruited from these settings:
l Sick/unemployed people made up a higher proportion of clients seen at a dedicated SSS shop/stall
(33% of a dedicated SSS shop/stall clients were sick/unemployed compared with ≤ 28% at other
locations; p< 0.001).
l A higher proportion of dedicated SSS shop/stall clients were in the youngest age group than was true
for all other settings except for well-being centres (18% dedicated SSS shop/stall clients and 19%
well-being centre clients compared with ≤ 11% at other locations; p< 0.001).
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Session attendance
The more sessions a client attended, the better the 4-week outcome (97% of clients who attended at least
nine sessions reported a quit at 4 weeks compared with just 16% of clients who attended two sessions;
p< 0.001) (see Table 15). However, it should be noted that 11 of the 23 level 2 providers in site 1 used
paper forms and these had to be returned to the specialist service after the 4-week quit outcome was
recorded, which meant that not all sessions may have been recorded. In contrast, practitioners who
entered data electronically at source could record up to 12 sessions. However, these paper-based providers
recruited only 87 clients.
Medication
Practitioners recorded which smoking cessation medication their clients were taking to help them
quit – this would normally happen during their behavioural support session. The derived variables from this
information focused on frequency and type (Table 16).
Frequency
There was a lot of variation in number of days between sessions; bearing this in mind the following key
points emerged from the data:
l the more occasions that medication was recorded as being taken, the more likely clients were to quit
[68% who had medication recorded on three or more occasions quit compared with 26% who took
medication on one or two occasions and 17% where medication was not recorded (p< 0.001)]
l younger people took medication on fewer occasions. Only 30% took medication on three or more
occasions compared with 44% or more in the other age groups (p< 0.001).
TABLE 16 Medication variables: distribution and quit rates
Medication variables n (N= 3069) %
Self-report
quit (%)
CO-validated
quit (%)
Medication (frequency of recording)
No occasions 93 3.0 24.7 17.2
1 occasion 998 32.5 32.9 21.8
2 occasions 616 20.1 46.8 32.1
3 occasions 540 17.6 70.0 56.5
4 occasions 471 15.4 88.5 74.5
5–10 occasions 338 11.0 89.9 77.5
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Medication (frequency truncated)
No occasions 93 3.0 24.7 17.2
1 or 2 occasions 1614 52.6 38.2 25.8
3–10 occasions 1349 44.0 81.5 68.1
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
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TABLE 16 Medication variables: distribution and quit rates (continued )
Medication variables n (N= 3069) %
Self-report
quit (%)
CO-validated
quit (%)
Medication and occasions
Single NRT only 1–2 occasions 407 13.3 37.6 26.8
Single NRT only 3 or more occasions 189 6.2 81.5 73.5
Combination NRT only 1–2 occasions 448 14.6 30.1 15.9
Combination NRT only 3 or more occasions 125 4.0 79.2 67.2
Varenicline only 1–2 occasions 614 20.0 42.8 31.9
Varenicline only 3 or more occasions 699 22.8 85.3 69.4
Other/mixed medication 1–2 occasions 145 4.7 44.8 27.6
Other/mixed medication 3 or more occasions 336 11.0 74.4 62.5
No medication recorded 93 3.0 24.7 17.2
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Medication (type only)
Single NRT only 596 19.4 51.5 41.6
Combination NRT only 573 18.7 40.8 27.1
Varenicline only 1313 42.8 65.4 51.9
Other/mixed medication 481 15.7 65.5 52.0
No medication recorded 93 3.0 24.7 17.2
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Varenicline use
Took varenicline 1445 47.1 64.3 50.7
Did not take varenicline 1611 52.5 50.2 38.3
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Bupropion use
Took bupropion 32 1.0 53.1 31.3
Did not take bupropion 3024 98.5 56.9 44.3
Missing 13 0.4 – –
p-value – – < 0.001 = 0.002
NRT combination use
NRT combination 962 31.4 52.1 38.8
Did not take NRT combination 2092 68.2 59.1 46.7
Missing 15 0.5 – –
p-value – – < 0.001 < 0.001
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TABLE 16 Medication variables: distribution and quit rates (continued )
Medication variables n (N= 3069) %
Self-report
quit (%)
CO-validated
quit (%)
NRT single use
NRT single 1003 32.7 58.7 47.2
Did not take NRT single 2051 66.8 56.0 42.8
Missing 15 32.7 – –
p-value – – < 0.168 < 0.024
NRT patch use
Used NRT patch 1321 43.0 52.7 41.2
Did not use NRT patch 1735 56.5 60.1 46.5
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Lozenge use
Took lozenge 390 12.7 55.4 40.3
Did not take Lozenge 2666 86.9 57.1 44.8
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Gum use
Took gum 222 7.2 59.0 43.7
Did not use gum 2834 92.3 56.7 44.1
Missing 13 0.4 – –
p-value – – < 0.001 = 0.006
Inhaler use
Used inhaler 545 17.8 48.4 36.9
Did not use an inhalator 2511 81.8 58.7 45.8
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Spray use
Used spray 303 9.9 50.5 35.3
Did not use mouth/nasal spray 2753 89.7 57.6 45.2
Missing 13 0.4 – –
p-value – – < 0.001 < 0.001
Minitab
Used Minitab 30 1.0 53.3 40.0
Did not use Minitab 3026 98.6 56.9 44.2
Missing 13 0.4 – –
p-value – – < 0.001 = 0.005
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Medication type
People who used combination NRT (taking two or more forms of NRT in the same week and never single
NRT) were no more likely to quit than those using a single form of NRT. In fact, a much lower proportion
were likely to achieve abstinence at 4 weeks (27% quit compared with 42% of people who took single
NRT). Combination NRT varied between 66% and 3% between study sites (p< 0.001).
Varenicline was the most common type of medication (43% used at least once). Varenicline use also varied
by study site (p< 0.001) and by NSSEC (33% sick/unemployed clients compared with 53% clients with
routine and manual occupations and 51% clients with professional, managerial and intermediate
occupations; p< 0.001). Only 1% took bupropion.
Type and frequency
Single NRT and combination NRT tended to be recorded on one or two occasions. Varenicline and
other/mixed medication were more likely to be recorded on three or more occasions. Quit rates were
approximately 32% or below if medications were recorded only on one or two occasions but were over
60% if they were noted on three or more occasions (p< 0.001). There were marked variations in
medication type and frequency by study site.
Accessing services
At baseline, participants were asked questions about how they had accessed the service (Table 17).
Over half already knew of their SSS because they had made a previous quit attempt (53%). Only 5%
of clients had heard about the service through marketing.
Men were more likely to be introduced by referral from a GP practice (21% compared with 17% of
women; p< 0.001). The youngest age groups were most likely to be introduced through friends
and family (22% compared with 11% or below for the other age groups; p< 0.001). ’Stoptober’
(a government-supported campaign to encourage smokers to quit for at least the month of October)
was mentioned as a route into the service for 81 clients.
The quit rates were similar regardless of the route by which people got to the service.
TABLE 17 Accessing services: distribution and quit rates
Accessing services n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Introduction to the SSS
Marketing 154 5.0 52.6 42.9
Friends and family 317 10.3 53.6 38.9
GP practice 568 18.5 58.8 45.8
Other organisations 211 6.9 47.9 38.9
Unknown 202 6.6 54.5 42.1
Previous quit attempt with services 1617 52.7 58.3 45.4
p-value – – = 0.035 = 0.150
Mention of Stopober
Mentioned Stoptober 81 2.6 48.2 44.4
No mention of Stoptober 2988 97.4 56.9 44.0
p-value – – < 0.001 = 0.933
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Some data collection issues to consider
The way in which data are collected has the potential to influence the smoking cessation outcomes
reported. Here we highlight this so that the prospective study results can be better understood. Four
methodological issues are described: first, the time of year that the client set their quit date; second, clients
not setting a quit date; third, the numbers of clients who were recruited to the ELONS study who had
more than one quit attempt with the SSS; and fourth, whether or not clients provided a saliva sample at
baseline (for analysis of long-term NRT use).
Clients in the ELONS study set quit dates between March 2012 and March 2013, as shown in Table 18.
These were clustered, however, with most being set between July and November 2012. This reflects the
staggered start and end of data collection for each site. There were 150 clients who did not set a quit date
from only three of the nine sites. These locations collected monitoring information before clients were
required to set a quit date and so needed to ask for consent to the ELONS study before they knew
whether or not clients were going to get as far as actually setting a quit date. These clients were not
excluded in the analysis – they form part of the prospective study data set.
TABLE 18 Distribution and quit rates of the data collection variables
Data collection variables n (N= 3069) % Self-report quit (%) CO-validated quit (%)
Month quit date set
March 2012 2 0.1 0.0 0.0
April 2012 24 0.8 70.8 62.5
May 2012 53 1.7 43.4 30.2
June 2012 137 4.5 57.7 47.5
July 2012 429 14.0 54.8 44.8
August 2012 505 16.5 53.5 42.0
September 2012 497 16.2 61.4 48.1
October 2012 589 19.2 63.8 50.1
November 2012 343 11.2 60.6 43.2
December 2012 152 5.0 63.2 44.1
January 2013 144 4.7 66.0 53.5
February 2013 41 1.3 80.5 58.5
March 2013 3 0.1 33.3 0.0
Missing quit date 150 4.9 0.00 0.0
p-value – – < 0.001 < 0.001
Saliva collection
Saliva collected 1874 61.1 54.5 41.5
Saliva not collected 1195 38.9 60.0 48.0
p-value – – = 0.003 < 0.001
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There were 22 clients, from five of the nine sites, who were recruited twice to the ELONS study. This
means they had more than one quit attempt with the service during the study period – they were ‘repeat’
attenders (this is not shown in Table 18).
Two-thirds of clients gave a saliva sample, as Table 18 illustrates. These clients were significantly less likely
to quit at 4 weeks. Younger clients were more likely to give a saliva sample (68% compared with 55%
and 57% for the two oldest age groups).
Comparing the ELONS study and ‘all cases’ data sets
The final ELONS study sample consisted of 3057 SSS clients, once pregnant clients and clients whose
advisor was unclear had been excluded. For the reasons described in Chapter 5, these participants
represented a small proportion of those who accessed SSSs in the study areas during the recruitment
period. The sample is therefore not representative of all service clients in those areas. This is important
as the ELONS study was designed to try and draw some overall conclusions about the longer-term
effectiveness of the support to stop smoking offered by services in England. As a first stage in the analysis,
therefore, we conducted comparisons between the ELONS study data and that available for all service
clients, drawn from the routine (QuitManager) data available for each site.
The ‘all cases’ database contained quit attempts with quit dates that took place at the nine study sites
from March 2012 to March 2013 (the months where any ELONS study client set a quit date; n= 71,800).
Quit attempts where the client was pregnant, under the age of 16 years or were a prisoner who attended
the specialist service were excluded because these clients were not recruited to the ELONS study
(n= 65,972). Additionally, to be consistent with the final ELONS study sample, quit attempts where the
practitioner was unknown were also excluded (n= 65,937). Thus, 5% of qualifying quit attempts that
were made in the nine study sites were included in the ELONS study. However, because the recruitment
period for each site was variable, if we just look at periods when the specialists and level 2 providers were
actually recruiting, 9% of quit attempts were included in the ELONS study. Recruitment rates were higher
for the specialist service (14%) than the level 2 providers (2%) at least partly because not all level 2
providers took part and those that did recruited for different periods.
The ‘all cases’ database was used to develop weights in order to calculate quit rates generalisable to the
nine services that took part in the ELONS prospective study. The frequencies of the variables included and
response rates are provided in Table 19. The response rate was the number of ELONS study clients divided
by the number of all cases clients multiplied by 100.
Clustering by service also had to be taken into account when producing final quit rates. This was because
different locations offered different behavioural support types and some sites we were not able to recruit
clients accessing some behavioural support types. The overall profiles of the ELONS study clients
behavioural support types, however, strongly reflected ‘all cases’ behavioural support types. This is
illustrated in Figure 6, which compares the behavioural support in each site the ‘all cases’ data set with the
behavioural support types of clients recruited to the ELONS prospective study.
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TABLE 19 Distribution of variables used for weighting in the ‘all cases’ and the ELONS study data sets
Variables ‘All cases’, n ELONS, n Response rate (%)
Behavioural support
Closed-group specialist 541 102 18.9
Open-group specialist 2159 550 25.5
Drop-in specialist 11,308 887 7.8
One-to-one specialist 21,796 1131 5.2
Level 2 GP practice 16,412 269 1.6
Level 2 pharmacy 9821 97 1.0
Other or unclear 3900 21 0.5
Gender
Female 34,955 1710 4.9
Male 30,982 1347 4.3
Age group (years)
16–24 7120 327 4.6
25–34 13,226 673 5.1
35–44 15,338 758 4.9
45–54 13,851 629 4.5
55–64 9933 456 4.6
≥ 65 6469 214 3.3
NSSEC
Routine and manual occupations 18,201 939 5.2
Managerial/professional and intermediate occupations 14,098 716 5.1
Sick/disabled and never worked/long-term unemployed 14,932 660 4.4
Other/unknown 18,706 742 4.0
Total 65,937 3057 4.6
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Short- and longer-term quit rates
The main results for the ELONS study are the short- and longer-term cessation rates achieved by
participants in the prospective study. The CO-validated raw quit rate at 4 weeks was 44.1% but after
weighting this reduced marginally to 41.2% (95% CI 34.9% to 47.9%). The raw quit rate in the longer
term, at 1 year, was 9.3% but after weighting this reduced marginally to 7.7% (95% CI 6.6% to 9.0%).
The weighted results are shown in Table 20. These also include the proportion of people who had
relapsed to smoking at 4 and 52 weeks post quit date, and also those lost to follow-up. Participants who
were lost to follow-up (22.6% at 4 weeks and 45.2% at 52 weeks) were assumed to be smoking,
consistent with an intention-to-treat analysis.
We also examined differences in short- and longer-term cessation outcomes by key variables of interest,
including client and service characteristics (Table 21). Quit rates in the short and longer term did vary
between groups of clients with particular characteristics, and the type of support provided by the SSSs.
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FIGURE 6 Distribution of behavioural support by location in the routine monitoring data and clients recruited to
the prospective study.
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TABLE 20 Short- and longer-term weighted quit status
Short- and longer-term weighted quit status Weighted (%) (95% CI)
Short-term quit status (4 weeks)
CO validated 41.3 (34.9 to 48.0)
Self-report not CO validated 12.2 (8.3 to 17.5)
Relapsed (including quit refuted by CO validation) 23.9 (15.8 to 34.5)
Lost to follow-up 22.6 (15.1 to 32.4)
Longer-term quit status (52 weeks)
CO validated 7.7 (6.6 to 9.0)
Self-report not CO validated 5.6 (5.1 to 6.1)
Relapsed at 4 or 52 weeks (including quit refuted by CO validation) 41.6 (31.0 to 53.0)
Lost to follow-up at 4 or 52 weeks 45.2 (34.6 to 56.2)
TABLE 21 Weighted CO-validated quit rates (per cents and weighted 95% CI), weighted mean age and well-being
(and weighted 95% CI) by key variables for the ELONS study at 4 and 52 weeks
Key variables n % 4 weeks (95% CI) 52 weeks (95% CI)
Behavioural support
Closed-group specialist 102 3.3 42.9 (28.6 to 58.6) 13.8 (8.7 to 21.3)
Open-group specialist 550 18.0 53.1 (36.4 to 69.1) 11.6 (6.5 to 20.1)
Drop-in specialist 887 29.0 39.6 (24.3 to 57.2) 7.6 (5.1 to 11.0)
One-to-one specialist 1131 37.0 46.1 (39.5 to 52.8) 10.2 (7.6 to 13.7)
GP practice service 269 8.8 36.1 (26.2 to 47.3) 5.1 (2.9 to 8.8)
Pharmacy service 97 3.2 38.2 (18.7 to 62.5) 5.2 (1.5 to 15.8)
Other or unclear 21 0.7 NA NA
Behavioural support (truncated)
Group specialist 652 21.3 – 12.1 (10.5 to 13.8)
Drop-in specialist 887 29.0 – 7.6 (5.1 to 11.0)
One-to-one specialist 1131 37.0 – 10.2 (7.6 to 13.7)
GP practice or pharmacy service 366 12.0 – 5.1 (2.8 to 9.3)
Other or unknown 21 0.7 – NA
Time of year of quit attempt
Other months 767 25.1 39.4 (33.6 to 45.5) 7.0 (5.2 to 9.4)
Summer – July and August 970 31.7 38.0 (31.4 to 45.0) 6.3 (4.4 to 8.9)
Back to school – September and October 1128 36.9 46.2 (37.8 to 54.8) 8.7 (6.4 to 11.7)
New Year – January and February 192 6.3 37.8 (24.5 to 53.3) 13.1 (5.1 to 29.6)
continued
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TABLE 21 Weighted CO-validated quit rates (per cents and weighted 95% CI), weighted mean age and well-being
(and weighted 95% CI) by key variables for the ELONS study at 4 and 52 weeks (continued )
Key variables n % 4 weeks (95% CI) 52 weeks (95% CI)
Age (years) (weighted mean)a
Not quit mean – – 41.1 (40.1 to 42.0) 43.3 (42.5 to 44.1)
Quit mean – – 47.2 (46.0 to 48.3) 46.8 (44.4 to 49.2)
Gender
Female 1710 55.9 40.1 (35.3 to 45.1) 7.2 (6.0 to 8.5)
Male 1347 44.1 42.5 (33.4 to 52.2) 8.4 (6.8 to 10.2)
Ethnicity
White British 2866 93.8 41.6 (35.7 to 47.8) 7.4 (6.1 to 9.0)
Other white 69 2.3 39.9 (18.2 to 66.3) 11.5 (4.5 to 26.0)
Asian (including mixed white and Asian) 64 2.1 25.1 (13.9 to 41.0) 3.6 (1.3 to 9.5)
Other and unknown 58 1.9 40.3 (17.5 to 68.3) 21.6 (7.0 to 50.1)
SES
0–1 indicators of low SES 1123 36.7 48.4 (38.5 to 58.4) 10.3 (8.4 to 12.7)
2–5 indicators of low SES 1934 63.3 37.1 (30.2 to 44.6) 6.2 (5.0 to 7.7)
WHO-5 Well-being Index (weighted mean)a
Not quit mean – – 51.6 (50.0 to 53.2) 52.7 (51.4 to 53.9)
Quit mean – – 55.5 (53.8 to 57.1) 59.3 (56.5 to 62.1)
Medication in week 1
Varenicline not recorded 1661 54.3 37.0 (31.7 to 42.7) 6.2 (4.9 to 7.7)
Took varenicline 1396 45.7 47.4 (39.1 to 55.8) 10.0 (7.2 to 13.8)
Dependence
Other 1681 55.0 45.4 (40.3 to 50.6) 9.8 (7.7 to 12.4)
Highly dependent 1376 45.0 35.7 (26.1 to 46.6) 4.9 (2.9 to 8.2)
Determination to quit
Other 328 10.7 26.6 (20.9 to 33.2) 5.9 (4.3 to 8.0)
Very/extremely determined 2729 89.3 43.0 (36.0 to 50.4) 8.0 (6.7 to 9.5)
Support from spouse partner
Other 1507 49.3 38.5 (32.3 to 45.1) 6.2 (4.5 to 8.5)
Support from spouse/partner 1550 50.7 43.9 (37.0 to 51.0) 9.2 (7.4 to 11.3)
Friends and family
Other 771 25.2 33.3 (27.5 to 39.7) 3.4 (2.6 to 4.4)
Half or fewer smoke 2286 74.8 43.7 (36.9 to 50.8) 9.1 (7.5 to 10.9)
Total 3057 100.0 41.2 (34.9 to 47.9) 7.7 (6.6 to 9.0)
NA, not available.
a There is some evidence of skew in the continuous variables, however, as a rule of thumb, skew and kurtosis can be
ignored below 0.8. Age raw data: mean, 42.52; median, 42.00; skew, 0.250; standard error skew, 0.044; kurtosis,
–0.715; standard error kurtosis –0.089. WHO-5 raw data: mean, 53.78; median, 56.00; skew, –0.333; standard error
skew, 0.044; kurtosis, –0.479; standard error kurtosis, –0.089.
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Client characteristics and abstinence
In the short term, at 4 weeks, quit rates were higher among older people and clients with higher levels
of well-being. There were no significant gender, socioeconomic or ethnic differences. Differences in
medication, dependence on tobacco, social network and support from a spouse or partner did not reach
significance for short-term quit rates. However, quit rates were higher among those who were more
determined to quit.
In the longer term, at 52 weeks, quit rates were higher among older people [mean age of quitters
46.8 years (95% CI 44.4 to 49.2 years) compared with a mean age of 43.3 years (95% CI 42.5 to
44.1 years) for non-quitters]. Less-disadvantaged people had a quit rate of 10.3% (95% CI 8.4% to
12.7%) compared with a quit rate of 6.2% (95% CI 5.0% to 7.7%) among more-disadvantaged people.
Clients with higher levels of well-being when they began their quit attempt were more likely to quit than
those with lower well-being [mean well-being score was 59.3 out of 100 (95% CI 56.5 to 62.1) compared
with 52.7 out of 100 (95% CI 51.4 to 53.9) for non-quitters]. There were no significant gender or ethnic
differences. Likewise, at 52 weeks, differences in medication, dependence on tobacco, determination to
quit and support from a spouse or partner did not quite reach significance. Quit rates were higher among
those whose social network was less populated with smokers, 9.1% (95% CI 7.5% to 10.9%) compared
with 3.4% (95% CI 2.6% to 4.4%).
Service characteristics, timing and abstinence
In the initial analysis, we differentiated six forms of behavioural support offered by services. These were
closed and open specialist groups, specialist drop-ins, one-to-one specialist and behavioural support
provided by GP practice employees and pharmacy employees. CIs overlapped for all forms of support but
there were only about 100 clients who received closed group support or pharmacy service support leading
to very wide CIs. Initially, the sample design was powered so that the smallest group size was 100 and the
next group size was 500. Furthermore, the power calculations were based on a quit rate of 15% rather
than 8%. Thus, CI overlap could be because of lack of power because both closed groups and pharmacies
consisted only of about 100 clients. As Table 21 shows, quit rates for both forms of group support were
similar and were higher than other forms of support, and quit rates for non-specialist services were similar
and lower than other forms of support groups. Thus some behavioural support groups were merged for
the 52-week analysis. Clients who received group support had significantly higher quit rates, 12.1%
(95% CI 10.5% to 13.8%) compared with clients who received support from a GP practice or pharmacy
service, 5.1% (95% CI 2.8% to 9.3%). Clients who received one-to-one or drop-in specialist support quit
rates were intermediate, 10.2% (95% CI 7.6% to 13.7%) and 7.6% (95% CI 5.1% to 11.0%), respectively.
At 52 weeks, there were no significant seasonality effects.
Multivariable predictors of abstinence in the short term
Multivariable logistic regression was undertaken in order to better understand which characteristics of
clients and services were most closely related to abstinence from smoking after taking other factors into
account at 4 and 52 weeks. These results are shown in Table 22.
Looking first at the 4-week predictors, shown in Table 22, clients who attended open groups had the
highest ORs of quitting in the short term, at 4 weeks, aOR 1.5 (95% CI 1.0 to 2.2). Clients who attended
open groups were significantly more likely to quit than clients who attended specialist one-to-one sessions.
Cessation at 4 weeks was associated with: attending services in the New Year, aOR 1.5 (95% CI 1.1 to
2.2); older age, aOR 1.032 (95% CI 1.026 to 1.039); affluence, aOR 1.3 (95% CI 1.1 to 1.6); white
(non-British) compared with Asian, aOR 2.5 (95% CI 1.1 to 5.5); lower dependence on tobacco, aOR 1.3
(95% CI 1.1 to 1.5); determination to quit, aOR 2.3 (95% CI 1.7 to 3.0); taking varenicline, aOR 1.6
(95% CI 1.4 to 1.9); higher levels of well-being, aOR 1.004 (95% CI 1.000 to 1.007); support from a
spouse or partner, aOR 1.3 (95% CI 1.1 to 1.5); or low levels of smoking among friends and family,
aOR 1.2 (95% CI 1.0 to 1.5). The difference between men and women was not significant.
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TABLE 22 Adjusted ORs (and 95% CI) by key variables in ELONs at 4 and 52 weeks
Key variables n (N= 3057) % 4 weeks (95% CI) 52 weeks (95% CI)
Behavioural support
Closed-group specialist 102 3.3 0.9 (0.6 to 1.5) N/A
Open-group specialist 550 18.0 1.5 (1.0 to 2.2) N/A
Drop-in specialist 887 29.0 0.7 (0.6 to 0.9) N/A
One-to-one specialist 1131 37.0 1 N/A
GP practice service 269 8.8 0.8 (0.5 to 1.3) N/A
Pharmacy service 97 3.2 0.9 (0.6 to 1.6) N/A
Other or unclear 21 0.7 0.6 (0.2 to 1.7) N/A
Behavioural support (truncated)
Group specialist 652 21.3 N/A 3.4 (1.7 to 6.7)
Drop-in specialist 887 29.0 N/A 1.7 (0.9 to 3.5)
One-to-one specialist 1131 37.0 N/A 2.3 (1.2 to 4.6)
GP practice or pharmacy service 366 12.0 N/A 1
Other or unknown 21 0.7 N/A 2.3 (0.5 to 11.6)
Time of year of quit attempt
Other months 767 25.1 1 1.2 (0.8 to 1.7)
Summer – July and August 970 31.7 1.2 (1.0 to 1.5) 1
Back to school – September and October 1128 36.9 1.4 (1.1 to 1.7) 1.2 (0.9 to 1.6)
New Year – January and February 192 6.3 1.5 (1.1 to 2.2) 1.7 (1.0 to 2.9)
Age (in years) – – 1.032 (1.026 to 1.039) 1.011 (1.002 to 1.020)
Gender
Female 1710 55.9 1 1
Male 1347 44.1 1.1 (0.9 to 1.3) 1.2 (0.9 to 1.5)
Ethnicity
White British 2866 93.8 1.3 (0.7 to 2.4) Did not enter
Other white 69 2.3 2.5 (1.1 to 5.5) Did not enter
Asian (including mixed white and Asian) 64 2.1 1 Did not enter
Other and unknown 58 1.9 2.4 (1.1 to 5.6) Did not enter
SES
0–1 indicators of low SES 1123 36.7 1.3 (1.1 to 1.6) 1.4 (1.1 to 1.9)
2–5 indicators of low SES 1934 63.3 1 1
WHO-5 Well-being Index (weighted mean) – – 1.004 (1.000 to 1.007) 1.007 (1.001 to 1.013)
Medication in week 1
Varenicline not recorded 1661 54.3 1 1
Took varenicline 1396 45.7 1.6 (1.4 to 1.9) 1.7 (1.3 to 2.3)
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Multivariable predictors of abstinence in the longer term
A number of factors contributed to whether or not SSS clients maintained abstinence from smoking in the
longer term. Compared with clients who received support from either a GP practice or pharmacy service,
the odds of quitting were three times higher for those who received group support, aOR 3.4 (95% CI 1.7
to 6.7) and the odds of quitting were twice as high for clients who received support on a one-to-one basis
from a specialist adviser, aOR 2.3 (95% CI 1.2 to 4.6).
For every year of age, clients were more likely to quit, aOR 1.011 (95% CI 1.002 to 1.020). There was no
evidence that men were more likely to maintain abstinence than women. Clients whose quit attempt
began in the New Year were more likely to quit than those who started during the summer holiday period,
aOR 1.7 (95% CI 1.0 to 2.9). More-affluent clients were more likely to have stopped smoking at 1 year,
aOR 1.4 (95% CI 1.1 to 1.9) than less-affluent clients.
Clients who had higher levels of well-being were more likely to be abstinent from smoking at 1 year.
Thus for every increase of 1 on the well-being scale (range 0–100), clients were more likely to be
non-smokers, aOR 1.007 (95% CI 1.0003 to 1.013). Clients who were less dependent on tobacco were
significantly more likely to quit, aOR 1.5 (95% CI 1.1 to 1.9). Clients whose quit attempt was supported by
a spouse or partner were significantly more likely to be abstinent at 1 year, aOR 1.4 (95% CI 1.0 to 1.8).
Clients whose social network included fewer smokers were more likely to quit, aOR 2.0 (95% CI 1.4 to
2.9). Starting a quit attempt taking varenicline was also associated with abstinence in the longer term,
aOR 1.7 (95% CI 1.3 to 2.3). Ethnicity and determination to quit were eliminated from the model by the
backwards-stepwise procedure.
TABLE 22 Adjusted ORs (and 95% CI) by key variables in ELONs at 4 and 52 weeks (continued )
Key variables n (N= 3057) % 4 weeks (95% CI) 52 weeks (95% CI)
Dependence
Other 1681 55.0 1.3 (1.1 to 1.5) 1.5 (1.1 to 1.9)
Highly dependent 1376 45.0 1 1
Determination to quit
Other 328 10.7 1 Did not enter
Very/extremely determined 2729 89.3 2.3 (1.7 to 3.0) Did not enter
Support from spouse partner
Other 1507 49.3 1 1.0
Support from spouse/partner 1550 50.7 1.3 (1.1 to 1.5) 1.4 (1.0 to 1.8)
Friends and family
Other 771 25.2 1 1.0
Half or fewer smoke 2286 74.8 1.2 (1.0 to 1.5) 2.0 (1.4 to 2.9)
Practitioner – – Variance= 0.140
(SE= 0.049)
No variance identified
N/A, not applicable; SE, standard error.
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Adherence to treatment
It is likely that an important determinant of successful quit attempts is the extent to which service clients
continue to attend sessions and also use stop smoking medication. One general term we can apply to
describe these two issues (attendance and medication use) is ‘adherence’. Owing to concerns about
reverse causality we could not include adherence in multilevel modelling. Instead, we tried to examine this
issue in some depth. The two measures of adherence collected were number of sessions of behavioural
support and number of occasions that medication was recorded.
As Table 23 shows, drop-off among the ELONS study clients from attending sessions was steady: a little
over 10% of the sample did not return following each session. In addition, about half the sample were
recorded as only taking medication on one occasion.
Adherence was much more strongly associated with cessation at 4 weeks than 52 weeks. This provides
some evidence that reverse causality does exist: clients who had not quit at 4 weeks did not continue to
attend sessions after 4 weeks. At 52 weeks differences were smaller but still significant for both number
of sessions and medication taken.
TABLE 23 Adherence distributions and weighted quit rates
Adherence measures n (N= 3057) %
Weighted quit at
4 weeks (%) (95% CI)
Weighted quit at
52 weeks (%) (95% CI)
Number of sessions
1 447 14.6 9.2 (2.3 to 30.0) 3.4 (0.8 to 13.3)
2 331 10.8 5.4 (1.5 to 17.4) 1.9 (0.8 to 4.2)
3 348 11.4 21.8 (12.8 to 34.6) 5.7 (2.8 to 11.4)
4 336 11.0 42.2 (26.6 to 59.4) 7.2 (3.6 to 13.6)
5 374 12.2 58.0 (47.3 to 67.9) 9.2 (4.7 to 17.0)
6 360 11.8 68.1 (53.3 to 80.0) 10.6 (6.4 to 17.0)
7 or 8 467 15.3 78.3 (69.4 to 85.2) 13.1 (8.5 to 19.7)
9 or more 374 12.2 84.0 (74.7 to 90.3) 16.1 (10.8 to 23.3)
Unknown 20 0.7 15.8 (1.3 to 72.7) 0.0 (0.0 to 0.0)
Occasions medication recorded (full)
No occasions or none recorded 101 3.3 11.1 (4.5 to 24.9) 5.0 (0.7 to 26.9)
1 occasion 991 32.4 13.2 (7.7 to 21.8) 4.6 (3.0 to 7.2)
2 occasions 616 22.0 30.1 (22.0 to 39.6) 7.3 (5.2 to 10.2)
3 occasions 540 17.7 57.4 (49.5 to 64.9) 8.9 (4.9 to 15.6)
4 occasions 471 15.4 76.7 (66.3 to 84.7) 9.4 (5.9 to 14.8)
5–10 occasions 338 11.1 80.7 (66.9 to 89.7) 14.1 (9.4 to 20.7)
Occasions medication recorded (short)
No occasions or none recorded 101 3.3 11.1 (4.5 to 24.9) 5.0 (0.7 to 26.9)
1 or 2 occasions 1607 52.6 20.0 (14.5 to 26.9) 5.7 (4.2 to 7.7)
3 or more occasions 1349 44.1 70.0 (63.9 to 75.5) 10.4 (8.3 to 12.9)
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Adherence to medication was explored further by taking into consideration the type of medication taken
(Table 24). The majority of clients who took either only single NRT or only combination NRT were recorded
only taking medication on one or two occasions. Similar proportions were recorded taking varenicline on
one or two occasions and three or more occasions. Thus those who took varenicline were more likely to
adhere to taking their medication.
The 4-week quit rates of clients who took all types of medication for three or more occasions were
significantly higher than those who took medication on one or two occasions. Differences are marked:
fewer than one-quarter of clients quit if medication was recorded only once or twice, whereas
approximately two-thirds or more of clients quit if they took medication three or more times (irrespective
of medication type).
Number of occasions on which NRT was recorded did not have a significant impact on quit rates but
clients who took varenicline on three or more occasions were significantly more likely to quit than clients
who took varenicline on one or two occasions. Quit rates of clients who took varenicline on three or more
occasions were also significantly higher than the quit rates of clients who took combination NRT on one to
two occasions or clients who took single NRT on three or more occasions.
If we consider what type of medication clients took at any point (Table 25), two-fifths of clients took
varenicline and one-fifth took either only single or combination NRT. Clients who at any point took more
than one form of NRT on one occasion (thus combination NRT) were significantly less likely to quit at
4 weeks. This is not consistent with evidence on the effectiveness of combination NRT and raises some
questions about the recording of combination therapy use in the study. There were no significant
differences at 52 weeks.
TABLE 24 Medication and adherence
Medication and adherence n (N= 3057) %
Weighted quit at
4 weeks (%)
(95% CI)
Weighed quit at
52 weeks (%)
(95% CI)
Single NRT only one or two occasions 407 13.3 23.4 (14.3 to 35.9) 7.5 (4.6 to 11.7)
Single NRT only three or more occasions 189 6.2 84.3 (67.4 to 93.3) 4.0 (2.0 to 7.9)
Combination NRT only one or two occasions 444 14.5 13.0 (8.6 to 19.3) 4.8 (2.8 to 7.9)
Combination NRT only three or more occasions 125 4.1 64.6 (52.5 to 75.0) 9.0 (3.6 to 20.7)
Varenicline only one or two occasions 611 20.0 22.6 (13.1 to 36.3) 5.4 (2.7 to 10.5)
Varenicline only three or more occasions 699 22.9 70.3 (65.6 to 74.6) 14.1 (10.9 to 18.1)
Other/mixed medication only one or two occasions 145 4.7 23.9 (15.5 to 34.9) 5.4 (3.0 to 9.4)
Other/mixed medication only three or more occasions 336 11.0 63.1 (57.4 to 68.4) 8.1 (5.0 to 12.6)
No medication recorded 101 3.3 11.1 (4.5 to 24.9) 5.0 (0.7 to 26.9)
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Clients who adhered to medication protocols (i.e. took medication for several weeks) have more chances
to change medication. Thus, we also looked at medication recorded in week 1 because then there was no
chance of dropping out through failure to quit. There were no significant differences in quitting detected
at 4 or 52 weeks.
Adherence among clients who were carbon monoxide-validated as quit at
4 weeks
In further analysis we investigated whether or not the number of sessions that clients who quit at 4 weeks
attended was associated with cessation at 52 weeks. Given that SSS clients normally attend and have
medication recorded once a week, we looked at whether or not clients attended up to four sessions or
had medication recorded up to four times. These results are shown in Table 26.
These results suggest that adherence has no discernible effect on quitting as CIs overlap. Note that the
vast majority of clients who quit at 4 weeks did attend for four sessions.
TABLE 25 Stop smoking medication taken at any point
Medication and time point n (N= 3057) %
Weighed quit at
4 weeks (%) (95% CI)
Weighed quit at
52 weeks (%) (95% CI)
Medication at any point
Single NRT only 596 19.5 43.8 (38.0 to 49.8) 6.3 (4.2 to 9.4)
Combination NRT only 569 18.6 25.1 (20.3 to 30.6) 5.8 (3.8 to 8.6)
Varenicline only 1310 42.9 48.1 (40.0 to 56.4) 10.1 (7.2 to 14.0)
Other/mixed medication 481 15.7 49.7 (40.8 to 58.7) 7.1 (5.1 to 10.0)
No medication recorded 101 3.3 11.1 (4.5 to 24.9) 5.0 (0.7 to 26.9)
Medication at week 1
Single NRT only 652 21.3 44.6 (39.0 to 50.3) 5.9 (4.1 to 8.4)
Combination NRT only 864 28.3 34.7 (27.3 to 42.8) 6.5 (4.8 to 8.7)
Varenicline only 1396 45.7 47.5 (39.1 to 56.0) 10.0 (7.2 to 13.8)
Other/mixed/none recorded 145 4.7 17.8 (10.8 to 28.1) 5.2 (1.5 to 16.2)
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TABLE 26 Adherence among clients who were CO validated as quit at 4 weeks only
Adherence measures n
Weighted CO-validated
52-week quit (%) (95% CI)
Sessions attended
One 65 21.0 (13.1 to 32.0)
Two 15 19.9 (10.8 to 33.8)
Three 55 16.3 (9.6 to 26.3)
Four or more 1210 15.4 (12.4 to 18.9)
Sessions unknown or not 4-week CO-validated quit 1712 2.1 (1.4 to 3.2)
Total 3057 –
Occasions medication recorded
No occasions 16 44.5 (6.2 to 90.6)
One occasion 217 22.3 (14.6 to 32.6)
Two occasions 198 20.5 (11.9 to 32.8)
Three occasions 305 13.6 (7.6 to 23.1)
Four or more occasions 613 13.3 (10.0 to 17.5)
Not 4-week CO-validated quit 1708 2.1 (1.4 to 3.2)
Total 3057 –
Single NRT only
One occasion 55 27.3 (7.9 to 62.0)
Two occasions 54 25.1 (9.6 to 51.4)
Three occasions 46 6.2 (1.3 to 25.3)
Four or more occasions 93 4.3 (1.4 to 12.5)
Total 248 –
Combination NRT only
One occasion 39 20.2 (9.7 to 37.3)
Two occasions 31 33.3 (17.7 to 53.8)
Three occasions 42 12.0 (2.1 to 46.6)
Four or more occasions 42 15.9 (4.5 to 43.2)
Total 154 –
Varenicline only
One occasion 120 20.6 (13.5 to 30.2)
Two occasions 76 14.6 (5.5 to 33.6)
Three occasions 150 19.5 (9.6 to 35.4)
Four or more occasions 335 17.0 (12.6 to 22.5)
Total 681 –
Total 3057 7.7 (6.6 to 9.0)
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Comparisons between the ELONS study and other studies
How do the short- and longer-term results from the ELONS study compare with previous studies? Some
limited comparisons can be made, although these come with a range of caveats (discussed further in
Chapter 10) owing to the observational nature of the data. There are two previous pieces of research
conducted by members of our team that employed very similar approaches. The first of these was the
previous ‘national evaluation’ of SSSs in England that was conducted between 2001 and 2004,17,18 already
mentioned in Chapter 1. This involved two areas of England – Nottingham and North Cumbria. The second
study was conducted in Glasgow between 2005 and 2007 and compared a pharmacy-based SSS with
another service providing closed-group behavioural support.28 Both reported abstinence rates at 1 year.
As Table 27 shows, the previous English evaluation in Nottingham and North Cumbria had a higher
CO-validated quit rate at 52 weeks (14.6%) than the ELONS study and a lower lost to follow-up rate
(37.5%). The difference in lost to follow-up occurred at all stages (4-week follow-up, 52-week telephone
and 52-week validation) but was highest for the 52-week telephone interview. The Glasgow evaluation
had a lower CO-validated quit rate. This was primarily because of a much higher loss to follow-up at
4 weeks. These comparisons are discussed in more detail in Chapter 10.
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TABLE 27 Quit rates and follow-up rates comparing the ELONS study with two other long-term evaluations of the
UK SSSs
Quit rates and follow-up rates
Nottingham/North
Cumbria 2002,
n (%) (N= 2069)
Glasgow 2007,
n (%) (N= 1785)
ELONSa 2012/13,
n (%) (N= 3057)
4-week follow-up
1. CO-validated quit 1129 (54.6) 401 (22.5) 1349 (44.1)
2. Self-report not CO validated 139 (6.7) 151 (8.5) 380 (12.4)
3. Self-report refuted by CO validation 4 (0.2) 16 (0.9) 6 (0.2)
4. Non-quitters 388 (18.8) 259 (14.5) 676 (22.1)
5. Lost to follow-up 409 (19.8) 958b (53.7) 646 (21.1)
Total 4-week self-report (excluding refuted by
CO test)
1268 (61.3) 552 (70.3) 1729 (56.5)
52-weeks follow-up (Russell Standard):
1. CO-validated quit (0–5 cigarettes since quit
date)
303 (14.6) 64 (3.6) 285 (9.3)
2. Self-report not CO validated 65 (3.1) 63 (3.5) 165 (5.4)
3. Self-report refuted by CO validation 8 (0.4) 1 (0.1) 18 (0.6)
4. Non-quitters at 52 weeks 525 (25.4) 264 (14.8) 583 (19.1)
5. Non-quitters at 4 weeks 392 (18.9) 259 (14.5) 676 (22.1)
6. Lost to follow-up at 52 weeks 367 (17.7) 179 (10.0) 684 (22.4)
7. Lost to follow-up at 4 weeks 409 (19.8) 955 (53.5) 646 (21.1)
Total 52-week self-report (excluding refuted by
CO test)
368 (17.7) 127 (7.1) 450 (14.7)
Alternative self-report quit rates at 52 weeksc
Point prevalenced NA 131 (7.3) 558 (18.3)
Continuous abstinence (not a puffe) 377 (18.2) 108 (6.1) 390 (12.8)
Alternative CO-validated quit rates at 52 weeks
Point prevalenced NA NA 348 (11.4)
Continuous abstinence (not a puffe) 303 (14.6) 62 (3.5) 260 (8.5)
Total eligible for follow-up at 52 weeks (all 4-week
self-report)
1272 (61.5) 568 (31.8) 1735 (56.7)
Total successfully followed up at 52 weeks 901 (43.5) 392 (22.0) 1051 (34.4)
Total eligible for CO validation at Russell Standard 376 (18.2) 128 (7.2) 475 (15.5)
Total given CO test 311 (15.0) 65 (3.6) 310 (10.1)
CO-validated quit rate of those successfully
followed up
34.5% 16.1% 27.1%
NA, not available.
a Unweighted results for the ELONS study are reported here.
b Three cases reported as lost to follow-up at 4 weeks appear to have been followed up at 12 months.
c These include all self-report (includes refutes).
d Whether or not the client had smoked within the previous 7 days in the ELONS study and the previous 2 weeks in the
Glasgow study.
e Measured since the quit date in the ELONS study and since 4-week follow-up in the Glasgow and Nottingham/North
Cumbria studies.
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Summary of key points
l The prospective study collected data from over 3000 SSS clients at 4 and 52 weeks after their quit
date. Only a small proportion (9%) of all service clients in the nine study areas were recruited. To
correct for this, weights were applied, drawing on an ‘all cases’ database created from routine data in
the study areas.
l Recruitment rates were higher for the specialist service (14%) than the level 2 providers (2%) at least
partly because not all level 2 providers took part and those that did recruited for different periods.
l In terms of smoking cessation in the short term, the raw quit rate at 4 weeks was 44.1%. With
weighting this reduced marginally to 41.2%. In comparison, the quit rate for England from April 2012
to March 2013 was 37%.31
l For smoking cessation in the longer term, the raw quit rate at 1 year was 9.3% but after weighting this
reduced to 7.7%.
l Predictors of smoking abstinence at 4 weeks were:
¢ attending an open group
¢ attending SSS in the New Year
¢ being older
¢ being more affluent
¢ having a lower dependence on tobacco
¢ being determined to quit
¢ having a higher well-being score
¢ having support from a spouse or partner
¢ having a social network not populated with smokers.
l Predictors of abstinence at 52 weeks were largely similar and included:
¢ attending group behavioural support or receiving one-to-one support from a specialist practitioner
¢ taking varenicline
¢ attending SSS in the New Year
¢ being older
¢ being more affluent
¢ having a lower dependence on tobacco
¢ having a higher well-being score
¢ having support from a spouse or partner
¢ having a social network not populated with smokers.
l Taking stop smoking medication and attending support sessions (described here as ‘adherence’) was
significantly associated with smoking cessation – more so at 4 weeks than at 1 year.
l Limited comparisons with previous evaluations of SSSs in England are possible. Quit rates for 4 and
52 weeks from the ELONS prospective study were lower than those identified in the previous national
evaluation in England, but higher than a recent study in Glasgow that examined closed-group and
pharmacy-based services.
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Chapter 7 Client satisfaction survey
A ll clients who participated in the prospective cohort (regardless of the outcome of their quit attempt)were sent a CSS to give feedback on the service they received. This chapter presents the rationale for
adding the CSS to the prospective studies, the recruitment approach, sample analysis and results. Results
are presented in two sections. Section one groups findings under six headings: client characteristics;
thoughts of the SSS overall; making initial contact with SSS; appointment times and venues; service
received; and medication. In order to assess whether or not levels of satisfaction have an influence on
abstinence from smoking, section two compares CSS findings with three key variables from the ELONS
prospective study data set: CO-validated quitting, location and behavioural support type.
Rationale
A questionnaire to measure client satisfaction with SSSs was developed by members of the research team
in 2008 as part of the DH’s ‘gold standard’ monitoring and evaluation guidance for SSSs.50 The questions
were designed to assess the overall level of client satisfaction with SSSs, with additional questions to look
at specific elements of the service, for example, appointment times, convenience of venue, type of support
received, willingness to recommend the service to others and smoking status. A copy of the questionnaire
is appended (see Appendix 1).
Stop Smoking Services are under no obligation to use a CSS, which means that there was no consistency of
use among the nine ELONS study sites. Some administered the survey but had no resource to analyse or make
use of the findings to improve their service; others asked some questions but not all. Thus, despite not being
directly relevant to research objectives, the research team thought that by offering to administer, analyse and
write up the CSS and feed findings back to sites, this might encourage sign-up from the selected SSSs.
This, in turn, would boost the study sample and contribute to answering the research objectives. In addition,
the CSS generated useful data, highlighting the value of the service provided to smokers trying to quit.
Recruitment, sample and analysis
The research team posted a self-complete questionnaire to all clients 4-weeks after their quit date was set
(regardless of the outcome of their quit attempt). To encourage response, two reminder mailings were
sent and a prize draw of £200 of high street vouchers was offered.
There were 1006 questionnaires received and the final data set had 996 cases (one was removed because
of missing data and nine discarded because they had been completed twice). This means that one-third
(33%) of the ELONS study participants completed this survey. Questionnaire data were entered into Excel
and then transferred to SPSS (version 19.0) for analysis. Respondents were also given the opportunity to
write additional comments about the service they received. These have been analysed thematically and
placed in the relevant sections, with quotes to illustrate where relevant. As a result of missing data, the
number of clients responding to each question will vary.
Findings
Client characteristics
Table 28 presents sample characteristics of clients who completed a CSS in comparison with the main ELONS
study sample. Of the respondents who completed a CSS, 71% were CO validated as abstinent from smoking
4 weeks after their quit date. In the overall ELONS study sample, the proportion of clients who had a
CO-validated quit was a lot lower (44%). Clients who were successful in their quit attempt were more likely to
complete the survey and this should be remembered when reviewing the findings.
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TABLE 28 Client satisfaction survey sample characteristics
CSS sample characteristics
Recruited to ELONS Responded to CSS
n (N= 3069) % n (N= 996) %
Smoking status
CO-validated quit 1350 44.0 711 71.4
Self-report quit 1737 56.6 831 83.4
Smoking 1332 43.4 165 16.6
Gender
Male 1355 44.2 558 56.0
Female 1714 55.8 438 44.0
Age group (years)
16–24 330 10.8 66 6.6
25–34 676 22.0 149 15.0
35–44 760 24.8 198 19.9
45–54 631 20.6 236 23.7
55–64 458 14.9 221 22.2
65–85 214 7.0 126 12.7
Ethnicity
White British 2877 93.7 937 94.1
Other white 70 2.3 22 2.2
Asian (including mixed white and Asian) 64 2.1 9 0.9
Black (including mixed white and black) 24 0.8 11 1.1
Other/unknown 34 1.1 17 1.7
SES
Professional managerial 718 23.4 243 24.4
Routine and manual 941 30.7 258 25.9
Unemployed/permanently sick 663 21.6 194 19.5
Other 747 24.3 301 30.2
Behavioural support type
Closed group 102 3.3 32 3.2
Open group 550 17.9 207 20.8
Drop-in 887 28.9 255 25.6
One-to-one specialist 1131 36.9 389 39.1
GP practice 270 8.8 79 7.9
Pharmacy 97 3.2 25 2.5
Other or unclear 32 1.0 9 0.9
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Overall opinions
Clients were asked for their overall opinion of the SSS, with 87% saying they were either very satisfied
or satisfied.
In open-ended responses, clients described the service they had attended as: ‘supportive’; ‘encouraging’;
‘very good’; ‘excellent’; ‘friendly’; ‘welcoming’; ‘reassuring’; ‘good advice’; ‘well-informed’; ‘enthusiastic’;
‘helpful’; and ‘understanding’.
Satisfaction with the support received was also high; 87% of respondents were either very satisfied or
satisfied with the support they received. In addition, nearly all respondents (96%) said that they would
recommend the SSS to other smokers who want to stop smoking. As one respondent wrote:
I would have struggled to stop smoking without the help of the service. I would definitely recommend
anyone wishing to stop smoking to use this service.
A further 94% would return to a SSS should they start smoking again and 86% felt that they would be
welcomed back:
I hope to never use the service again but would not hesitate to if the requirement came about again.
Perhaps not surprisingly, positive feedback was more likely among ‘quitters’ (i.e. respondents who had a
successful quit attempt at 4 weeks) than ‘non-quitters’. This is examined further in this chapter.
Making initial contact with Stop Smoking Service
Respondent feedback on making initial contact and arranging an appointment with the SSS was also
extremely positive (Table 29). The majority of respondents (94%) said it was easy to contact the SSS and
the majority (88%) were given an appointment date or told how long they would need to wait to receive
one. Three-fifths (60%) waited 5 or fewer days for their first appointment (22% were seen straight or
away or within 24 hours) and the majority (92.5%) felt the time they waited was acceptable. One-third
(31%) were contacted by the SSS before their first appointment to encourage and motivate them to
attend (it should be noted that in some service clients are seen straight away so this question was not
relevant to some participants).
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Appointment times and venue
Appointment times and venues were rated very highly with 95% of respondents reporting that
appointment times were convenient, and a further 97% stating that the venue was also convenient
(Table 30). Child care costs were irrelevant for 83% of the sample. Three respondents said that they were
offered support with child care costs. Two-fifths (41.5%) were given the choice of whether they would like
an individual or group appointment.
Similar findings were evident from the open-ended comments, with an appreciation of the flexible
consultation approach and the different type of behavioural support on offer:
As working full time was unable to attend weekly appointments – staff arranged telephone
consultations which was great otherwise would most probably have stopped going.
I liked the idea of walk in centre, every Wednesday, just for smokers and the one to one appointments
which I had every week with the same person. To me it was better than a group session.
TABLE 29 Making initial contact with SSSs
Initial contact with SSSs
Responded to CSS
n (N= 940–988) %
Easy to contact SSS
Yes 926 93.7
No 29 2.9
Unsure 33 3.3
Given appointment date
Yes 852 87.6
No 95 9.8
Unsure 26 2.7
How long for appointment date (days)
0–5 568 60.4
6–10 281 29.9
≥ 10 91 9.7
Length of time acceptable
Yes 902 92.5
No 31 3.2
Unsure 42 4.3
Contact from SSS before appointment
Yes 303 31.2
No 553 56.9
Unsure 116 11.9
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However, there were suggestions for improvement, which mainly centred on having more flexible
appointment times, a wider choice of behavioural support, a longer treatment period, more telephone
contact to maintain morale and introducing a diet class to address potential weight gain after
smoking cessation.
There are no evening appointments at my local clinic, which makes things difficult for those who work
full time.
I would have preferred individual appointments to group therapy.
I feel that instead of having to attend for just 4 weeks it should be rolled out to at least 8. From past
experience I feel 4 weeks is too quick.
Maybe a text or phone call between appointment time, i.e. 2 weeks is a long time to leave someone
without encouragement. I liked the way my smoking service only encourages a full quit.
Maybe introduce a dieting class, i.e. dieting support. I think many people especially woman don’t
want, or find it hard to quit smoking because they put on too much weight.
TABLE 30 Appointment times and venues
Appointment times and venues
Responded to CSS
n (N= 972–996) %
Time convenient
Yes 936 95.2
No 23 2.3
Unsure 24 2.4
Place convenient
Yes 955 97.0
No 18 1.8
Unsure 12 1.2
Child care support
Yes 3 0.3
No 157 15.8
Unsure 7 0.7
Not applicable/did not answer 829 83.2
Able to choose group or one to one
Yes 403 41.5
No 460 47.3
Unsure 109 11.2
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Service received
Respondents were either satisfied or very satisfied with support from SSS staff (89%). Nine out of 10 (90%)
rated the information and advice they received as very helpful or helpful and a further 82% found the
written advice helpful/very helpful. Finally, 86% found having their CO checked at every visit helpful or
very helpful. This was also the view from the open-ended comments; however, there were some important
comments about practitioners. As we have already seen, in the main, practitioners were highly praised and
appreciated but there were some comments that suggested that practitioner/client rapport was inadequate
in some way. The same applied to continuity of practitioners, that is, not seeing the same practitioner at
each visit and being able to make contact. Both the ELONS study secondary analysis and prospective data
sets revealed that the individual practitioner had a significant influence, at least on short-term quit rates.
A couple of us had not fully stopped smoking, whereas most had. The attitude displayed by one nurse
seemed patronising and dismissive. It needed to be more constructive. It put me off going back and
without the support which was otherwise good I failed to stop.
[Name of practitioner] was the best person for the job, she was dead easy to talk to about anything
but the woman who took over from her made me feel really unsettled in a telephone consultation
therefore never went back!!!
It would be helpful to see the same person every week. Sometimes I saw different people and had to
keep introducing myself and explaining how long I’d given up etc.
Medication
Respondents indicated that the information given about different types of stop smoking medication was
helpful (94%) and 92% reported that it was easy to obtain their medication of choice [with a half (49.8%)
via GP prescription] (Table 31).
TABLE 31 Medication
Medication
Responded to CSS
n (N= 974–993) %
Medication information helpful
Yes 929 93.9
No 20 2.0
Unsure 40 4.0
Source of medicationa
GP prescription 485 49.8
Chemist (bought myself) 27 2.8
Chemist (with a voucher) 132 13.6
Chemist (with service letter or prescription) 174 17.9
SSS 198 20.3
Ease of accessing medication
Yes 897 91.8
No 54 5.5
Unsure 26 2.7
a Percentage more than 100% as a few respondents indicated more than one option, so each one was
analysed separately.
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However, analysis of open-ended comments highlighted two areas for consideration: a lack of information
on the side effects of medication and difficulty obtaining medication.
Side effects of varenicline need to be highlighted – include info on all possible side effects.
Explain more about how stopping smoking will affect your immunity to illness. I have never had so
many colds/flu infections/virus infections as this in my life since I stopped smoking.
Chemist don’t carry enough stock! Most weeks I have to wait for some. Normally next day+ costs of
travel again.
It would be better if stop smoking staff could give out medication as I had to make three trips with
letters, prescriptions etc. to finally get medication 5 days later.
Client satisfaction survey findings and the ELONS prospective
study data set
Satisfaction levels by three key variables from the ELONS study data set (CO-validated quitting, location
and behavioural support type) are explored in this section. CO-validated abstinence from smoking (in the
short term) was chosen in order to explore whether or not any of the satisfaction variables might point to
facilitators for cessation. Location was chosen because some issues with satisfaction may be study site
specific and so may be relevant for only some sites. Finally, behavioural support was chosen as one of the
aims of the ELONS study in order to assess the effectiveness of various forms of behavioural support and
establish whether or not the support that clients receive affects their satisfaction.
Some sites and behavioural support categories did not support analysis owing to insufficient respondent
numbers and were merged into ‘other’ categories. Note that different sites offered different forms of
behavioural support and recruitment was higher for some support types than others. The percentage of
respondents from each location for each support type is tabulated (Table 32). Nearly two-thirds (63%)
of GP practice respondents were from site 1 and 96% of open-group respondents were from site 6.
TABLE 32 Percentage of clients from each site for each behavioural support type
Behavioural
support group
Site 1, %
(n= 94)
Site 2, %
(n= 245)
Site 4, %
(n= 136)
Site 6, %
(n= 245)
Site 8, %
(n= 156)
Other sites,
% (n= 117)
Total,
%
Total, n
(N= 996)
Open group 3.9 – – 96.1 – – 100.0 207
Drop-in – 39.6 22.0 – 22.0 16.5 100.0 255
One-to-one
specialist
3.6 33.7 18.5 9.3 24.2 10.8 100.0 389
GP practice 63.3 15.2 2.5 5.1 – 13.9 100.0 79
Other supporta 33.3 1.5 9.1 9.1 13.6 33.3 100.0 66
Percentage of
clients from each
site
9.4 24.6 13.7 24.6 16.0 11.7 100.0 –
a Other support included closed groups (n= 32), pharmacy (n= 25), other level 2 (n= 8) and other/unclear (n= 1).
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Response categories for the 5-point Likert scales were merged to enable analysis. Chi-squared tests were
conducted between CO-validated quitting and all the satisfaction variables. If there was a significant
difference between quitters and non-quitters (p< 0.05) then chi-squared tests were conducted for location
and behavioural support types. Results are presented where p< 0.05.
Overall satisfaction and supportiveness of staff
Those who were CO validated as having stopped smoking were slightly more likely to be very satisfied
with the services overall (64% vs. 51%) and less likely to state they were satisfied or unsure, unsatisfied
and very unsatisfied (Table 33). A similar pattern emerged for satisfaction with staff supportiveness. Of the
quitters, 68% were very satisfied with staff supportiveness versus 54% of non-quitters. The highest level of
satisfaction with supportiveness was among respondents who attended open groups (70% very satisfied).
Returning to the services
The majority of respondents (those who were abstinent from smoking and those who had not stopped or
relapsed by 4 weeks) said they would return to the SSS if they needed help with another quit attempt
(Table 34). There was a small but significant difference: 96% of quitters said they would return compared
with 89% of non-quitters.
Although the majority of respondent’s thought they would be welcomed back, quitters were slightly more
likely to say they would be welcomed (88% vs. 79%). This may reflect differences in behavioural support
as it was only among respondents who had attended open groups where over 90% believed they would
be welcomed back.
TABLE 33 Comparing satisfaction with service between quitters and non-quitters, study sites and
behavioural support
Behavioural support type Very satisfied (%) Satisfied (%) Unsure, unsatisfied, very unsatisfied (%)
Quitting (p = 0.001)
Not CO validated as quit 51.1 33.3 15.6
Quit (CO validated) 64.4 23.8 11.8
Total 60.6 26.5 12.9
Quitting (p < 0.001)
Not CO validated as quit 54.1 31.4 14.5
Quit (CO validated) 67.5 23.0 9.5
Total 63.7 25.4 10.9
Behavioural support (p = 0.014)
Open group 70.0 24.2 5.8
Drop-in 62.5 29.2 8.3
One-to-one specialist 64.0 22.0 14.0
GP practice 58.2 27.8 13.9
Other support 53.0 31.8 15.2
Total 63.7 25.4 10.9
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TABLE 34 Client views on key aspects of service provision
Client views Yes (%) No or unsure (%)
Return to SSS
Quitting (p< 0.001)
Not CO validated as quit 89.3 10.7
Quit (CO validated) 96.3 3.7
Total 94.3 5.7
Welcomed back to SSS
Quitting (p< 0.001)
Not CO validated as quit 79.2 20.8
Quit (CO validated) 88.2 11.8
Total 85.6 14.4
Behavioural support (p= 0.011)
Open group 92.2 7.8
Drop-in 87.3 12.7
One-to-one specialist 82.9 17.1
GP practice 81.0 19.0
Other support 80.3 19.7
Total 85.6 14.4
Whether or not given written information
Quitting (p= 0.017)
Not CO validated as quit 89.8 10.2
Quit (CO validated) 94.3 5.7
Total 93.0 7.0
Location (p< 0.001)
Site1 90.3 9.7
Site 2 92.1 7.9
Site 4 87.2 12.8
Site 6 99.2 0.8
Site 8 91.1 8.9
Other sites 93.2 6.8
Total 93.0 7.0
Medication information helpful
Quitting (p< 0.001)
Not CO validated as quit 88.7 11.3
Quit (CO validated) 96.0 4.0
Total 93.9 6.1
Location (p< 0.001)
Site1 83.9 16.1
Site 2 94.3 5.7
continued
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Information provided
The majority of respondents were given written information, however, those who had stopped smoking by
4 weeks were slightly more likely to report that they had been given written information (94% vs. 90%).
There was a significant difference between locations but even the site with the lowest provision achieved
87% clients being given written information.
Of those who had stopped smoking, 96% found information about medication helpful compared with
89% of those who had not. Helpfulness of information about medication was lower in site 1 (84%) than
other sites (or site groups) analysed where over 90% agreed that information about medication was
helpful. Comments about medication from site 1, which came from respondents who attended a variety of
behavioural support types, included reports that side effect issues were not covered, they were encouraged
to take medication when they did not want it and that their choice of medication was not easily available:
I’d like to see that mild smokers are taken just as seriously as heavy smokers, in the sense that the
whole course of patches should be offered not only an inhaler, I did manage to get some but only
with protest.
Carbon monoxide validation at each session
Carbon monoxide-validated quitters were slightly more likely to state that they had a CO-validation test
at each session than those quit but not CO validated (95% vs. 91%). Among those who had taken a
CO-validated test at each session (see Table 34), quitters were more likely to say it was very helpful than
non-quitters (73% vs. 63%). There was a significant difference between location, with respondents from
site 6 reporting highest levels of helpfulness (81%) and site 1 respondents were least likely to say that
the CO-validation test was very helpful (57%). This may reflect the behavioural support type: 87% of
open-group clients said that a CO test during each session was very helpful, compared with 59% of GP
practice clients. Site 8 was chosen for the study because of its low CO-validation rate. Clients in site 8
were most likely to say that they were unsure about CO validation or they found it unhelpful or very
unhelpful (13% compared with an average of 9% in all other sites).
TABLE 34 Client views on key aspects of service provision (continued )
Client views Yes (%) No or unsure (%)
Site 4 92.5 7.5
Site 6 96.3 3.7
Site 8 93.7 6.3
Other sites 98.3 1.7
Total 93.9 6.1
Whether or not given CO test each session (p = 0.011)
Not CO validated as quit 90.8 9.2
Quit (CO validated) 95.3 4.7
Total 94.0 6.0
CLIENT SATISFACTION SURVEY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Summary of key points
l A consistent pattern emerged that suggests that smokers who accessed SSSs, in the ELONS study areas
and responded to the survey, had a very positive experience, for both quitters and non-quitters. The
vast majority who replied to the questionnaire indicated that they would recommend the service to
others and return should the need arise.
l There were several examples of good practice, when SSSs offered more than they are required to do by
the DH (e.g. contacting clients before their first appointment to encourage them to attend and offering
child care and a choice of behavioural support options).
l Additional comments highlighted the importance of practitioner/client rapport, and multilevel
modelling of the ELONS study secondary analysis and prospective study data sets suggests that this is
an important factor in a successful quit attempt, at least in the short term.
l Despite quantitative findings suggesting that medication was easy to acquire, additional comments
pointed to a more complex picture where the process of obtaining medication was overcomplicated
and time-consuming for some respondents.
l Suggested improvements centred on evening appointment times, having a choice of group or
one-to-one support and a longer period of support.
l Analysis of client satisfaction between quitters and non-quitters, SSS location and behavioural support
types revealed some small but significant differences:
¢ Quitters were more likely to be satisfied with staff supportiveness and happier to return to the
services if needed, with the information provided and CO validation.
¢ Open-group clients were happier about staff supportiveness, returning to the service and CO
testing. GP practice clients were least comfortable with CO testing. It must be noted that
open-group clients were mostly recruited from a single site.
l Finally, despite an encouraging response rate (response to self-completion postal surveys are generally
low, even with repeated reminders) clients who were motivated to complete the survey were also more
likely to have had a successful quit attempt. This means the views of those who did not quit are
under-represented.
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Chapter 8 Well-being study
Well-being can improve after smoking cessation, but smokers often have concerns about stoppingbecause they believe smoking itself brings benefits, such as reduced stress levels.51 The ELONS study
provided an opportunity to examine changes in well-being before and after stopping smoking to add to
our understanding of this issue.
Rationale
Additional information on the health and well-being of the ELONS prospective study participants was
collected for a number of reasons. First, it has been argued that the ultimate aim of health care is to
improve quality of life.52 It would, therefore, be expected that a health intervention, such as a smoking
cessation programme, would improve well-being,53–55 but previous research has highlighted some
unintended consequences.52,56 In addition, as well as being a desired outcome of a health interventions,
well-being may also be a predictor of successful smoking cessation.55–59 No studies that we could identify
had examined changes in well-being among clients of NHS SSSs and thus we decided to include a focus
on this in the current study.
Recruitment
As part of the baseline monitoring data collection for the prospective study, clients were asked additional
questions about their health and well-being. In addition, all clients, regardless of their smoking status,
were sent postal questionnaires at 4 and 52 weeks post quit date, which included questions on well-being
(see Appendix 1).
Measures
Medical conditions variables
Health was operationalised as the presence or absence of medical conditions. Practitioners collected
detailed information on medical conditions for two reasons. First, SSSs provide medication to support
smoking cessation and other medications need to be understood to make sure the medication is
appropriate. Second, we wished to consider medical conditions because there is an association between
many medical conditions and smoking. For the ELONS study, each service was required to ask about a list
of medical conditions for consistency. Medical conditions reported by clients were amalgamated into the
following for analysis: any medical condition; heart, blood and circulatory conditions; lung and respiratory
conditions; mental health conditions; client had a condition but none of the above conditions were
present; and a limiting medical condition (in conjunction with the limiting illness variable).
Well-being variables
Well-being data were chiefly collected through the WHO-5 Well-being Index45 (Box 1). The WHO-5
Well-being Index has been used in studies on diabetes, suicide, substance abuse, obesity and depression.
In a sample of over 3000 clients who received health trainer services in the West Midlands,60 the WHO-5
Well-being Index score improved by 37.5% (from a score of 44.1 to a score of 60.7) after receiving
the service.
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The five items that make up this scale were asked at three time points: baseline, as an extension to the
client satisfaction postal survey, at 4 weeks and a further postal survey sent to all the ELONS study
participants at 52 weeks.
A score for the WHO-5 Well-being Index is derived by summing the responses to the five constituent
items and multiplying by four, which provides a continuous variable with a potential range of 0 to 100.
The range and skew were calculated. A dichotomised variable can also be derived: a concerning level
(as opposed to a good level) of well-being occurs where the overall well-being score is under 13 or any
individual item score is 0 or 1.
Additional questions on well-being were asked in the 4-week and 52-week postal surveys, including a
‘components of well-being’ scale modified from the validated psychosocial benefits from home scale61–63 to
apply to smoking cessation clients. The components, measuring protection, control, prestige and response
to change, are theoretically related to ontological security but also implicitly assume that well-being is
affected by outside, and therefore modifiable, sources rather than fixed personality traits. Thus the ten
items are intended to measure psychosocial feelings, which may connect well-being to external factors
(Table 35). These items were included in both postal surveys.
BOX 1 The WHO-5 Well-being Index
Over the last 2 weeks
I have felt cheerful and in good spirits.
I have felt calm and relaxed.
I have felt active and vigorous.
I woke up feeling fresh and rested.
My daily life has been filled with things that interest me.
Response scale
All of the time= 5.
Most of the time= 4.
More than half the time= 3.
Less than half the time= 2.
Some of the time= 1.
At no time= 0.
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Socioeconomic status
An alternative measure of SES was used in the analysis described here because of possible contamination
between the prospective study measure of SES, and health and well-being with the inclusion of
permanently sick and eligibility for free prescriptions. Here, a three-category variable was used: low SES
[(unemployed or basic education or social renting) and no high SES conditions, n= 1179] mid SES (mixed
or no indicators of low or high SES, n= 1480) and high SES (owns home and either has a professional/
managerial occupation or has tertiary education and no low SES conditions, n= 300).
Analysis
The analysis for this element of the ELONS study was intended to be exploratory. The following questions
were examined:
l What was the level of response to the well-being questions?
This analysis was undertaken in order to see whether or not the WHO-5 Well-being Index scale was
acceptable to respondents and whether or not the samples of respondents who answered the
well-being questions were adequate for analysis.
l Did health and well-being at baseline predict quitting at 4 weeks and 52 weeks?
This analysis was undertaken in order to consider first, whether or not well-being and smoking
cessation were significantly associated, and second, which health and well-being variables should be
included in the final model of factors predicting quitting reported on elsewhere in this report.
l How did well-being change over time among quitters and non-quitters?
This analysis was undertaken in order to explore whether or not findings of a systematic review50 (that
well-being improves after cessation) were replicated among the ELONS study clients or whether or not
attending the smoking cessation services had unintended adverse consequences for well-being.
l Which clients had the highest well-being at baseline, 4 weeks and 52 weeks?
This analysis was undertaken to explore first, the stability of the concept of well-being over time
(for instance, if the same factors constantly associated with well-being), second, which factors are
associated with well-being, and third, which psychosocial factors may link external factors to
well-being.
What was the level of response to the well-being questions?
The number of clients who responded to the well-being questions at baseline and in the 4- and 52-week
surveys were as follows: 2959 clients responded at baseline only, 953 responded at 4 weeks only, 939 at
baseline and 4 weeks, 479 at 52 weeks only, 471 at baseline and 52 weeks, 325 at all three points and 77
had no well-being score at any point (see Table 45 for more details about the responses). Response rates
were low at 4 and 52 weeks, as was expected from a postal survey, but were adequate to proceed with
analysis given that there was good representation from all demographic groups (see Table 46) and
convergence was achieved in multivariable modelling.
TABLE 35 Ontological security items (all answered on a 5-point Likert scale with responses ranging from strongly
agree to strongly disagree)
Concept Items
Protection I can deal with stress; I feel safe
Control I feel in control; I can do what I want, when I want
Prestige Most people would like a life like mine; I feel I’m doing well in life
Response to change My life has a sense of routine; I worry about things going wrong (reversed);
I enjoy a challenge; I’m frightened of change (reversed)
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Did health and well-being at baseline predict quitting?
The aim of this analysis was to establish whether or not clients’ levels of well-being at the start of their quit
attempt was related to quitting or if more traditional measures of medical conditions were preferable.
Outcomes of logistic regression analyses were 4-week and 52-week CO-validated quitting. For 4-week
quitting, practitioner was added as a level two variable. For 52-week quitting, there was no evidence of
variance between practitioners consistently, so single-level modelling was used. Each medical condition and
well-being variable was analysed separately. Other fixed-effect variables included in the models were
location, behavioural support type, month quit attempt started, age, gender, ethnicity, SES, whether or not
they had taken varenicline, dependence on tobacco and determination to quit (4 weeks only), supportive
spouse or partner, and friends and family smoking status.
How did well-being change over time among quitters and non-quitters?
The aim of this analysis was to explore whether or not quitting smoking was associated with changes in
well-being.
Initially the distribution of the continuous well-being score was examined in order to establish whether
parametric or non-parametric statistics should be used in this analysis.
Mean well-being of quitters and non-quitters
Weighted means were calculated, using the same weights as the prospective study analysis, overall and by
4- and 52-week CO-validated quitting. Means were calculated for clients who had data at different
combinations of time points (e.g. baseline and 4 weeks or baseline and 52 weeks). The sample size was
kept constant by adding dummy data (e.g. the mean) to clients who did not have a well-being score at
4 weeks or 52 weeks, and an indicator variable was created to distinguish between clients with real data
(as they had answered the questions) and clients with dummy data. The weighted means (excluding clients
with dummy data) were tabulated and drawn on a line graph (see Figure 7 and Table 37).
Which clients had the highest well-being at baseline, 4 and 52 weeks?
In this analysis the aim was to explore associations with well-being in order to understand how high levels
of well-being may be achieved. This may be helpful because clients with higher well-being are more likely
to be able to successfully quit smoking long term.
There was no evidence of variance between practitioners at baseline, so single-level models were used for
modelling well-being at baseline; however, practitioner was included a random effect at the second level
for 4 weeks and 52 weeks. Modelling occurred in two stages. In the first stage, variables that had been
used in the prospective study analysis were included in addition to well-being. Non-significant variables
(with the exception of a priori variables: location, behavioural support, quit attempt start date, age, gender
and SES) were excluded from the model. For modelling of well-being collected in the 4-week and 52-week
postal surveys there was then a second stage where ontological security variables were added as
continuous variables. Non-significant optional variables were removed and multicollinearity was checked.
Which ontological security variables explained why other variables were
associated with quitting?
Each ontological security variable that was significant in the final model was added individually to the
stage one model and the changes in coefficients of other independent variables were noted. This final
analysis was undertaken only for well-being measured at 4 weeks because of the smaller response to the
postal survey at 52 weeks.
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Findings
Did health and well-being at baseline predict quitting?
The analysis presented below suggests that well-being at baseline was a predictor of abstinence from
smoking in the short and longer term, but medical conditions were not.
Logistic regression modelling was used to examine whether or not health and well-being at baseline predicted
quitting at 4 weeks and 52 weeks once other factors had been taken into account (Table 36). This analysis
suggested that none of the medical conditions variables predicted either short- or long-term quitting.
Well-being analysed as a continuous variable did predict abstinence but not as a dichotomous variable.
How did well-being change over time among quitters and non-quitters?
Well-being at baseline approximately followed a normal distribution. Skew was below ± 0.8 and could be
disregarded so parametric statistics could be used. The range of well-being scores was between 0 and 100
and so could be viewed as a percentage.
TABLE 36 Odds ratios (95% CI) of quitting at 4 and 52 weeks in final modelsa when each medical condition or
well-being measure is added separately
Health or well-being scale
CO-validated quit at
4 weeks (95% CI)
CO-validated quit at
52 weeks (95% CI)
Medical conditions
Any 0.92 (0.78 to 1.08) 0.85 (0.65 to 1.12)
Heart, blood, circulation 1.01 (0.81 to 1.26) 0.81 (0.56 to 1.16)
Respiratory 0.88 (0.72 to 1.07) 0.86 (0.62 to 1.19)
Mental health 0.91 (0.73 to 1.13) 0.75 (0.50 to 1.12)
Other condition but none of above 0.97 (0.76 to 1.24) 1.12 (0.77 to 1.63)
Severely limiting (vs. no condition) 0.77 (0.55 to 1.09) 0.59 (0.32 to 1.11)
WHO-5 Well-being Index
Continuous: 1% increase in well-being 1.004 (1.00004 to 1.007) 1.007 (1.0013 to 1.014)
Dichotomy: good vs. concerning level of well-being 1.11 (0.94 to 1.31) 1.10 (0.85 to 1.43)
a Models control for location, behavioural support type, time of year of quit attempt, age, gender, ethnicity, SES, whether
or not they have taken varenicline, dependence on tobacco and determination to quit, supportive spouse or partner, and
friends and family smoking status.
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The weighted well-being mean of the sample was 53.15 (95% CI 51.96 to 54.34) (Table 37). Clients who
did not manage to quit for 4 weeks had lower well-being at baseline than those who quit (Figure 7). In
addition, the mean well-being at baseline of 52-week quitters was higher than those who did not manage
to quit for 52 weeks. CIs did not overlap for 4-week quitters and non-quitters, and CIs of clients who did
manage to quit for 52 weeks did not overlap with those who did not manage to quit for 52 weeks,
4 weeks and the sample overall. This indicates that there were significant differences between these
client groups.
TABLE 37 Mean well-being (95% CI) at baseline, 4 weeks and 52 weeks, overall and by CO-validated quit status
at 4 and 52 weeks for groups of clients who answered (and did not answer) well-being questions at various
time points
Follow-up and quit status Baseline (95% CI) 4 weeks (95% CI) 52 weeks (95% CI)
4 weeks
Total 53.15 (51.96 to 54.34) 57.29 (55.25 to 59.32) –
Not quit 51.48 (49.83 to 53.13) 51.82 (47.98 to 55.66) –
Quit 55.48 (53.80 to 57.16) 59.93 (57.60 to 62.26) –
Responded to WHO-5 scale questions at 4 weeks if answered baseline and 4 weeks
Total 54.90 (52.96 to 56.84) 57.43 (55.39 to 59.48) –
Not quit 49.90 (46.41 to 53.40) 52.08 (48.22 to 55.94) –
Quit 57.30 (55.01 to 59.58) 59.99 (57.65 to 62.34) –
52 weeks
Total 53.15 (51.96 to 54.34) 57.29 (55.25 to 59.32) 52.76 (49.91 to 55.62)
Not quit 52.62 (51.36 to 53.88) 56.40 (54.11 to 58.69) 49.01 (45.72 to 52.31)
Quit 59.31 (56.47 to 62.14) 61.80 (57.82 to 65.77) 65.29 (61.29 to 69.28)
Responded to WHO-5 scale questions at 52 weeks if answered baseline and 52 weeks
Total 51.63 (48.96 to 54.31) – 53.10 (50.26 to 55.93)
Not quit 49.47 (46.24 to 52.70) – 49.34 (46.05 to 52.63)
Quit 58.64 (54.64 to 62.64) – 65.29 (61.29 to 69.28)
Responded to WHO-5 scale questions at 52 weeks if answered all three points
Total 53.60 (50.54 to 56.67) 57.43 (55.39 to 59.48) 55.42 (52.31 to 58.52)
Not quit 51.02 (47.13 to 54.90) 54.18 (50.41 to 57.96) 52.19 (48.48 to 55.90)
Quit 60.20 (56.12 to 64.27) 61.28 (57.33 to 65.24) 63.64 (58.81 to 68.47)
Shaded cells indicate overlapping CIs between quitters and non-quitters.
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Confidence intervals for weighted means of well-being for non-quitters over the three time points
overlapped when clients provided data at three time points. CIs for non-quitters also overlapped for
both time points if the clients provided data at any two time points. The well-being scores of quitters
consistently increased over time but CIs of the first time points overlapped with those of later time points.
However, CIs for quitters and non-quitters at each time point did not overlap. This is an indication that
quitters had significantly higher well-being than non-quitters.
Which clients had the highest well-being at baseline, 4 and 52 weeks?
A summary of variables that were associated with well-being at each time point is presented in Table 38.
Full models with all coefficients are presented in Appendix 2 (see Tables 46 and 47 ).
Factors associated with higher well-being at baseline
At baseline, multivariable modelling suggested that the factor with the strongest association with
well-being was absence of a mental health condition. Thus, clients without a mental health condition had
well-being scores nearly 10 points higher than those with a condition (see Tables 38 and 46 for more
details). Other factors with significant associations with well-being at baseline were high SES, with the
most affluent clients having well-being scores that were 4 points higher than the most disadvantaged
clients. Support from spouse or partner, determination to quit, lower dependence on tobacco, taking
varenicline and the absence of a physical medical condition (such as not having heart, blood or circulatory
problems) were all significantly associated with well-being at baseline. Age had a U-shaped relationship
with well-being, where well-being was poorest in those aged 45–54 years compared with clients aged
16–24 years and 65–85 years. Asian clients had significantly higher well-being than non-British white
clients, although numbers of these clients were very small.
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FIGURE 7 Well-being over time by smoking status.
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Factors associated with higher well-being at 4 weeks
Well-being scores at 4 weeks were associated with: successful cessation; age; Asian ethnicity (compared
with non-British whites); absence of heart, blood and circulatory diseases; and five ontological security
items (I enjoy a challenge; I feel I’m doing well in life; I feel in control; I can deal with stress; and most
people would like a life like mine) (see Tables 38 and 47 for more details). If ontological security items
were not entered, then dependence on tobacco (low dependence), no mental health issues, and spouse
and partner support were significantly associated with well-being (see Appendix 2, Table 47).
As the inclusion of the ontological security items caused attrition in the coefficients of other variables, this was
explored further by adding each ontological security variable separately (Tables 39 and 40). Attrition in the
well-being coefficients of the youngest and oldest clients, the highest SES groups and those who had a
spouse/partner supporting their quit attempt was particularly marked when the item ‘I’m doing well in life’ was
added to the model. Attrition in the well-being scores of clients with an absence of mental health conditions
was particularly marked when the item ‘I feel in control’ was added to the model. Feeling in control partly
attenuated the relationship between well-being and quitting but the association still remained significant.
Factors associated with higher well-being at 52 weeks
At 1 year after the quit date, only the ontological security items [I enjoy a challenge, I can do what I want
when I want, I feel in control, I feel safe, I worry about things going wrong (reversed), I feel I’m doing well
in life, My life has a sense of routine] and being abstinent from smoking at 52 weeks were associated
with well-being (see Tables 38 and 47). However, if the ontological security items were not entered into
the model, well-being was associated with cessation at 52 weeks and also the following variables collected
at baseline: age, low dependence and not having either a lung/respiratory or a mental health condition
(see Table 47).
Summary of key points
l The WHO-5 Well-being Index was integrated successfully into routine questions asked of service clients
at baseline. This suggests services could ask about well-being if useful for monitoring purposes.
l Clients who arrived at the SSS and who had higher levels of well-being at the start of their quit
attempt were significantly more likely to be non-smokers at 4 weeks and 52 weeks.
l In addition, well-being among those who stopped smoking remained higher than that of continuing
smokers at all measurement points. There was a linear rise in the levels of well-being among quitters,
however, the CIs of quitters’ well-being at baseline, 4 weeks and 52 weeks overlapped.
l The most consistent factors associated with well-being at baseline, 4 weeks and 52 weeks were: not
having a diagnosed mental health condition; low dependence on tobacco; and young or older age.
l Clients aged 45 to 54 years had lower well-being scores than younger and older clients at all three
time points, although differences were not always significant.
l Clients who had higher levels of well-being were consistently more likely to agree that they enjoyed a
challenge, were doing well in life and felt more in control than other clients. A mediator of the association
between dependence on tobacco and well-being appeared to be not being able to cope with stress.
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Chapter 9 Longer-term nicotine replacement
therapy study
This chapter presents findings from the additional research on longer-term NRT use that was addedto the ELONS study after the prospective study had commenced. This work was made possible
by additional funding from the UK Centre for Tobacco Control Studies to Lion Shahab at University
College London, who collaborated with the ELONS study team and drew on additional advice from
Professor Ann McNeill of King’s College London.
Like previous chapters it begins by describing the value that this adds to the ELONS study. Next is a
description of the method, sample and analytical approach, followed by the findings and a summary of
key points.
Rationale and study aims
There is good evidence from both population studies and clinical trials that the provision of NRT to
smokers who cut down their cigarette consumption results in more sustained decreases in cigarette
consumption and improves their chances of stopping smoking completely.64,65 Cutting down with NRT is
associated with both increased motivation to stop and improved quit rates64,66 and does not increase
overall nicotine intake.67 Trials have also shown that extended use of NRT by ex-smokers may result in
better long-term abstinence rates.68,69 For this reason, NRT in the UK is licensed for smoking reduction,
that is, dual use, and available to smokers who cannot or are unwilling to stop smoking completely, as a
long-term harm reduction measure70 NRT licensing is also being changed to allow its use for harm
reduction purposes among ex-smokers.71
Harm reduction refers to the reduced psychological or physiological harm from substance use without
complete cessation.66 In the case of tobacco use, harm reduction may refer to the partial substitution of
cigarettes with non-combustible forms such as NRT to reduce cigarette consumption or for temporary
abstinence. However, harm reduction may also constitute the complete and permanent substitution of
cigarettes with less harmful products, switching smokers from combustible to non-combustible nicotine
delivery devices, including NRT.72
The reason for focusing on NRT is that the burning of tobacco causes the most harm and not nicotine per
se.73 Nonetheless, there is considerable worry among potential users74 and SSS staff75 regarding the safety
of long-term NRT use.
There is little research in this topic, and the studies that have looked at this issue suggest that long-term
NRT use is safe and any associated health risks are small,76 certainly compared with continued smoking.77,78
Yet, surprisingly few data exist on the impact of long-term NRT use in terms of health outcomes in the
general population. Most data come from clinical trials, which have samples that tend to differ in
important ways from general population samples79 and in which NRT is provided free together with
behavioural support, which may affect normal usage patterns. By contrast, most NRT in the UK is used
without advice and bought over the counter,80 and in many other countries (unlike in the UK) it is rarely
provided for free on prescription.81 Consequently, there is a need for further research in the area of harm
reduction (as recently indicated by NICE)82 as investigating this issue will allow more precise quantification
of the likely benefits or harms of substituting cigarettes with NRT among current and ex-smokers.
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
To help add to research to this topic, this addition to the ELONS study aimed to:
l examine the prevalence of long-term NRT use among current smokers and ex-smokers
l explore the impact of long-term NRT use on biomarkers of nicotine exposure and stress among
current smokers and ex-smokers.
Methods and sample
All clients recruited to the ELONS study were asked by practitioners to provide two saliva samples at
baseline and (if they received a home visit and had provided samples at baseline) an additional two saliva
samples at 52 week follow up. The saliva samples were collected to measure two biomarkers of interest:
cotinine, the primary metabolite of nicotine as a biomarker of exposure; and alpha-amylase, a digestive
enzyme and indicator of autonomic nervous system activation that correlates with acute and chronic stress
as a biomarker of risk/potential harm.83
In order to maximise recruitment to the main ELONS study, clients were able to consent to participate even
if they did not want to provide saliva samples. In addition, saliva sample collection at baseline was not
conducted with some community practitioners (level 2 practitioners) who were not willing or able to
conduct this element. For these two reasons, not all the ELONS study participants took part in the
additional research on long-term NRT use. This addition to the prospective study also included a randomly
selected sample of clients who were not abstinent at the 4-week follow-up who were also sent a saliva kit
through the post at 12-months follow-up and asked to return samples in a reply paid envelope. This was
done in order to obtain a comparable sample of smokers. The saliva kit contained two Salivettes®, a letter
from the project lead asking for help and detailed instructions on how to collect their own sample as well
as a £10 Marks and Spencer voucher.
This request to provide a saliva sample resulted in 1875 useable saliva samples for analysis (which
represents 61% of the ELONS study participants). At 12-month follow-up, salvia samples were obtained
from 169 of a potential 320 participants (i.e. those who took part in the follow-up telephone interview,
were abstinent from smoking and had given a saliva sample at baseline). In addition a random sample
(n= 392) of participants who had given a saliva sample at baseline and were known to have relapsed at
4-week follow-up were contacted at 12-month follow-up and asked to provide a saliva sample. This
resulted in saliva samples from 89 participations.
Analysis
Data were analysed with IBM SPSS Statistics 20.0.0. Comparisons were made between those who did and
did not respond to the follow-up phone call and questionnaire, and between those who did and did not
provide a saliva sample at baseline and at follow-up. Differences were assessed with chi-squared tests and
independent t-tests for categorical and continuous variables, respectively.
Owing to the typically positively skewed distribution of cotinine and alpha-amylase values, and a relatively
small sample size, non-parametric Kruskal–Wallis tests were used to compare differences between smokers
and quitters with and without NRT use. As we were concerned about the potential of confounders, we
conducted a sensitivity analysis to assess the impact of these on the results. We used a generalised linear
model, which enabled adjustment for potential confounders with a gamma distribution and a log link
(all 0 values were replaced with 0.001) to account for the non-normal distribution.
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Given the longitudinal study design, where participants were essentially their own control, we conducted
an analysis to see how levels of biomarkers changed over time as this would tell us about the influence of
using NRT or stopping smoking on these health indices. For the mixed-design analysis (looking at change
across time), generalised linear models with a normal distribution and identity link were run using the
change score in biomarkers to determine the impact of NRT use and smoking status on these biomarkers
over time. Statistical significance was set at the standard level (p< 0.05), and the Bonferroni correction
was applied in post-hoc analyses. Prevalence estimates are weighted where indicated (see Chapter 5,
Weighting for further information) but, unless otherwise stated, all data are unweighted.
Please note that given the complexity of study design, respondents were treated in the analysis according
to their last status, that is, relapsers at 4 weeks who had stopped smoking by the 12-month follow-up
were counted as quitters, and self-reported quitters at 12-months who failed CO assessment were counted
as relapsers and analysed accordingly.
Findings
Findings are divided into two sections:
l prevalence of longer-term NRT use
l impact of longer-term NRT use.
Prevalence of longer-term nicotine replacement therapy use among current
smokers and ex-smokers
A total of 1047 participants (34.4% of the whole sample) provided information on long-term NRT use and
therefore form the analytic sample for the prevalence analysis. As shown in Table 41, those who were lost
at follow-up were younger, had smoked for a shorter period of time, were less likely to have a medical
condition and were less likely to be white or cohabiting.
Of clients followed up, 61.5% (95% CI 58.4% to 64.6%, n= 583) claimed that they had used NRT
during their initial quit attempt. (Note: all prevalence estimates in this section are weighted but n numbers
are unweighted.) However, this estimate is likely to include over-the-counter use, as this number is
substantially higher than the number of participants recorded as using NRT by the services as shown in
Table 41 (34.4%, 95% CI 31.4% to 37.4%; n= 310). Figure 8 provides a breakdown of clients’ length of
use of NRT as a function of smoking status at follow-up and type of NRT used long term. As can be seen,
most clients who started on NRT used it for at least 8 weeks and more than one in five (21.5%, 95% CI
18.3% to 25.0%, n= 137) used it for longer than the standard 3 months. However, long-term use was
relatively rare with fewer than 1 in 10 participants still using non-combustible nicotine products at
12-months follow-up (8.4%, 95% CI 6.4% to 11.0%; n= 50). Prevalence of NRT use was even lower
when excluding participants who used e-cigarettes only (6.0%, 4.3% to 8.3%; n= 35) and use of
e-cigarettes was also relatively uncommon (2.9%, 1.8% to 4.7%; n= 18). However, it should be noted
that these data include smokers and non-smokers, and most people had relapsed.
Generally, there were few differences between those clients who had relapsed between the 4-week and
12-month follow-up and those who had remained abstinent in terms of their NRT use (see Figure 8a).
However, long-term ex-smokers were much more likely still be using non-combustible nicotine products at
12-month follow-up than relapsers (OR 4.25, 95% CI 2.15 to 8.40); concurrent use among relapsers stood
at 3.7% (95% CI 2.0% to 6.5%, n= 12) compared with 14.0% (95% CI 10.3% to 18.7%, n= 38)
among continuous abstainers. The difference between ex- and current smokers was attenuated but
remained significant when excluding those who used e-cigarettes only (OR 2.91, 95% CI 1.38 to 6.11)
with 3.5% (95% CI 1.9% to 6.3%, n= 10) of relapsers and 9.5% (95% CI 6.4% to 13.8%, n= 25) of
abstainers still using NRT.
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TABLE 41 Baseline characteristics as a function of availability of follow-up questionnaire data
Baseline characteristics
Follow-up at 12 months
Responded (N= 1047) Did not respond (N= 681)
Sociodemographic/health characteristics
Age (years), mean (SD) 46.4 (14.0) 41.1 (13.7)***
Female, % (n) 55.0 (576) 53.6 (365)
White, % (n) 97.2 (1018) 94.7 (645)**
Cohabiting, % (n) 53.4 (559) 47.3 (322)*
Routine/manual occupation, % (n) 30.9 (323) 34.5 (235)
Degree or equivalent, % (n) 10.6 (111) 10.4 (71)
Medical condition, % (n) 59.5 (622) 52.9 (360)**
Smoking characteristics
HSI, mean (SD) 3.28 (1.45) 3.22 (1.46)
Smoking length < 10 years, % (n) 10.9 (114) 17.4 (118)***
Quit attempt last 12 months, % (n) 41.7 (434) 41.0 (275)
SSS treatment characteristics
Intervention type, % (n)
Closed group 3.2 (34) 2.9 (20)
Open (rolling) group 20.8 (218) 17.6 (120)
Drop-in clinic 26.5 (277) 27.2 (185)
One-to-one support 49.2 (515) 51.9 (353)
Other 0.3 (3) 0.3 (2)
Medication, % (n)
Single NRT 17.4 (182) 17.9 (122)
Combination NRT 12.2 (128) 15.1 (103)
Varenicline 50.2 (526) 48.5 (330)
Other 19.0 (199) 17.0 (116)
None 1.1 (12) 1.5 (10)
*, p= 0.05; **, p= 0.01; ***, p= 0.001; HSI, Heaviness of Smoking Index; SD, standard deviation.
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Figure 8b provides a breakdown of the prevalence of products used as well as the incidence of multiple
use. Overall, e-cigarettes were the most popular product followed by the nicotine lozenge, patch and gum.
Microtab (Nicorette®, McNeil) and nasal spray were the least popular products. Around 20% of clients
were using multiple products. Owing to the small numbers involved (only 50 clients used products long
term), there was insufficient power to detect meaningful differences between those who had remained
abstinent and those who had relapsed. However, the use of the nicotine patch appeared particularly
prevalent among current smokers, while the use of e-cigarettes, gum and the inhaler was more common
among ex-smokers.
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FIGURE 8 Prevalence of (a) length of NRT use following quit date; and (b) product type used long term.
a, Continuing users at follow-up (this includes e-cigarettes and provides base for Figure 8b). b, No use of nicotine
nasal spray.
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Impact of longer-term nicotine replacement therapy use on biomarkers of
nicotine exposure and stress among current smokers and ex-smokers
A total of 258 participants (8.5% of the whole sample) provide baseline and follow-up saliva samples and
therefore formed the analytic sample for the biomarker analysis. Table 42 shows the characteristics of
those who did or did not provide saliva samples at baseline or follow-up. As can be seen, those providing
samples at baseline were younger, more likely to be male and non-white, and slightly less likely to be
cohabiting. There were also some differences in the treatment sought (they were less likely to have used
varenicline or gone to a drop-in clinic) but there were few differences in terms of smoking characteristics.
TABLE 42 Baseline characteristics as a function of baseline and follow-up sample availability
Baseline characteristics
Baseline Follow-up at 12 months
Sample
available
(n= 1875)
No sample
available
(n= 1170)
Sample
available
(n= 258)
No sample
available
(n= 454)
Sociodemographic/health characteristics
Age, mean (SD) 41.7 (14.1) 43.7 (14.1)*** 45.7 (13.4) 42.2 (14.6)**
Female, % (n) 52.7 (989) 60.9 (713)*** 51.6 (133) 48.7 (221)
White, % (n) 95.0 (1782) 97.5 (1141)*** 96.5 (249) 93.8 (426)
Cohabiting, % (n) 45.4 (852) 49.5 (579)* 53.9 (139) 44.9 (204)*
Routine/manual occupation, % (n) 30.6 (573) 31.1 (364) 25.2 (65) 30.6 (139)
Degree or equivalent, % (n) 8.9 (167) 10.5 (123) 10.5 (27) 9.3 (42)
Medical condition, % (n) 55.5 (1041) 57.3 (670) 57.4 (148) 58.4 (265)
Smoking characteristics
HSI, mean (SD) 3.39 (1.46) 3.37 (1.43) 3.19 (1.54) 3.51 (1.41)**
Smoking length < 10 years, % (n) 16.6 (308) 13.6 (159)* 9.3 (24) 14.3 (65)
Quit attempt last 12 months, % (n) 41.3 (752) 41.6 (485) 38.1 (98) 38.4 (172)
SSS treatment characteristics
Intervention type, % (n) – *** – *
Closed group 4.5 (84) 1.5 (18) 6.6 (17) 4.6 (21)
Open (rolling) group 19.0 (357) 16.2 (189) 21.3 (55) 13.9 (63)
Drop-in clinic 25.4 (476) 35.2 (411) 24.4 (63) 30.4 (138)
One-to-one support 50.8 (952) 46.8 (547) 47.7 (123) 50.7 (230)
Other 0.3 (6) 0.3 (4) 0 (0) 0.4 (2)
Medication, % (n) – *** – **
Single NRT 17.3 (323) 23.0 (269) 17.4 (45) 15.2 (69)
Combination NRT 21.4 (400) 14.2 (166) 16.3 (42) 27.3 (124)
Varenicline 41.4 (774) 45.7 (534) 48.4 (125) 37.4 (170)
Other 16.9 (316) 14.4 (165) 16.3 (42) 19.2 (87)
None 2.9 (55) 3.0 (35) 1.6 (4) 0.9 (4)
*, p= 0.05; **, p= 0.01; ***, p= 0.001; HSI, Heaviness of Smoking Index; SD, standard deviation.
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At follow-up, those who provided a saliva sample were older and more likely to be cohabiting. Again,
there were some treatment differences (they were less likely to have used a drop-in clinic but more likely to
have used varenicline). Clients for whom a follow-up sample was available had lower baseline levels of
dependence (likely reflecting the lower response rate among those who smoked at 4 weeks compared
with those who had stopped at 4 weeks).
Table 43 provides an overview of available viable cotinine and alpha-amylase saliva samples as function
of smoking status and NRT use. Unfortunately, some samples provided insufficient saliva or were
contaminated and, therefore, cotinine and/or alpha-amylase levels could not be determined (5.7%). In
addition, a number of participants (18.1%) provided only one rather than two saliva samples at either
baseline or follow-up, which meant not all analytes could be assessed. However, in each of the relevant
subgroups at least 50% of the analytic sample had a complete set of data on all analytes, and at least
67% and 58% had both baseline and follow-up data on cotinine and alpha-amylase, respectively.
TABLE 43 Biomarker results availability by follow-up NRT use and smoking status
Biomarker results availability
Smokers Quitters
NRT use
(n= 18)
No NRT use
(n= 73)
NRT use
(n= 12)a
No NRT use
(n= 153)
Baseline assessment
Cotinine sample, % (n) 94.4 (17) 93.2 (68) 91.7 (11) 95.4 (146)
Alpha-amylase sample, % (n) 66.7 (12) 61.6 (45) 75.0 (9) 71.2 (109)
Follow-up assessment
Cotinine samples, % (n) 88.9 (16) 94.5 (69) 75.0 (9) 97.4 (149)
Alpha-amylase samples, % (n) 72.2 (13) 58.9 (43) 75.0 (9) 72.5 (111)
All assessments
Cotinine samples, % (n) 83.3 (15) 89.0 (65) 66.7 (8) 92.8 (142)
Alpha-amylase samples, % (n) 61.1 (11) 57.5 (42) 75.0 (9) 67.3 (103)
All samples, % (n) 61.1 (11) 53.4 (39) 58.3 (7) 66.0 (101)
a Original sample (n= 14) included two e-cigarette only users who have been removed.
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
As can be seen in Table 44, there were some differences in baseline cotinine levels between groups
(p= 0.025). Those who had stopped smoking at follow-up and were still using NRT had higher levels than
other groups. However, these overall differences in baseline cotinine became barely significant when
adjusting for potential confounders (age, gender, ethnicity, occupation, any medical condition and nicotine
dependence; p= 0.245) and after taking into account multiple comparisons, quitters who used NRT at
follow-up, did not differ from any other group. In addition to older age (p= 0.011), dependence as
measured by the Heaviness of Smoking Index was the only other significant predictor (p< 0.001). There
were no differences as a function of NRT use and smoking status at follow-up in baseline levels of
alpha-amylase (p = 0.956). This was confirmed in adjusted analysis (p = 0.185), which showed that older
age (p= 0.001), being non-white (p= 0.021) and having any medical condition (p= 0.002) were
associated with higher alpha-amylase activity at baseline.
There was a clear difference between groups in follow-up cotinine levels (p< 0.001), confirmed in adjusted
analysis (p< 0.001). Non-NRT users who were abstinent had significantly lower cotinine values than
smokers with (p= 0.017) or without concurrent NRT use (p< 0.001) but not compared with quitters who
used NRT (p= 0.232). Baseline nicotine dependence was the only other significant predictor (p< 0.001).
Yet, even among CO-validated non-smokers at follow-up who indicated that they did not use NRT, over
one in five had cotinine values above the usual cut-off level, suggesting either a high rate of deception in
this group or undeclared use of other nicotine-containing products. No differences were apparent in
alpha-amylase levels at follow-up (p= 0.684), confirmed in adjusted analysis (p= 0.734). Only lower
dependence at baseline had an association with greater follow-up alpha-amylase activity (p= 0.004) but
none of the other covariates or factors were associated.
TABLE 44 Biomarker results by follow-up NRT use and smoking status
Biomarker results
Smokers Quitters
NRT use
(n= 18)
No NRT use
(n= 73)
NRT use
(n= 12)
No NRT use
(n= 153)
Baseline assessment
Cotinine (ng/ml), mean (SEM) 280.2 (36.7) 320.1 (22.0) 414.3 (90.4) 270.1 (13.7)
Alpha-amylase (U/ml), mean (SEM) 75.6 (41.2) 32.6 (4.4) 32.8 (7.4) 34.9 (3.2)
Follow-up assessment
Cotinine (ng/ml), mean (SEM) 280.6 (36.6)a 333.1 (22.3)a 324.4 (102.5) 45.8 (9.7)b,c,d
Alpha-amylase (U/ml), mean (SEM) 48.3 (17.7) 39.4 (5.7) 42.6 (17.7) 43.7 (4.2)
SEM, standard error of the mean.
a Statistically significantly different (p= 0.05) from quitters using no NRT.
b Statistically significantly different (p= 0.05) from smokers using NRT.
c Of the sample of CO-verified quitters with no self-reported NRT use (n= 141), this means that 31 (22.2%) had values
above the usual cut-off level of 15 ng/ml to identify smokers.
d Statistically significantly different (p= 0.05) from smokers using no NRT.
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Changes in biomarkers from baseline to follow-up were analysed in those with complete data (Figure 9).
For cotinine values, greater dependence at baseline was associated with an increase in cotinine levels
(p= 0.047). In addition, over and above an expected main effect of smoking status (p< 0.001), there was
a significant NRT use by smoking status interaction (p= 0.021). This can be seen clearly in Figure 9a.
Compared with current smokers, there was a significant reduction in cotinine values only among quitters
who did not use NRT or put differently, smoking status did not have an impact on cotinine values among
those who used NRT but did among those who did not. By contrast, there was no discernible impact of
either smoking status or NRT use on alpha-amylase activity (see Figure 9b). However, there was a marginal
effect of dependence (p= 0.062) and ethnicity (p= 0.052) on changes in alpha-amylase activity. Both
lower baseline nicotine dependence and non-white ethnicity were associated with an increase in
alpha-amylase activity across time.
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FIGURE 9 Change in (a) cotinine levels; and (b) alpha-amylase activity from baseline to follow-up as a function of
NRT use and smoking status at follow-up. a, Plotted on log-2 scale.
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Summary of key points
l Just over one-third of the ELONS prospective study participants provided information on longer-term
NRT use (n= 1047) and were included in this addition to the main ELONS study.
l Of clients followed up at 12 months, 61.5% reported that they had used NRT during their initial quit
attempt. However, this is likely to include over-the-counter use, as this number is substantially higher
than the number of participants recorded as using NRT by the services (34.4%).
l Most clients who started on NRT used it for at least 8 weeks and more than one in five (21.5%) used it
for longer than the standard 3 months.
l Long-term use was relatively rare, with fewer than 1 in 10 participants still using non-combustible
nicotine products at 12 months’ follow-up (8.4%).
l Within this category of non-combustible nicotine products were e-cigarettes. Few participants reported
their use at 1 year, just 2.9%, although these data include smokers and non-smokers and most people
had relapsed by 1 year post quit date. However, e-cigarettes were the most popular single product at
1 year (used more commonly than the gum, lozenge or patch).
l Long-term ex-smokers had much higher odds of still using non-combustible nicotine products at
12-month follow-up than those who relapsed. Concurrent use among relapsers was 3.7%, compared
with 14.0% of continuous abstainers. This difference remained significant even after removing those
who used e-cigarettes only.
l In terms of the biomarker analysis, 258 participants (8.5% of the whole ELONS study sample) provided
baseline and follow-up saliva samples and were included. Greater levels of cotinine (a metabolite of
nicotine) were associated with greater self-reported dependence. As expected, within-group analysis
showed that smokers who had stopped had significantly lower cotinine levels at follow-up than those
who had relapsed to smoking at follow-up. However, this was the case only for ex-smokers who did
not use NRT. Cotinine levels for smokers who had stopped at follow-up but who used NRT long term
had not changed from baseline to follow-up and neither did cotinine levels for those who had relapsed
to smoking (irrespective of NRT use). There were no differences as a function of NRT use and smoking
status at follow-up in baseline levels of alpha-amylase, a biomarker of stress.
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Chapter 10 Discussion
The UK remains one of very few countries in the world that offers free at the point of use treatmentservices for people seeking support to stop smoking.10 These services form an important part of a wider
network of policies aimed to reduce smoking rates, including policies such as tobacco taxation, mass
media campaigns, bans on advertising and Smokefree laws.15 The ELONS study was designed to provide
up-to-date evidence on the effectiveness of these SSSs, building on earlier research. As routine data
collected by the services report on only short-term outcomes and are limited in detail, this study was also
intended to examine longer-term outcomes and explore the factors that influence quit rates.
The findings raise a number of issues. Here we reflect on the results, focusing on key themes:
l short- and longer-term cessation rates in context
l the influence of client characteristics
l the influence of service characteristics
l satisfaction with services
l well-being
l longer-term use of NRT
l limitations
l future research.
Short- and longer-term cessation rates in context
This study examined smoking cessation in the short term (at 4 weeks) in two ways: through an analysis of
routine data and through the prospective study. Our prospective study results were broadly comparable
with those from routinely collected data from services. Among 3000 smokers attending SSSs in nine areas
of England, we found that just over 4 in 10 (41.2%) were biochemically validated as abstinent from
smoking at 4 weeks post quit date. Our secondary analysis of routine data from 49 of 150 services in
England found 4-week quit rates of 48% when self-reported data were included, falling to 34% when
biochemical validation had occurred. This same analysis found that services were reaching up to 10% of
smokers in their area in the year from July 2010, with the majority coming from more-deprived areas. NICE
guidance previously recommended that services aim to reach at least 5% of their smoking population in a
year.21 These results provided suggest that (a) routine data provide a useful and not inaccurate indicator of
short-term smoking cessation outcomes and (b) services are continuing to effectively reach smokers and
support them to stop.
In the longer term, we found that fewer than 8% of smokers were still abstinent from smoking 1 year
after setting a quit date with their local service. Outcomes were influenced by characteristics of clients and
there was also a clear link with service characteristics such as the type of behavioural support received, and the
background and training of the smoking cessation practitioner.
Cessation rates identified in this study were lower at both 4 and 52 weeks than in our previous research
conducted over a decade ago as part of a ‘national’ evaluation of the services in England shortly after
they were established.17,18 At face value it might be assumed that service standards had slipped in the
intervening period, but our view is that this is too simplistic an explanation. Our earlier work was
conducted with just two (albeit large) services that performed better than the national average based on
comparisons with routine data. The ELONS study purposively selected nine services that offered different
types of interventions in a range of settings, some of which reported quit rates higher than the national
average while others reported lower rates. In addition, the configuration of services has changed in the last
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decade and there is clearly a greater reliance on community practitioners (such as pharmacists and practice
nurses) with lower short-term quit rates delivering support rather than specialist smoking cessation staff.
Others have argued that the smoking population itself may have changed84,85 and that remaining smokers
are more nicotine dependent and find it harder to stop. Research design differences between the studies
may also explain some of the difference.
Despite rates of abstinence from smoking being lower in the ELONS study than in some previous studies
with service clients, they remain significantly higher than in untreated populations. Previous research with
‘self-quitters’ not participating in a smoking treatment programme has estimated abstinence rates at 25%
at 4 weeks,42 which is considerably lower than the overall 4-week quit rate (41%) and the lowest 95% CI
boundary (36%). At 1 year, abstinence rates with self-quitters are approximately 3%,86 considerably lower
than the 8% found here. Thus the behavioural support and stop smoking medication provided by the
services makes a significant difference and improves outcomes for individual smokers. The ELONS study is
consistent with previous studies in demonstrating this.7,17
The ELONS study only assessed smoking status up to 1 year after an initial quit attempt, yet it is possible to
extrapolate our results to estimate the number of life-long non-smokers achieved.
The study took place during the financial year 2012–13. In that year, routine data returns from all SSSs in
England showed that 724,247 quit dates were set.87 Applying the ELONS study results (8% quit at 1 year),
55,767 would have been CO validated as abstinent at 1 year. The best estimates of the relapse rate to
smoking after 1 year are 35%.88 This would leave 36,249 lifelong abstinent quitters. This is a substantial
figure and is one indicator of the ongoing value of the life-saving treatment that the services provide.
The influence of client characteristics
Consistent with other studies, we found that smoking cessation outcomes varied significantly between
different groups of people who accessed SSSs. At 1 year, for example, a number of client characteristics
were associated with either maintaining abstinence of having relapsed to smoking. As other studies have
found, the odds of maintaining a quit attempt increased with age.89,90 This may be caused by a range of
factors including learning from previous quit attempts, contact with health services, personal circumstances
(such as the death of loved ones owing to smoking-related disease) or for some, additional time to commit
to focusing on getting the most from the support on offer. Individuals with higher levels of well-being
when they began their quit attempt were more likely to be successful in the longer term, as were those
who had fewer smokers in their social network – neither of these findings are surprising but being aware
of these factors may be useful for practitioners treating smokers.
Although some predictors of relapse to smoking identified in previous studies did not quite reach
significance here (e.g. level of dependence on smoking, lower levels of determination to quit), others did,
including deprivation. More disadvantaged clients were less likely to remain abstinent from smoking at
1 year, as our previous work and that of others has shown.18,91,92 Thus, although SSSs are able to reach
significant numbers of smokers living in disadvantaged areas,19 these smokers face additional barriers to
quitting. This poses challenges for service delivery, and requires time and resources to ensure particularly
effective forms of support (including medication) are delivered to those who need it most.
The influence of service characteristics
Client characteristics cannot be easily modified, but service characteristics can, and our findings show that
some interventions are more effective than others. We found that smokers supported to quit with
specialist services (including group behavioural support and one-to-one support from a specialist) were
more likely to have stopped smoking in the longer term. This is consistent with other studies24,44,93 and
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reflects the training and expertise that specialist practitioners have, and also that they see more smokers
than part-time (level 2) practitioners and are therefore more likely to maintain standards of knowledge and
practice. Time and resource pressures in settings such as GP practices and pharmacies may also contribute
to poorer outcomes for clients of non-specialists.94,95
Important differences in outcomes between forms of behavioural support were also identified. Clients
attending open groups achieved the highest quit rates and maintained the highest ORs compared with
other forms of behavioural support, even after controls. These results reflect those of our previously
published paper26 on the success of open groups.
In addition, we found that drop-ins (i.e. where people can simply drop-in to see a SSS practitioner without
an appointment) did not result in as positive cessation outcomes as other types of support types. Potential
reasons for this lower performance might include less client motivation contact (especially if demand is
high) or drop-ins being selected by smokers who were less likely to quit, or that practitioners have limited
capacity to plan and deliver effective behavioural support within this setting.
One of the objectives of this study was to provide guidance on interventions that will have maximal
benefits. From the secondary analysis it would appear that the services that had the highest impact
focused on quit rates rather than throughput. The results from the prospective study suggest that services
will be particularly effective in terms of achieving long-term cessation if they provide groups or one-to-one
support by specialist practitioners.
Satisfaction with services
Feedback from patients or clients is important to inform service development. In our satisfaction survey of
SSS clients, we found that those who responded had a positive experience, and this was true both for
those who were successful in stopping smoking and those who were not. The vast majority of participants
who replied to the questionnaire indicated that they would recommend the service to others and return
should the need arise. In addition, we found several examples of good practice where SSSs have offered
more than they are required to do by national service standards.96 This included, for example, contacting
clients before their first appointment to encourage them to attend and offering child care and a choice of
behavioural support options.
Additional comments highlighted the importance of practitioner/client rapport. In addition, despite many
clients finding stop smoking medication easy to acquire, additional comments pointed to a more complex
picture where the process of obtaining medication was overcomplicated and time-consuming for some
respondents. Suggested improvements to the SSS centred on evening appointment times, having a choice
of group or one-to-one support and a longer period of support.
Analysis of client satisfaction between quitters and non-quitters, SSS location and behavioural support
types revealed some small but significant differences. Those who had stopped smoking were more likely to
be satisfied with staff supportiveness and happier to return to the services if needed, with the information
provided and CO validation. Open-group clients were also more positive about staff supportiveness,
returning to the service and CO testing. GP practice clients were least comfortable with CO testing.
Despite an encouraging response rate (response to self-completion postal surveys are generally low, even
with repeated reminders) clients who were motivated to complete the survey were also more likely to have
had a successful quit attempt. This means the views of those who did not quit are under-represented.
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Well-being
As outlined earlier in the report, we included a modest exploratory study of well-being and smoking
cessation within the ELONS prospective study. Positive well-being at baseline significantly predicted
abstinence from smoking 1 year later. Although few other studies have looked at positive well-being,
research has found that psychological distress and mental health conditions can reduce the chances of
successfully stopping smoking.57,97,98 Smokers in these previous studies have reported experiencing more
negative moods shortly after quitting that may be related to relapse.98
In our analysis we did not find that levels of well-being changed significantly over time, unlike a previous
systematic review.50 Those who stopped smoking did tend to have higher well-being than non-quitters at
all time points. This suggests that the level of well-being at baseline is important as a predictor of who may
quit smoking, and that this difference is maintained.
Clients who managed to stop smoking in the ELONS study and who completed the well-being survey were
more likely to agree that they felt in control. Feelings of control have not received much attention in the
context of smoking cessation, although perceived control has been found to positively influence intention
to quit smoking.99 In addition, having financial difficulties, which could signify feelings of a lack of control,
has been associated with fewer quit attempts and less success in the quit attempts that did take place.100
Clients who were more dependent on tobacco at baseline had lower well-being at all three time
measurement points. This was possibly mediated by being unable to cope with stress. Other studies have
found that stress is associated with higher levels of smoking.101,102 Neurologically, this may be related to
higher levels of cortisol and adrenocorticotrophic hormone as a response to stress.103 However, despite
smokers stating that they smoke to cope with stress, higher levels of stress have been found among
smokers,104 which then declines with smoking cessation.105 Thus, smoking tobacco (rather than stopping)
appears to be associated with heightened feelings of stress. This is an important message for services to
communicate to clients.
Well-being was low among many smokers approaching the SSS, and well-being is a predictor of smoking
cessation success. This raises the issue of whether or not it could be helpful to train practitioners in
techniques such as cognitive–behavioural therapy, or alternatively employ practitioners already qualified
with cognitive–behavioural therapy, in order to address feelings of stress and insufficient control.
Longer-term use of nicotine replacements therapy
We found that over one in five NHS SSS clients who achieved short-term abstinence reported continuing
to use NRT beyond the standard treatment length of 3 months. However, complete substitution of
cigarettes with non-combustible nicotine products long term was less common, at just below 10%. In our
previous ‘national’ evaluation of SSSs in England, conducted in Nottingham and North Cumbria in 2002,
self-reported longer-term NRT use at 1 year was just 5%.106 This means that more people may now be
using cleaner forms of nicotine longer term, with 6% of our sample reporting using NRT at 1 year and
2.9% using e-cigarettes at 1 year post quit date. Recent policy and licensing changes in favour of harm
reduction70,82 may have offered some reassurance in this regard, although it is worth noting that the
reported rate of longer-term e-cigarette usage in the ELONS study is low compared with the estimates of
one in five smokers or recent ex-smokers using e-cigarettes in the general population.107
Concurrent long-term use of NRT among SSS clients in the study who have relapsed to smoking, reflecting
partial substitution, was much lower, at less than 4%. This is in agreement with similar figures from the
general population suggesting that longer-term NRT use among smokers is rare.108 Indeed, concurrent NRT
use among smokers, either for temporary abstinence or for cutting down, has remained relatively stable
since 2002109 and mostly reflects short-term use.108
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This study provides some rare insights in the exposure to nicotine associated with single use or long-term
dual use of NRT as well as its impact on a biological indicator of stress, alpha-amylase. Clinical trials
suggest that permanent replacement of cigarettes with NRT among ex-smokers can result in 40% of
baseline levels of nicotine being substituted by nicotine-replacement products.110,111 Although the
cross-sectional analysis did not detect a significant increase in cotinine levels among ex-smokers using NRT
compared with those not using NRT, the within-group analysis suggests that virtually all baseline nicotine
may be replaced by NRT among long-term ex-smokers. This finding is against a background of excluding
participants from analysis based on CO verification of their smoking status and concurrent use of other
nicotine delivery devices, that is, e-cigarettes. Moreover, confirming previous research,67,112 the concurrent
use of NRT among smokers did not appear to increase their nicotine intake. These findings reflect that
smokers are very adept at titrating nicotine levels, with some nicotine otherwise obtained from cigarettes
being replaced by nicotine from NRT.113 However, our results indicate this may also apply to ex-smokers,
which is consistent with a strong genetic component in nicotine intake,114 but at odds with clinical studies
showing that nicotine substitution from NRT tapers off over time.110 The fact that long-term use among
ex-smokers did not result in a decrease in cotinine levels, however, does not mean that long-term use
maintains addiction to nicotine. Although we controlled for baseline characteristics, the study design
cannot exclude reverse causation, that is, the fact that particular individuals who happen to have a high
sensitivity to nicotine intake, use NRT for longer.
Although it is unlikely that a substantially increased nicotine intake from NRT would be harmful,115,116 it
clearly is a concern for some people and a potential barrier to effective use of nicotine products.74 Our
results do not suggest that NRT use leads to an increased intake compared with continued smoking.
Moreover, there was no evidence that use of NRT (either concurrently or among ex-smokers) was
associated with an increase in a biomarker of stress response, alpha-amylase, used as a proxy here to
signal potential harm. The somewhat paradoxical finding that greater activity in alpha-amylase at follow-up
and an increase in alpha-amylase activity across time were both associated with lower nicotine
dependence is likely because tobacco smoke has been shown to acutely inhibit alpha-amylase activity.117
Given that lower nicotine dependence was associated with lower exposure to tobacco smoke, as measured
by cotinine levels, and smaller increases in cotinine levels from baseline, the inhibitory action of tobacco
smoke on alpha-amylase in this group of users was therefore likely to be smaller. Altogether, these
findings suggest that long-term NRT use is safe and not associated with increased health risks, certainly
compared with continued smoking.78
Limitations
Each element of the ELONS study had a number of limitations. For example, in the secondary analysis our
estimates of the reach of the services were based on estimates of both the number of smokers and the
population in the PCT. We also assumed that smoking declined uniformly by 4% in all PCTs between 2003
and 2005, and also in 2009, when it is likely that the smoking rate declined more in PCTs with an affluent
population and less in PCTs with a more disadvantaged population.118 For all but the impact analysis we
assumed that each client in the database was unique when we estimated that 8% of clients used the SSS
more than once during the year. However, the consistency of our estimates between PCTs (the majority
between 5% and 12%) and the consistency of quit rates calculated for unique clients and client records
gives support to the technique used.
Other limitations pertain to the use of routine monitoring data with pre-set variables: SES was measured
using NSSEC, IMD and free prescriptions. NSSEC is complicated to classify and may not reflect SES for
clients who are not the chief income earner of the household. IMD was included at PCT level, which is
large geographically and may explain the lack of significant results. Eligibility for free prescriptions can be
for medical or age reasons in addition to low income. In the analysis all ethnic minorities were compared
with white people. Ethnicity was not disaggregated further because of small numbers.
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The secondary analysis includes only data from PCTs who agreed to their QuitManager data set being used
for research purposes. North 51 is based in Nottingham, which may be the reason for a concentration of
PCTs in central England. Nevertheless there are PCTs included in all regions of England from County
Durham and Darlington in the North East to Bristol in the South West. Comparison with 2010/11 data for
all English PCTs found similar rates of self-report quit and CO validation. Furthermore, the self-reported
quit rate for all English SSSs from April 2010 to March 2011 was also 49%, and 70% were CO validated43
compared with 74% in the secondary analysis sample suggesting that the sample were representative of
the whole.
Some of the limitations of the secondary analysis were ameliorated by the prospective study. These
include, for example, only short-term follow-up data collected for routine monitoring, which may be of
lower quality, and inconsistently collected data on levels of tobacco dependence and social support, which
could not be used in the analysis. Data on the practitioner type was also poorly collected, perhaps partly
because the DH does not publish it.
However, the prospective study also had limitations, the most substantial being recruitment. Reasons for
this are discussed in detail in Chapter 5, but were partly because of the cumbersome consent process to
the study required by ethical review and the need for all aspects to be classified as research (rather than
service evaluation) to be eligible to become a NIHR portfolio study and access service support costs. This
type of consent process would be expected and appropriate in a trial or study of a new intervention, but it
is problematic in an observational study of an existing service. Far simpler questions and a simpler process
(such as those we have been permitted to use in earlier studies with NHS SSSs) could still have protected
client confidentiality.
In addition, policy and service changes also affected recruitment, as described in Chapter 5. The result was
that we recruited only a small proportion of eligible service clients in each study area. To overcome the low
response rate we have used weighting and multivariable analysis. However, CIs of quit rates for many
behavioural support types were wide and it may be that some non-significant differences are a consequence
of the study being underpowered.
Owing to selection of the PCTs for the secondary analysis and the prospective study being limited to
services that used Quit Manager software, this could raise issues of validity – specifically representativeness.
If we redid, in particular the prospective study, with completely different areas, we might have obtained
slightly different results. This is an important caveat. That said, we did try as much as possible to recruit
areas in varying parts of the country that offered a range of types of interventions as outlined in Chapter 5.
However, it is should be remembered that the 4-week quit rate for the prospective study was 41.2%,
which is remarkably similar to the quit rate for England from April 2012 to March 2013 (37%)31 given the
impact profile of the PCTs that enrolled in the study (see Chapter 4). Moreover, the ELONS prospective
study sample differed little in terms of demographic characteristics to all the clients that attended the nine
services. This should go some way to allay concerns about representativeness.
There are data collection issues common to both the secondary analysis and the prospective study that
focus on issues of definition of interventions that were beyond our control. In brief, we were dependent
on local understandings of what formed different behavioural support types for example, and different
settings for delivery and practitioner categories. In the 4-week analysis in the prospective study we were
also dependent on local data collection being accurate and timely, which we suspect it was not in all
cases. Busy practitioners do not always collect the best data, for a variety of reasons. This may explain
some of the differences between the 4-week results that go against the findings of previous studies,7,17 in
particular our findings around combination NRT not being as effective as other medication forms. This
finding was not carried through into the 52-week results, where we saw results that were more consistent
with previous research.
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We treated group clients as independent, whereas the chances of a group member quitting may depend
to some extent on the other group members and the culture of the group. The effect of a group is very
difficult to take into account especially for open groups where members change and the number of
sessions attended may vary markedly.119–121
The well-being and client satisfaction elements of the ELONS study also had limitations. At baseline, the
WHO-5 items were included in routine monitoring questions administered by practitioners so almost all
participants had well-being data at this stage. At follow-up the well-being questions were included in
postal surveys sent to clients’ home addresses, as was the satisfaction questionnaire. As with most postal
surveys, the response rate was low and caution is therefore required in interpreting the results. For the
well-being element in particular, it is also the case that the analysis reported was largely exploratory and
any conclusions can only be tentative.
The longer-term NRT element added to the ELONS study also had a number of limitations. Despite an
initial large sample size, dropout across the main study was inevitably substantial, resulting in relatively few
clients with complete baseline and follow-up data on biomarkers. In addition, the baseline sample differed
from the sample followed up. However, differences were relatively modest and therefore unlikely to have
substantially biased findings. In addition, weighting was used in the assessment of long-term NRT use
prevalence, which should account for differential dropout. Although clients self-selected into groups rather
than being experimentally assigned, this reflects real-world use of NRT. Moreover, the study design
allowed clients to be their own control, thus further reducing confounding. Assessment was carried out
with established, ecologically valid measures and smoking status verified.
Future research
The study raises a number of issues for future research. First, a significant gap in the research relates to the
use of e-cigarettes. When the ELONS study was commissioned in 2010/11, e-cigarette use was still
relatively rare, but has grown significantly since then. Although we asked about e-cigarette use in the
longer-term NRT study, we did not address it elsewhere. Recent monitoring data and reports from service
managers indicate that the ‘rise’ of e-cigarettes has coincided with a significant drop in SSS client
numbers, particularly in the period since the ELONS study was conducted. Future research should examine
this issue, and also look at effective ways to combine e-cigarette use with the support provided by services.
Useful pilots and some ongoing research in England are already under way, but more is needed.
In addition, previous research has shown that effective behavioural support delivered by trained
practitioners roughly doubles smokers’ chances of successfully stopping.122,123 However, there was great
variety in the type and, in all likelihood, the quality of the behavioural support provided to the ELONS
study participants. This study did not set out to capture factors that affect the quality of behavioural
support such as the training status of practitioners (whether NCSCT certified or not), the presence,
perception and use of treatment protocols, and the amount of support and supervision available to
individual practitioners. This is both a limitation of the ELONS study and an issue to be explored in more
detail in further research. Within that, a priority should be to explore in more detail what factors influence
the success of a rolling-group model of behavioural support when compared with other options.
For the well-being element, no formal tests for differences between well-being scores over time or
between quitters and non-quitters were undertaken. In further analysis, regression models or propensity
scores could be used to test relationships more precisely. Alternatively a qualitative approach to well-being
may yield insights. For example, interviews or a diary over the quit attempt may aid understanding of how
and when well-being changes occur and their relationship to failure or success of the quit attempt. Slightly
broader research may also be helpful in this area, examining issues such as insecurities in housing,124
relationships125 and income,100 which may impact on the success of quit attempts. While these wider
contributors to poorer well-being are difficult to tackle, helping to create resilience in smokers who face
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
multiple life challenges may help them to move away from tobacco, which will yield mental as well as
physical health benefits for them in the longer term.
We began to explore longer-term use of nicotine-containing products in this study but there is a sizeable
research agenda on this topic that is still to be explored. In particular, further research would benefit from
measuring a wider array of biomarkers of smoking-related harm, such as lung function tests or carcinogen
metabolites to confirm our preliminary results.
Although there are some obvious and clear conclusions from this evidence base (such as behavioural
support type and client demographic characteristics) that can guide service delivery, there are some
questions that are more difficult to answer – for example, why do some services find it easier to meet
targets than others? It is likely that a process evaluation collating qualitative evidence from individual
poorly performing services and services with excellent performance would provide further insights into this
important area. Additionally, despite non-quitters appearing to be highly satisfied with the services, the
low response rate to the CSS calls for more qualitative research among clients who drop out and relapse
to understand how the service can support these groups.
Finally, there is a need for ongoing research on NHS SSSs that is useful to inform policy, including
determining the factors that contribute to the ongoing development and sustainability of the services.
This is useful not only in a UK context but to inform work in other countries to establish or improve
the provision of services to support smokers to stop using tobacco.
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Chapter 11 Conclusions
This detailed observational study of smoking treatment services in England has yielded a number offindings that allow us to draw conclusions about the factors that influence outcomes for clients, as well
as describe effectiveness in the short and longer term.
In terms of smoking cessation in the short term, the findings of the ELONS study are broadly comparable
with those from routinely collected data from services. From our prospective study of just over 3000
smokers attending SSSs in nine areas of England, we found that just over 4 in 10 (41.2%) were
biochemically validated as abstinent from smoking at 4 weeks post quit date. The secondary analysis of
routine data from 49 of 150 services in England found 4-week quit rates of 48% when self-reported data
were included, falling to 34% when biochemical validation had occurred. This same analysis found that
services were reaching up to 10% of smokers in their area in the year from July 2010, with the majority
coming from more deprived areas. NICE guidance previously recommended that services aim to reach at
least 5% of their smoking population in a year.21 These results provide a useful indicator that (a) routine
data provide a helpful and not inaccurate indicator of short-term smoking cessation outcomes and
(b) services are continuing to effectively reach smokers and support them to stop.
No routine data exist on longer-term cessation at 1 year and it is some time since a study in England has
looked at this issue. We found that just fewer than 8% of smokers were still abstinent from smoking
1 year after setting a quit date with their local service. If these results are applied to all of England, then
we estimate that in the year 2012–13 the services supported 36,249 clients to become non-smokers for
the remainder of their lives, which is a significant number.
A range of factors, including many linked to the characteristics of clients, but also service characteristics,
influenced smoking cessation outcomes in the prospective study. For example, smokers supported to quit
with the specialist service were more likely to stop smoking in the longer term. In addition, the ELONS
study builds on previous research that shows that longer-term outcomes are influenced by the type of
behavioural support a smoker receives – rolling groups resulted in better outcomes than other forms
of behavioural support.
Three additional elements were added to the ELONS study that were more exploratory in nature. These
focused on client satisfaction, well-being and longer-term NRT use. Overall, we found that those who
responded to the satisfaction survey were positive about the support they received and would recommend
SSSs to others. We found that assessment of well-being using a standard set of questions could be
included in routine monitoring and that smokers who had higher levels of well-being when they first
started attending services were more likely to be non-smokers at 4 weeks and 1 year later. Assessing
well-being may therefore help give advisers an indication of who may need more support during their quit
attempt. It may also provide an opportunity to help clients make links with other local services or networks
who could assist them in improving other aspects of their lives that may be responsible for lower levels
of well-being.
The longer-term NRT study found that use of NRT while smoking did not appear to increase overall
nicotine intake. Its long-term use among former SSS clients who remained abstinent was not uncommon
compared with concurrent use among smokers. Long-term use of NRT did not appear to have a
detrimental effect on the chronic stress response among smokers or ex-smokers and did not increase
exposure to nicotine among smokers. In contrast, it was associated with continuing high cotinine levels
among ex-smokers. This analysis provides some reassurance about longer-term nicotine use when not
delivered through tobacco. It builds on earlier research indicating that long-term NRT use is not associated
with increased health risks as assessed here, and is certainly safer than continued smoking.
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Appendix 1 Data collection instruments
The ELONS prospective study had three stages of data collection.  
 
Screening/Baseline Assessment (at quit date): 
• At baseline, when participants set a quit date, monitoring data was collected by SSS 
advisers along with an optional saliva sample. This included the same routine 
questions that SSS were already collecting as well as extra question of relevance to 
ELON. 
 
4 weeks post quit date: 
• Self-reported smoking status and CO measurement collected by SSS advisers.  
• Advisers also recorded number of weeks of pharmacotherapy (medication) taken and 
the number of sessions each client attended.  
• Client satisfaction and wellbeing questionnaire was posted to participants’ home 
address. 
 
52 weeks post quit date: 
• All participants who had quit at four weeks were followed up by telephone interview 
to identify self-reported smoking status. If they reported that they were abstinent from 
smoking, a home visit was arranged to record CO measurement and collect a saliva 
sample.  
 
Data collection tools for each stage are included below.   
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
ELONS prospective study baseline data collection  
Data confidentiality and security 
This information will be stored on a secure computer and sent in an anonymised form to a 
University research team who are helping us to improve our service. 
For practitioner to complete: 
Practitioner type: (primary role) 
1 Practice nurse 
2 GP 
3 Health Care 
Assistant 
4 Health trainer 
5 Receptionist 
6 Pharmacist  
7 Dispenser 
8 Counter Assistant 
9 Dentist 
10 Dental nurse 
11 Specialist smoking practitioner 
12 Other (please write in) 
 
 
  ……………………………. 
Setting: (where session(s) with this client take place) 
1 GP practice 
2 Pharmacy 
3 Hospital 
4 Dental practice 
5 Workplace/college/school 
6 Community centre/church 
7 Children’s centre 
8 Prison 
9 Home visit 
10 Other (please write in) 
 
…………………………….             
Intervention type: 
1 One to one 
2 Drop in 
 
3 Open/rolling group 
4 Closed group 
 
5 Other (please write in) 
……………………………. 
Medication given to this client: (tick all that apply) 
1 Single NRT 
2 Combination NRT 
3 Champix/Varenicline 
4 Zyban/Buproprion 
5 No medication  
For client to complete: 
DOB: Gender 1 Male 2 Female 
Title: First name: Surname: 
Address: Post Code: 
Home Telephone No: 
Other Telephone No: 
Mobile: 
Email: 
Who referred you to this service? 
1 Myself  2 GP    3 Other Health Professional 4 Other …………………….  
How did you hear about this service? 
1 Friend 
Are you in paid employment?  
    1 Yes    2 No 
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2 Work 
3 Paper 
4 Radio 
5 Poster 
6 Bus 
7 GP   
8 Other Health Professional     
9 Pharmacy 
10 Word of mouth 
11 From a national advert 
12 Leaflet           
13 Other….(please specify) 
……………………………….. 
 
If you answered ‘yes’, what is your occupation? 
 
……………………………………………………. 
If you answered ‘no’,  
Are you: 
1 Unemployed?                  
2 Full-time student?                 
3 Sick/disabled and unable to work?          
4 Retired?                    
5 Homemaker/full time parent/carer                  
Do you get free prescriptions?  
1 Yes    2 No 
 
Which ethnic group would you describe yourself as belonging to (tick one only):  
White 
1 British  
2 Irish  
3 Any other White background  
 Dual Heritage 
4 White & Black Caribbean 
5 White & Black African  
6 White & Asian 
7 Any other Dual Heritage background 
Asian or Asian British 
8 Indian 
9 Pakistani       
10 Bangladeshi  
11 Any other Asian background  
 
  
Black or Black British 
12 Caribbean 
13 African 
14 Any other Black background 
 
Other Ethnic Group 
15 Chinese  
16 Any other ethnic group  
 
17 I do not wish to disclose this  
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Which best describes your 
highest level of educational 
qualification?  
  
1 Still at school 
2 No formal 
qualification 
3 GCSE/O-grade/equiv. 
4 A-level/equivalent 
5 Apprenticeship 
6 Other vocational qf 
7 Degree 
8 Higher degree 
Which best describes your housing 
situation? (please tick the option 
that best applies to you) 
 
1 Own outright   
2 Own with mortgage  
3 Social/Council Renting 
4 Private Renting  
5 Other, please state  
 
…………………………….. 
What is your current 
marital status? 
 
1 Never married 
2 Married/civil 
partnership 
3 Cohabiting
  
4 Divorced 
5 Separated 
6 Widowed 
 
 
How many people (including 
yourself) live in your home?    
 
Adults (aged 16 or over, 
include yourself)  
     
………………………….  
 
 Children (aged 0-15) 
   
………………………….  
 
Thinking about your friends and 
family only, how many smoke? 
 
0 Not applicable 
1 None smoke 
2 A few smoke 
3 About half smoke 
4 Most smoke 
5 All smoke 
 
Now thinking about the people you 
work or study with, how many 
smoke? 
0 Not applicable 
1 None smoke 
2 A few smoke 
3 About half smoke 
4 Most smoke 
5 All smoke 
Over the last twelve 
months would you 
say your health has 
on the whole 
been……..?  
 
1 Good 
  
2 Fairly Good
  
3 Not Good 
 
Does anyone in your home 
smoke regularly?   
   
1 Yes    
2 No     
3 Does not apply to me 
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Have you made a 
serious attempt 
to stop smoking 
in the last 12 
months? i.e. you 
decided that you 
would try to 
make sure you 
never smoked 
again? 
 
1 Yes 
2 No  
Which, if any, of the following did you try to 
help you stop smoking during the most recent 
serious quit attempt? 
(Please tick all that apply) 
 
1 Nicotine replacement bought over the 
counter 
2 Nicotine replacement prescribed by GP 
3 Zyban (bupropion) 
4 Champix (varenicline) 
5 Attended an NHS stop smoking session 
6 Smoking helpline  
7 None of the above 
On average, how many 
cigarettes do you 
usually smoke per day?  
   
1 10 or less   
2 11-20   
3 21-30    
4 31 or more  
 
How many years have 
you been smoking? 
………………years 
How soon after 
you wake up do 
you smoke your 
first cigarette?  
 
1 Within 5 
minutes 
2 6-30 minutes 
3 31-60 
minutes 
4 After 60 
minutes 
 
 
Do you have anyone who will support you to 
stop smoking? 
1 Yes  
2 No  
If yes, who? (please tick all that apply) 
1 Spouse/partner 
2 Family member  
3 Friend  
4 Work Colleagues 
5 Other (please specify ………….. 
How determined are 
you to give up smoking 
at this attempt?  
 
1 Not at all 
determined 
2 Quite determined 
3 Very determined 
4 Extremely 
determined  
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Do you have any 
medical 
conditions? 
(please tick all 
that apply) 
1 High blood 
pressure 
2 Heart 
problems 
3 Diabetes 
4 Respiratory 
problems 
5 Stroke 
6 Ulcers 
7 Bad 
circulation 
8 
Under/overactive 
thyroid 
9 Skin 
problems 
10 Mental health 
problems 
11 Physical 
disability 
12 
Other…………
… 
 
 
Please indicate for each of the five statements which is closest to how you 
have been feeling over the last two weeks.  
(Please tick ONE box for EACH statement) 
Over the last two weeks:  
1. I have felt cheerful and in good 
spirits 
5 all of the time 
4 most of the time  
3 more than half the time 
2 less than half the time 
1 some of the time 
0 at no time 
4. I woke up feeling fresh and 
 rested  
5 all of the time 
4 most of the time  
3 more than half the time 
2 less than half the time 
1 some of the time 
0 at no time 
2. I have felt calm and relaxed 
5 all of the time 
4 most of the time  
3 more than half the time 
2 less than half the time 
1 some of the time 
0 at no time 
 
5. My daily life has been filled 
with things that interest me 
5 all of the time 
4 most of the time  
3 more than half the time 
2 less than half the time 
1 some of the time 
0 at no time 
3. I have felt active and vigorous 
5 all of the time 
4 most of the time  
3 more than half the time 
2 less than half the time 
1 some of the time 
0 at no time 
 
 
How much do your medical conditions limit you in any way from 
completing your everyday activities? (e.g. mobility)  
1 Severely   
2 Moderately 
3 Not at all 
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52 week telephone interview schedule  
 
EVALUATING LONGER TERM OUTCOMES IN NHS STOP SMOKING SERVICES 
(ELONS) 
DRAFT TELEPHONE QUESTIONNAIRE: 52 WEEK FOLLOW-UP –FINAL version 
 
INTRODUCTION 
Please could I speak to <named participant>? 
 
IF NOT THROUGH TO NAMED PERSON AND ASKED WHY CALLING: 
 <Named participant> is taking part in a research study evaluating NHS stop smoking 
services called ELONS and I’m calling about this.  
 
ONCE THROUGH TO NAMED PERSON: 
Good morning / afternoon/ evening about a year ago you tried to stop smoking with help 
from your local <stop smoking service/pharmacy/GP practice/dentist>. You also very kindly 
agreed to take part in a research study called ELONS to evaluate the help you received. As 
part of this research study I am calling to find out how you are getting on. It will only take a 
few minutes. My name is _________ and I am from TNS BMRB, the independent research 
company which is conducting follow up calls for the ELONS Research Study. 
 
IF NECESSARY: 
 When you agreed to take part in the ELONS Research Study you gave consent to be 
contacted to see how you are getting on with your attempt to quit smoking. 
 
SECTION A: ELONS CORE QUESTIONS 
ASK ALL 
Q1. Have you smoked in the last 7 days? [SC] 
Yes  
No  
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ASK ALL  
 
Q2. We understand that you attended an NHS stop smoking service about a year ago. You 
had successfully stopped smoking when they followed you up 4 weeks after your original 
quit date. Have you smoked at all since then? 
IF RESPONDENT IS UNSURE WHAT A QUIT DATE IS: This is the date you agreed to 
stop smoking.  
 
No, not at all 
Yes, between 1 and 5 cigarettes 
Yes, more than 5 cigarettes 
 
SECTION B: UCL ADDITIONAL QUESTIONS 
ASK ALL 
Q3. Thinking back to your quit attempt with your local < stop smoking service/pharmacy/GP 
practice/dentist> a year ago, did you use any nicotine replacement therapy, e.g. nicotine gum, 
patch, inhaler, nasal spray, mouth spray, microtab, lozenge or any other supplementary 
products, e.g. electronic cigarette? [SC] 
Yes – ASK Q4 
No – SKIP TO Q6a 
Can’t remember 
 
ASK Q4 IF Q3 = ‘YES’ 
Q4. How long did you use this additional support for? READ OUT [SC] 
Less than a day 
Less than a week  
More than 1 week and up to a month 
More than 1 month and up to 2 months 
More than 2 months and up to 3 months 
More than 3 months and up to 6 months 
More than 6 months and up to a year 
Still using it 
Can’t remember [DO NOT READ OUT] 
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ASK Q5 IF Q4 = 8 
Q5. And can you tell me which of the following forms of support you are still using? Tick all 
that apply. READ OUT [MC, RANDOMISE] 
1. Nicotine gum 
2. Nicotine patch 
3. Nicotine inhaler 
4. Nicotine nasal spray 
5. Nicotine mouth spray 
6. Nicotine microtab 
7. Nicotine Lozenge 
8. Electronic cigarette 
9. Other (SPECIFY) 
10. Can't remember [DO NOT READ OUT] 
 
SECTION C: AGREEMENT FOR FOLLOW UP VISIT 
ASK Q6a or b IF Q1 = ‘NO’ 
IF A SALIVA SAMPLE HAS BEEN GIVEN AT THE BASELINE (DEFINED FROM 
SAMPLE FILE) 
Q6a.  
As part of this research study, we would like to send one of our interviewers to visit you for a 
breath test* and also to collect a saliva sample? These are common ways of looking at the 
effects of stopping smoking and you may remember giving them at your local stop smoking 
service. It will only take a few minutes and our interviewer can either come to your home or 
your workplace, whichever is most convenient for you? 
Yes 
No 
 
ADDITIONAL INFORMATION ON CO BREATH TEST IF REQUIRED 
* The breath test involves blowing into a machine that measures the amount of carbon 
monoxide in your breath 
 
IF A SALIVA SAMPLE HAS NOT BEEN GIVEN AT THE BASELINE (DEFINED FROM 
SAMPLE FILE) 
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Q5b. As part of this research study, we would like to send one of our interviewers to visit you 
for a breath test*. This is a common way of looking at the effects of stopping smoking and 
you may remember giving one at your local stop smoking service. It will only take a few 
minutes and our interviewer can either come to your home or your workplace, whichever is 
most convenient for you? 
Yes 
No 
ADDITIONAL INFORMATION ON CO BREATH TEST IF REQUIRED 
* The breath test involves blowing into a machine that measures the amount of carbon 
monoxide in your breath 
 
IF NOT ASKED Q6a/b, THANK AND CLOSE 
 
IF Q6a/b = ‘NO’, THANK AND CLOSE 
 
IF Q6a/b = ‘YES’, SAY: Thank you, please can I check your address and contact telephone 
number and someone will be in touch over the next few days to arrange a convenient time. 
READ OUT CONTACT DETAILS TO CONFIRM AND UPDATE IF NECESSARY. 
CHECK THIS IS THE BEST NUMBER TO CONTACT THEM ON. 
 
OPEN TEXT BOX TO RECORD ANY ADDITIONAL INFORMATION FOR THE FACE 
TO FACE VISIT (TO BE PASSED ON TO THE FACE TO FACE INTERVIEWER) 
 
THANK AND CLOSE  
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Client satisfaction and well-being survey
 
 
 
Evaluating long term outcomes of NHS Stop Smoking Services (ELONS) 
CONFIDENTIAL NHS STOP SMOKING SERVICE CLIENT SATISFACTION 
SURVEY 
 
It is important that NHS Stop Smoking Services know if there is anything that they 
could do to improve the support that they provide to smokers. Your views about this 
are very important to us and will be treated in the strictest confidence. The results of 
this survey will be used for research and service development purposes. Please 
answer the following questions as honestly as you can, and return in the prepaid 
envelope provided. Thank you. 
 
Please TICK the appropriate box for EACH question: 
 
 
 1. Overall, how satisfied are you with the support you have received to stop smoking? 
Very satisfied
1 
 
satisfied
2 
 
unsure
3 
unsatisfied
4 
Very unsatisfied
5 
2. Would you recommend this service to other smokers 
who want to stop smoking? 
No 
0 
Unsure 
1 
Yes 
2 
3. In the event that you started smoking again, would 
you go back to the service for help with stopping 
smoking? 
No 
0 
Unsure 
1 
Yes 
2 
4. If you returned to the service for help with stopping 
smoking in the future, do you think that you would be 
welcomed back? 
 
No
0 
Unsure
1 
Yes
2 
5. Have you smoked since your last appointment with the service?
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 No, not a single puff 
     
1 
Yes, just a few puffs 
    
2 
Yes, 1-5 cigarettes 
 
3 
More than 5 
cigarettes 
4 
6. Was it easy to contact the stop smoking service when you 
had decided that you wanted to stop smoking? 
No 
0 
Unsure 
1 
Yes 
2 
7. When you contacted the stop smoking service, were you 
given an appointment date or told how long you would have 
to wait to see someone? 
No 
0
Unsure 
1
Yes 
2
8. How long did you have to wait before your first 
appointment/group (please enter number of days)? 
 
    .days 
 
9. Was the length of time you had to wait for your first 
appointment acceptable to you? 
No 
0 
Unsure 
1 
Yes 
2 
   
10. Was there contact from the stop smoking service before 
your appointment to encourage and motivate you to attend 
treatment? 
No 
0 
Unsure 
1 
Yes 
2 
  
11. Are the appointment times you were given 
convenient for you? 
No 
0
Unsure 
1
Yes 
2
12. Is the place where you go for your appointments 
convenient for you to get to? 
No 
0 
Unsure 
1 
Yes 
2 
13. Have you been offered support with childcare 
costs? 
Not 
applicable 
4 
No 
0 
Unsure 
1 
Yes 
2 
14. Were you given a choice of an individual appointment or a 
group session appointment? 
 No 
0 
Unsure 
1 
Yes 
2 
15. How satisfied are you with how supportive staff have been? 
 Very satisfied 
1 
satisfied 
2 
Unsure 
3 
unsatisfied 
4 
Very unsatisfied 
5 
16. How helpful have the information and advice that staff have given you during your  appointment 
been? 
 
Very helpful 
1 
   helpful 
2 
Unsure 
3 
Unhelpful 
4 
Very 
unhelpful 
5 
17. How helpful has the written information that staff have given to you been? 
 None given 
0 
Very helpful 
1 
helpful 
2 
Unsure 
3 
Unhelpful 
4 
Very 
unhelpful 
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5 
18. Do you find having your carbon monoxide (CO) reading done at every visit helpful? 
 CO not taken 
every visit 
0 
 
Very helpful 
1 
 
helpful 
2 
 
Unsure 
3 
 
Unhelpful 
4 
 
Very 
unhelpful 
5 
19. Was the information that you were given about the choice of medication helpful?  
 No 
0 
Unsure 
1 
      Yes 
2 
20. How did you get your medication? 
  
GP prescription 
 
1 
 
Chemist (bought 
myself)  
2 
 
Chemist (with a 
voucher)  
3 
Chemist (with 
service letter 
or 
prescription) 
4 
The stop 
smoking 
service 
 
5 
21. Was it easy to get hold of your medication once you had 
chosen which medication you were going to use for your 
stop smoking attempt? 
No 
0 
Unsure 
1 
Yes 
2 
If there are any changes that you would like to see to the Stop Smoking Service, or if there was 
anything they did particularly well, then please give details here: 
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Evaluating long term outcomes of NHS Stop Smoking Services (ELONS) 
 
CONFIDENTIAL CLIENT WELLBEING QUESTIONNAIRE 
Please answer the following questions about how things are going: 
Q1. On the whole how happy are you with your life in general? Look at the faces and TICK the box 
under the face which shows best how you feel. 
            
            
            
             
 1 2 3 4 5 6 7  
 
 
Q2. Please indicate for each of the five statements which is closest to how you have been feeling 
over the last two weeks. Notice that higher numbers mean better wellbeing. 
Example: If you have felt cheerful and in good spirits more than half of the time during the last two 
weeks, put a tick in the box with the number 3 in the lower right corner 
Please tick ONE box for EACH statement. 
 
Over the last two weeks: all of 
the 
time 
most 
of the 
time 
more 
than half 
of the 
time 
less than 
half of 
the time 
some 
of the 
time 
at no 
time 
1 I have felt cheerful and in good 
spirits 
5 4 3 2 1 0 
2 I have felt calm and relaxed 
5 4 3 2 1 0 
3 I have felt active and vigorous 
5 4 3 2 1 0 
4 I woke up feeling fresh and rested 
5 4 3 2 1 0 
5 My daily life has been filled with 
things that interest me 
5 4 3 2 1 0 
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Q3. How many of the people you know smoke? 
Please tick ONE box for EACH statement. 
 not 
applicable 
none 
smoke 
a few 
smoke 
about half 
smoke 
most 
smoke 
all  
smoke 
Friends 
0 1 2 3 4 5 
People I work with or study with 
0 1 2 3 4 5 
 
Confidential Client Wellbeing Questionnaire 
 
 
Q4. Below are some opinions that people might have about themselves. How strongly do you agree 
or disagree with each one? 
Please tick ONE box for EACH statement. 
 strongly 
agree 
agree neither 
agree nor 
disagree 
disagree 
 
disagree 
strongly 
I enjoy a challenge 
5 4 3 2 1 
I can deal with stress 
5 4 3 2 1 
I’m frightened of change 
5 4 3 2 1 
I can do what I want, when I want  
5 4 3 2 1 
Most people would like a life like mine 
5 4 3 2 1 
      
I feel in control  
5 4 3 2 1 
I feel safe  
5 4 3 2 1 
I worry about things going wrong 
5 4 3 2 1 
I feel I’m doing well in life 
5 4 3 2 1 
My life has a sense of routine 
5 4 3 2 1 
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Q5. If you have made any changes to your life to help you quit please write in the box: 
 
 
 
 
 
 
 
THANK YOU VERY MUCH FOR COMPLETING THIS QUESTIONNAIRE. We could 
not do this study without your help. 
 
Please could you just look back to check that you haven’t missed any questions  
Now please send it back to us in the prepaid envelope provided. 
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Appendix 2 Supplementary tables from
well-being study
The main aims of the ELONS prospective study were to determine the proportion of SSS clients whoremained abstinent from smoking 12 months after setting a quit date, and which clients were most
likely to have stopped. A novel aspect of the ELONS study was that data on well-being was also collected
from participants, not something normally done by the services. Well-being at baseline was a predictor of
both short- and long-term quitting (see Chapters 6 and 8). Data on well-being were also collected through
postal surveys at 4 weeks and 12 months post quit date (or since first contact for the 150 clients who did
not set a quit date) in order to explore whether or not well-being changed over the course of a quit
attempt and which client and service characteristics were associated with well-being at different time
points. The main results of this analysis are presented in Chapter 8. This Appendix contains three tables
that provide extra information supporting the findings presented in Chapter 8.
Table 45 presents information on clients’ levels of response to the main measure of well-being used in the
study (whether or not it was possible to calculate a score for the WHO-5 Well-being Index) in the postal
surveys compared with the ELONS prospective study sample at baseline and all clients who set a quit date
with the services when clients in each service were being recruited to the ELONS study.
Tables 46 and 47 present multivariable linear regression results, presenting client and service characteristics
that were associated with well-being at baseline, 4 weeks and 12 months. Table 46 presents results of
analyses of associates including the previous dependent variables and additionally ‘ontological security’.
Ontological security was operationalised as 10 items intended to measure feelings of being protected, in
control, prestige and response to change. The analysis with well-being at 4 weeks as the outcome includes
ontological security collected in the 4-week postal survey and the analysis with well-being at 12 months as
the outcome includes ontological security collected in the 12-month postal survey.
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TABLE 45 Participation in the ELONS study overall, and the well-being element of the 4- and 52-week
postal surveys
Variables
All cases ELONS
4-week postal
survey
52-week postal
survey
n % n % n % n %
Age (years)
16–24 7120 11 327 10.7 65 6.8 28 5.8
25–34 13,226 20 673 22.0 147 15.4 47 9.8
35–44 15,338 23 758 24.8 194 20.4 97 20.3
45–54 13,851 21 629 20.6 229 24.0 109 22.8
55–64 9933 15 456 14.9 210 22.0 140 29.2
65–85 6469 10 214 7.0 108 11.3 58 12.1
Total 65,937 100.0 3057 100.0 953 100.0 479 100.0
Gender
Female 34,955 53 1710 55.9 531 55.7 267 55.7
Male 30,982 47 1347 44.1 422 44.3 212 44.3
Total 65,937 100.0 3057 100.0 953 100.0 479 100.0
NSSEC
Routine and manual occupations 18,201 28 939 30.7 251 26.3 112 23.4
Managerial/professional and intermediate
occupations
14,098 21 716 23.4 239 25.1 133 27.8
Sick/disabled and unemployed 14,932 23 660 21.6 188 19.7 86 18.0
Other/unknown 18,706 28 742 24.3 275 28.9 148 30.9
Total 65,937 100.0 3057 100.0 953 100.0 479 100.0
Behavioural support
Closed group 541 1 102 3.3 30 3.1 18 3.8
Open group 2159 3 550 18.0 202 21.2 84 17.5
Drop-in 11,308 17 887 29.0 247 25.9 130 27.1
One-to-one specialist 21,796 33 1131 37.0 374 39.2 188 39.2
GP practice 16,412 25 269 8.8 75 7.9 45 9.4
Pharmacy 9821 15 97 3.2 23 2.4 9 1.9
Other or unclear 3900 6 21 0.7 2 0.2 5 1.0
Total 65,937 100.0 3057 100.0 953 100.0 479 100.0
CO-validated quit at 52 weeks
Not quit – – 2772 90.7 775 81.3 351 73.3
Quit – – 285 9.3 178 18.7 128 26.7
Total – – 3057 100.0 953 100.0 479 100.0
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TABLE 46 Multivariable regression modelling of well-being at baseline, 4 weeks and 52 weeks including data
collected at baseline and quitting as dependent variablesa
Variables
Well-being at baseline Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI) n Beta (95% CI)
Smoking cessation behavioural support
Specialist group 634 2.31
(–0.81 to 5.43)
232 –0.68
(–6.19 to 4.82)
102 –5.07
(–13.24 to 3.11)
Specialist drop-in 856 –0.80
(–3.02 to 1.42)
247 –0.52
(–4.11 to 3.07)
130 3.28
(–1.95 to 8.52)
Specialist one to one 1090 0 374 0 188 0
Provided by GP practice or
pharmacy
358 0.46
(–3.29 to 4.21)
98 0.10
(–5.98 to 6.18)
54 –6.43
(–15.59 to 2.73)
Other or unclear 21 9.60
(0.38 to 18.81)
2 5.11
(–24.12 to 34.33)
5 –0.34
(–20.17 to 19.50)
Time of year
Other months 736 1.11
(–2.38 to 4.61)
227 –0.37
(–6.15 to 5.40)
135 –6.42
(–15.71 to 2.88)
Summer – July and August 933 1.75
(–1.70 to 5.21)
300 0.29
(–5.22 to 5.80)
168 –5.58
(–14.82 to 3.66)
Back to school – September
and October
1100 2.24
(–1.12 to 5.60)
354 2.56
(–2.87 to 7.98)
149 –3.77
(–12.95 to 5.42)
New Year – January and
February
190 0 72 0 27 0
Age group (years)
16–24 314 5.61
(2.66 to 8.57)
65 9.05
(3.28 to 14.82)
28 13.80
(4.72 to 22.88)
25–34 651 3.46
(1.09 to 5.83)
147 6.66
(2.34 to 10.97)
47 3.77
(–3.67 to 11.21)
35–44 734 2.33
(0.06 to 4.60)
194 3.48
(–0.50 to 7.46)
97 6.32
(0.33 to 12.31)
45–54 608 0 229 0 109 0
55–64 442 1.60
(–1.00 to 4.19)
210 2.27
(–1.61 to 6.15)
140 3.96
(–1.53 to 9.44)
65–85 210 5.62
(2.23 to 9.00)
108 5.44
(0.66 to 10.23)
58 7.71
(0.71 to 14.71)
Gender
Male 1302 1.18
(–0.37 to 2.73)
422 0.58
(–2.16 to 3.32)
267 0.34
(–3.64 to 4.33)
Female 1657 0 531 0 212 0
SES
Low SES (unemployed/basic
education/social rent)
1179 0 333 0 134 0
Mid SES 1480 3.14
(1.48 to 4.79)
503 1.39
(–1.63 to 4.41)
276 4.10
(–0.51 to 8.72)
High SES (owns home and
professional manager/tertiary
education)
300 3.92
(1.17 to 6.66)
117 4.04
(–0.50 to 8.58)
69 4.70
(–1.80 to 11.21)
continued
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TABLE 46 Multivariable regression modelling of well-being at baseline, 4 weeks and 52 weeks including data
collected at baseline and quitting as dependent variablesa (continued )
Variables
Well-being at baseline Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI) n Beta (95% CI)
Ethnicity
White British 2776 3.49
(–1.63 to 8.61)
895 3.10
(–5.93 to 12.14)
454 –
Other white 66 0 21 0 8 –
Asian (including mixed Asian
and white)
62 7.50
(0.04 to 14.96)
9 21.83
(5.60 to 38.06)
2 –
Ethnicity other or unknown 55 2.71
(–4.79 to 10.22)
28 2.79
(–8.93 to 14.51)
15 –
Smoking dependence
Not recorded as dependent 1634 3.19
(1.62 to 4.75)
562 3.31
(0.55 to 6.07)
276 5.31
(1.19 to 9.43)
Dependent 1325 0 391 0 203 0
Determination to quit
Determined 2688 3.43
(0.77 to 6.10)
873 – 425 –
Not recorded as determined 271 0 80 – 54 –
Quit attempt supported by spouse/partner
Supported 1530 2.50
(0.96 to 4.04)
511 4.83
(2.14 to 7.53)
235 –
Other 1429 0 442 0 244 –
Proportion of friends and family who smoke
Half or more do not smoke 2249 1.80
(–0.04 to 3.63)
165 – 83 –
Other 710 0 788 – 396 –
Took varenicline in first week
Took varenicline 1356 2.48
(0.88 to 4.08)
476 – 224 –
Varenicline not recorded 1603 0 477 – 255 –
Mental health condition
Yes 471 0 146 0 69 –
Not recorded 2488 9.95
(7.81 to 12.10)
807 10.77
(7.05 to 14.49)
410 9.94
(4.24 to 15.65)
Heart, blood or circulatory conditions
Yes 512 – 196 – 101 –
Not recorded 2447 3.39
(1.19 to 5.59)
757 – 378 –
Respiratory or lung condition
Yes 624 – 216 – 116 –
Not recorded 2335 6.30
(4.37 to 8.23)
737 – 363 6.60
(1.84 to 11.36)
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TABLE 46 Multivariable regression modelling of well-being at baseline, 4 weeks and 52 weeks including data
collected at baseline and quitting as dependent variablesa (continued )
Variables
Well-being at baseline Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI) n Beta (95% CI)
Has other condition not included above
Yes 349 – 121 – 71 –
No condition or has one of
above conditions
2610 2.79
(0.32 to 5.25)
832 – 408 –
CO-validated quit rate
Quit at 4 weeks 1315 N/A 268 0 304 N/A
Not quit at 4 weeks 1644 – 685 6.11
(3.05 to 9.17)
175 –
CO-validated quit rate
Quit at 52 weeks 282 N/A 178 N/A 351 –
Not quit at 52 weeks 2677 – 775 – 128 11.76
(7.23 to 16.29)
Practitioner variance – 11.4 (4.2) – 0.9 (4.4) – 10.2 (12.4)
Client-level unexplained variance
(standard error)
– 422.3 (11.2) – 415.6 (19.5) – 444.9 (30.6)
–2log likelihood – 26338.65 – 8453.027 – 4290.095
Total (N) 2959 – 953 – 479 –
N/A, not applicable.
a Location was also included in the model but is not presented.
TABLE 47 Multivariable regression modeling of well-being at 4 weeks and 52 weeks including data collected at
baseline, ontological security collected in the postal surveys and quitting as dependent variablesa
Variables
Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI)
Smoking cessation behavioural support
Specialist group 232 1.69 (–1.18 to 4.57) 102 –0.89 (–6.64 to 4.85)
Specialist drop-in 247 –0.50 (–5.34 to 4.33) 130 2.81 (–0.87 to 6.49)
Specialist one to one 374 0 188 0
Provided by GP practice or pharmacy 98 4.07 (–19.04 to 27.18) 54 –0.24 (–6.68 to 6.19)
Other or unclear 2 –0.67 (–5.97 to 4.63) 5 8.42 (–5.33 to 22.17)
Time of year
Other months 227 –1.55 (–6.12 to 3.02) 135 –2.89 (–9.32 to 3.55)
Summer – July and August 300 0.16 (–4.21 to 4.53) 168 –1.65 (–8.04 to 4.75)
Back to school – September and October 354 0.73 (–3.56 to 5.01) 149 –2.65 (–8.99 to 3.68)
New Year – January and February 72 0 27 0
continued
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TABLE 47 Multivariable regression modeling of well-being at 4 weeks and 52 weeks including data collected at
baseline, ontological security collected in the postal surveys and quitting as dependent variablesa (continued )
Variables
Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI)
Age group (years)
16–24 65 4.38 (–0.22 to 8.99) 28 4.97 (–1.34 to 11.27)
25–34 147 3.70 (0.25 to 7.15) 47 1.52 (–3.62 to 6.66)
35–44 194 1.96 (–1.20 to 5.13) 97 1.76 (–2.45 to 5.96)
45–54 229 0 109 0
55–64 210 1.17 (–1.92 to 4.26) 140 –0.22 (–4.06 to 3.62)
65–85 108 3.43 (–0.41 to 7.28) 58 1.79 (–3.10 to 6.69)
Gender
Male 422 0.32 (–1.83 to 2.47) 267 1.05 (–1.75 to 3.84)
Female 531 0 212 0
SES
Low SES (unemployed/basic education/social rent) 333 0 134 0
Mid SES 503 –2.26 (–4.64 to 0.12) 276 –2.09 (–5.32 to 1.15)
High SES (owns home and professional managerial/
tertiary education)
117 –2.08 (–5.70 to 1.53) 69 –0.63 (–5.14 to 3.89)
Ethnicity
White British 895 3.68 (–3.50 to 10.87) 454 N/A
Other white 21 0 8 –
Asian (including mixed Asian and white) 9 20.43 (7.50 to 33.36) 2 –
Ethnicity other or unknown 28 3.04 (–6.23 to 12.32) 15 –
Smoking dependence
Not recorded as dependent 562 – 276 –
Dependent 391 – 203 –
Determination to quit
Determined 873 – 425 –
Not recorded as determined 80 – 54 –
Quit attempt supported by spouse/partner
Supported 511 – 235 –
Other 442 – 244 –
Proportion of friends and family who smoke
Half or more do not smoke 165 – 83 –
Other 788 – 396 –
Took varenicline in first week
Took varenicline 476 – 224 –
Varenicline not recorded 477 – 255 –
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TABLE 47 Multivariable regression modeling of well-being at 4 weeks and 52 weeks including data collected at
baseline, ontological security collected in the postal surveys and quitting as dependent variablesa (continued )
Variables
Well-being at 4 weeks Well-being at 52 weeks
n Beta (95% CI) n Beta (95% CI)
Mental health condition
Yes 146 – 69 –
Not recorded 807 – 410 –
Heart, blood or circulatory conditions
Yes 196 2.83 (0.10 to 5.56) 101 –
Not recorded 757 0 378 –
Respiratory or lung condition
Yes 216 – 116 –
Not recorded 737 – 363 –
Has other condition not included above
Yes 121 – 71 –
No condition or has one of above conditions 832 – 408 –
Ontological security
I enjoy a challenge – 2.40 (0.88 to 3.93) – 2.21 (0.32 to 4.10)
I can deal with stress – 4.28 (3.01 to 5.56) – –
I’m frightened of change (reversed) – – – –
I can do what I want, when I want – – – 2.75 (1.27 to 4.23)
Most people would like a life like mine – 2.32 (0.98 to 3.66) –
I feel in control – 5.49 (3.86 to 7.13) – 6.78 (4.40 to 9.16)
I feel safe – – – 3.46 (1.34 to 5.57)
I worry about things going wrong (reversed) – – – 1.92 (0.56 to 3.29)
I feel I’m doing well in life – 6.02 (4.51 to 7.52) – 5.59 (3.43 to 7.75)
My life has a sense of routine – – – 2.16 (0.35 to 3.97)
CO-validated quit rate
Quit at 4 weeks 268 2.88 (0.45 to 5.31) 304 N/A
Not quit at 4 weeks 685 0 175 –
CO-validated quit rate
Quit at 52 weeks 178 N/A 351 5.24 (2.03 to 8.46)
Not quit at 52 weeks 775 – 128 0
Practitioner variance – 1.41 (3.0) – 8.7 (6.9)
Client-level unexplained variance (standard error) – 258.7 (12.2) – 209.5 (14.5)
–2log-likelihood – 8003.832 – 3936.1
Total 953 – 479 –
N/A, not applicable.
a Location was also included in the model but is not presented.
DOI: 10.3310/hta19950 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 95
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dobbie et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155


Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
